data_2ehr_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ehr _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.329 0 CA-C-O 121.421 0.456 . . . . 0.0 112.475 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.458 HG22 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.401 HG22 ' C ' ' A' ' 18' ' ' ILE . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.601 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.543 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.469 HD21 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.46 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.549 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.453 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 8.5 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.453 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.431 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.431 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.448 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.46 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.549 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.41 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.4 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.492 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.42 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.417 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.457 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.426 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.486 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.454 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.455 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 94' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.459 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.491 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.462 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.8 m-20 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.543 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.458 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.601 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.457 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.426 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.481 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.417 0.454 . . . . 0.0 112.489 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.456 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.406 ' C ' HG22 ' A' ' 19' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.406 HG22 ' C ' ' A' ' 18' ' ' ILE . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.453 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.556 HD12 ' CZ ' ' A' ' 104' ' ' PHE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 29.4 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.455 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.419 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.419 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.538 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 68' ' ' ALA . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.459 ' CD1' HD13 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.409 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.455 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.455 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.447 HD21 ' CB ' ' A' ' 94' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.41 HG21 ' CD1' ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.447 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.436 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.7 m-20 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.518 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.455 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.481 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 2.6 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' SER . . . . . 0.456 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.431 0.462 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.454 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.462 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.454 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 37.2 mm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.465 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.44 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.44 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.46 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.454 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.457 ' O ' ' CG2' ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.457 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.404 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.446 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.418 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.456 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.451 HD21 ' CB ' ' A' ' 94' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.47 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.593 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.456 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.451 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.6 m-20 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.446 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 CA-C-O 121.399 0.444 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.435 HG21 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.413 HG21 ' C ' ' A' ' 18' ' ' ILE . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.451 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.451 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.461 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.567 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.653 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.461 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 21.1 mm . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.4 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.461 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.438 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.438 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.452 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.459 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.41 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.41 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.4 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.401 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.49 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.467 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.457 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.494 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' SER . . . . . 0.408 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.653 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.445 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.457 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 75.6 m-20 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.547 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.435 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CG ' HD12 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' SER . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 CA-C-O 121.422 0.457 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.417 ' C ' HG22 ' A' ' 19' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.417 HG22 ' C ' ' A' ' 18' ' ' ILE . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.568 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.465 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.463 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.573 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 35' ' ' GLY . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 33.3 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.543 ' CE2' ' HG3' ' A' ' 74' ' ' LYS . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.435 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.452 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.463 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.437 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.573 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.493 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.543 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.467 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.42 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.437 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.433 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.454 ' CD2' ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.474 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.494 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.437 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.474 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.494 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.8 m-20 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.437 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.515 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.467 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.42 ' CG ' HD13 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 CA-C-O 121.44 0.466 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.448 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 HD13 ' CD1' ' A' ' 69' ' ' LEU . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.599 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.522 ' H ' ' ND2' ' A' ' 100' ' ' ASN . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.456 ' CD2' HG21 ' A' ' 21' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.468 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.459 ' N ' HG23 ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.435 ' O ' ' N ' ' A' ' 75' ' ' ILE . 27.9 mm . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.415 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.47 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.437 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.437 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.447 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.568 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.454 ' O ' ' N ' ' A' ' 68' ' ' ALA . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.464 ' CD1' HD13 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.441 ' CE ' ' O ' ' A' ' 69' ' ' LEU . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.415 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.422 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.453 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.429 HG12 ' CB ' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.464 ' CD2' ' HA ' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.433 ' HB1' ' CB ' ' A' ' 90' ' ' GLU . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.45 ' NE2' ' O ' ' A' ' 33' ' ' ILE . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.433 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 83' ' ' LEU . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.47 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.429 ' CB ' HG12 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.453 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.599 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.2 t-20 -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.535 ' CZ ' HD12 ' A' ' 31' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.422 ' CG ' HD12 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 CA-C-O 121.431 0.462 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.413 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.41 HG21 ' C ' ' A' ' 18' ' ' ILE . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.447 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.45 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.579 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 9.1 mm . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.439 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.435 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.454 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.45 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.462 ' CD1' HD13 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 53' ' ' PHE . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.452 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.454 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.455 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.434 HD21 ' CB ' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.488 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.455 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.488 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.4 m-20 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.413 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.452 ' CG ' HD13 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 CA-C-O 121.41 0.45 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.53 ' NH1' ' N ' ' A' ' 108' ' ' SER . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' C ' HG22 ' A' ' 19' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.418 HG22 ' C ' ' A' ' 18' ' ' ILE . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.593 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.464 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.456 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.449 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 31.1 mm . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.401 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.47 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.419 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 68' ' ' ALA . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.468 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.447 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.437 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.456 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.46 HD21 ' CB ' ' A' ' 94' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.449 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.595 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.423 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.45 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.46 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.45 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.418 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 12.7 t-20 -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.561 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.593 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.489 ' CG2' ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.437 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 CA-C-O 121.459 0.477 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.683 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.448 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.445 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.547 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.462 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.477 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 42.9 mm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.462 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.445 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.445 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.454 HD11 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.456 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.547 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.43 ' O ' ' N ' ' A' ' 68' ' ' ALA . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.407 ' CD2' HG23 ' A' ' 106' ' ' VAL . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.434 ' HD3' ' CD2' ' A' ' 76' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.434 ' CD2' ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.442 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.443 HG11 ' CB ' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.44 HD21 ' CB ' ' A' ' 94' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.454 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.596 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.443 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.6 m-80 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.442 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.566 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.683 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 CA-C-O 121.421 0.456 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.424 HG22 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.411 HG21 ' C ' ' A' ' 18' ' ' ILE . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.651 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.457 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.456 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.439 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 9.0 mm . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.438 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.438 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.462 HD13 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.444 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.444 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.422 ' CD2' HG23 ' A' ' 106' ' ' VAL . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.412 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.422 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.485 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.461 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.441 HD23 ' CB ' ' A' ' 94' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . 0.443 ' N ' HD21 ' A' ' 85' ' ' ASN . 0.9 OUTLIER -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.429 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.429 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.447 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.443 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.447 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.4 m-20 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.4 ' CB ' HG11 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.4 HG11 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.424 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.651 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 69' ' ' LEU . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.422 ' CG ' HD13 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.432 0.462 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.407 ' C ' HG23 ' A' ' 19' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.407 HG23 ' C ' ' A' ' 18' ' ' ILE . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.617 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.569 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.444 ' HG2' ' CG2' ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.447 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.51 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.593 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.463 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.408 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 41.5 mm . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.463 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.464 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.51 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.402 ' C ' ' N ' ' A' ' 68' ' ' ALA . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.402 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.465 ' CD1' HD13 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.42 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.407 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.407 ' CD2' ' HE3' ' A' ' 74' ' ' LYS . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.485 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.475 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.45 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 57.9 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.457 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.452 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.45 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.457 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.7 m-80 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.459 ' CB ' HG23 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.512 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.459 HG23 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.617 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.406 ' CG ' HD13 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 CA-C-O 121.43 0.461 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.409 ' C ' HG23 ' A' ' 19' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.409 HG23 ' C ' ' A' ' 18' ' ' ILE . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.592 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.569 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.451 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.455 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.566 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.445 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.498 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 27.3 mm . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.402 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.441 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.45 HD11 ' N ' ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.459 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.435 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.566 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 68' ' ' ALA . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.411 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.402 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.447 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.459 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.451 HG13 ' CB ' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.435 HD22 ' CB ' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.498 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' SER . . . . . 0.453 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HB2' ' N ' ' A' ' 87' ' ' SER . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.458 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.505 ' CG1' ' CE ' ' A' ' 96' ' ' LYS . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.451 ' CB ' HG13 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.487 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.507 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.451 ' CG2' ' HG3' ' A' ' 23' ' ' ARG . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.592 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.447 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 CA-C-O 121.421 0.456 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.41 ' C ' HG21 ' A' ' 19' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.41 HG21 ' C ' ' A' ' 18' ' ' ILE . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.599 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.47 ' CB ' HG11 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.47 HG11 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.55 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.623 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.439 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 33.3 mm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.426 HG23 ' N ' ' A' ' 55' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.444 ' HB3' ' N ' ' A' ' 33' ' ' ILE . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.47 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.439 ' O ' ' N ' ' A' ' 68' ' ' ALA . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.458 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.45 HG11 ' CB ' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.429 HD21 ' CB ' ' A' ' 94' ' ' ALA . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 83' ' ' LEU . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.439 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.623 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.45 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.412 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.1 m-20 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.458 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.566 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.41 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.599 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 CA-C-O 121.424 0.458 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.423 ' C ' HG21 ' A' ' 19' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.423 HG21 ' C ' ' A' ' 18' ' ' ILE . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.443 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.593 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.61 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 24.5 mm . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.473 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.485 ' O ' ' N ' ' A' ' 68' ' ' ALA . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.427 ' CD2' HG21 ' A' ' 106' ' ' VAL . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.409 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.462 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.455 HD21 ' CB ' ' A' ' 94' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.47 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.61 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.428 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.447 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.473 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.455 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.447 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.473 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.1 m-20 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 19.3 t-20 -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.561 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.419 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 69' ' ' LEU . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.409 ' CG ' HD12 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.298 0 CA-C-O 121.378 0.432 . . . . 0.0 112.528 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.584 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.498 ' CG ' ' CG2' ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.458 ' CB ' HG12 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.458 HG12 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.452 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.603 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.447 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.421 ' O ' ' C ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.497 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 30.6 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.422 ' HB2' ' C ' ' A' ' 33' ' ' ILE . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.404 ' CD1' ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.479 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.448 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.467 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.451 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.497 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.446 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.452 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.454 ' CB ' HG12 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.452 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.7 m-20 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.448 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.527 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.498 ' CG2' ' CG ' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.584 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.45 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 CA-C-O 121.416 0.453 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.473 ' CD ' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.632 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.572 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.433 ' HG2' ' CG2' ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.5 m-80 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.452 HD22 ' CG2' ' A' ' 21' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.536 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.435 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 42.5 mm . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.459 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.458 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.408 ' HD3' ' CD2' ' A' ' 76' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.43 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.427 HG12 ' CB ' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.458 HD23 ' CB ' ' A' ' 94' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.6 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.446 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.446 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.492 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.458 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.446 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.492 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.9 m-80 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.489 ' CB ' ' CG1' ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.488 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.572 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.489 ' CG1' ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.473 ' CG2' ' CD ' ' A' ' 17' ' ' ARG . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.43 ' CG ' HD13 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.332 0 CA-C-O 121.458 0.477 . . . . 0.0 112.495 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.443 HG22 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.443 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.642 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.45 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 28' ' ' SER . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.461 ' N ' HG22 ' A' ' 27' ' ' VAL . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.454 HD21 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.45 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.55 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 41.1 mm . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.441 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.461 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.45 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.471 ' O ' ' N ' ' A' ' 68' ' ' ALA . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.471 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.455 ' CD2' HG22 ' A' ' 106' ' ' VAL . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.416 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.488 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.461 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.454 HD21 ' CB ' ' A' ' 94' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.459 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.595 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.458 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.484 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.454 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.484 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 68.8 m-20 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.412 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.443 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.642 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 69' ' ' LEU . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.46 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.277 0 CA-C-O 121.444 0.469 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.455 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.41 ' C ' HG22 ' A' ' 19' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.41 HG22 ' C ' ' A' ' 18' ' ' ILE . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.49 ' CD1' ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.553 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.442 ' CD ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 21' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.527 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.464 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 13.1 mm . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.48 ' CZ ' ' HG3' ' A' ' 74' ' ' LYS . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.464 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.527 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.406 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.406 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.48 ' HG3' ' CZ ' ' A' ' 53' ' ' PHE . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.463 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.462 ' CD2' ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.488 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.441 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.427 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.461 HD23 ' CB ' ' A' ' 94' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.456 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.497 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.461 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.3 m-20 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.441 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.553 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.435 ' CG2' ' HG3' ' A' ' 23' ' ' ARG . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.49 ' CD2' ' CD1' ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.463 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.494 0.497 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.423 ' C ' HG22 ' A' ' 19' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.423 HG22 ' C ' ' A' ' 18' ' ' ILE . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.551 HD11 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.559 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.465 HD21 ' CG2' ' A' ' 21' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.463 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.458 HG12 ' CB ' ' A' ' 63' ' ' ALA . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.442 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.464 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 7.6 mm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.5 ' CE1' ' HG3' ' A' ' 74' ' ' LYS . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.436 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.443 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.443 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.451 ' N ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.481 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.46 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.4 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HB2' ' CD1' ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.5 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.423 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.491 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.459 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.457 HD23 ' CB ' ' A' ' 94' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.464 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.406 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.457 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.7 m-20 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.446 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.505 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.559 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.425 HG11 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.406 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.551 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.423 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-O 121.449 0.472 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.409 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.42 ' C ' HG23 ' A' ' 19' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.42 HG23 ' C ' ' A' ' 18' ' ' ILE . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.635 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.564 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.465 ' NE ' ' HB2' ' A' ' 100' ' ' ASN . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.486 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.486 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' HG22 ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.575 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.481 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 13.4 mm . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.405 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.472 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.47 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.405 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.433 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.49 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.441 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.441 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.456 HD23 ' CB ' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.481 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' HIS . . . . . 0.593 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.451 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.456 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.451 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.5 m-20 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.441 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.486 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.564 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.635 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.413 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' SER . . . . . 0.409 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -48.11 -22.35 0.61 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.919 0.39 . . . . 0.0 110.869 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.9 t -121.24 -40.88 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.841 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.68 152.39 26.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 t -140.92 136.71 32.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.838 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 p -137.33 110.02 7.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.99 78.11 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 71.2 1.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.701 2.268 . . . . 0.0 112.354 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 64.91 44.82 3.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -117.34 116.13 26.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.595 ' O ' ' CD1' ' A' ' 13' ' ' TRP . 7.5 t 50.76 45.31 27.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.857 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -66.66 107.25 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.595 ' CD1' ' O ' ' A' ' 11' ' ' SER . 65.8 m95 -88.2 108.61 19.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -66.31 -162.71 1.26 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.475 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.458 HG22 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.401 HG22 ' C ' ' A' ' 18' ' ' ILE . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.601 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.543 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.469 HD21 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.46 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.549 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.453 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 37.94 -121.3 0.97 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.38 83.74 1.71 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.52 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.8 mt-30 -123.03 155.06 37.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.853 0.359 . . . . 0.0 110.887 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 6.0 t -127.03 -10.84 5.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.09 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 t -142.68 128.2 16.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.132 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.5 mt -143.52 163.56 15.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.121 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.458 ' HE3' ' N ' ' A' ' 44' ' ' LYS . 0.7 OUTLIER -51.26 132.24 28.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' A' ' 44' ' ' LYS . 14.0 tpp180 -70.12 -67.79 0.47 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 42' ' ' ARG . 3.9 mp -34.53 -32.91 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 42' ' ' ARG . 19.7 ttpt -43.18 134.79 3.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.865 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.18 120.69 9.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.927 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -164.01 -153.28 7.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -128.54 -6.75 5.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.893 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -61.94 175.95 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.911 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.593 ' N ' ' CD1' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -123.15 153.47 39.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.918 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -15.29 6.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -49.26 179.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 8.5 mm -86.89 131.85 33.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.453 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.431 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.431 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.448 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.46 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.549 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.41 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.4 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.492 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.42 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.417 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.457 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.426 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.486 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.454 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.455 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 94' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.459 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.491 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.462 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.8 m-20 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.543 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.458 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.601 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.457 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.426 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -73.3 123.66 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.554 HD11 ' CZ2' ' A' ' 13' ' ' TRP . 12.5 mt -62.37 169.97 2.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.8 t -52.87 86.72 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 109' ' ' LEU . 26.9 t -154.37 -176.84 6.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.809 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' THR . . . . . 0.448 ' N ' ' OG ' ' A' ' 111' ' ' SER . 34.5 p -131.39 144.14 52.17 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.548 0.689 . . . . 0.0 111.144 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -163.8 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.676 2.25 . . . . 0.0 112.296 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.8 tpt180 -131.51 157.51 43.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.846 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 114' ' ' ARG . 9.2 p -98.6 163.34 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.14 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.423 HD12 ' C ' ' A' ' 117' ' ' PRO . 0.7 OUTLIER -80.44 151.75 72.3 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.635 0.731 . . . . 0.0 111.139 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.423 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.743 2.296 . . . . 0.0 112.317 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.3 t -70.87 144.43 50.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.2 m -74.82 154.08 38.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.829 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.22 -18.69 0.26 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.2 t -81.89 130.87 35.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.816 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.7 t -149.51 126.55 11.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.52 80.57 0.19 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.6 Cg_endo -69.76 0.51 5.54 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.68 2.253 . . . . 0.0 112.352 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.434 ' C ' ' O ' ' A' ' 8' ' ' PRO . 26.0 m-20 -34.4 146.96 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -134.85 118.69 17.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.871 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.554 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 18.4 p -157.32 163.04 39.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.58 69.68 1.47 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.826 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.554 ' CD1' ' HB2' ' A' ' 11' ' ' SER . 50.9 m95 -85.95 116.42 24.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.913 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.481 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -75.46 -158.1 6.9 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.489 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.456 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.406 ' C ' HG22 ' A' ' 19' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.406 HG22 ' C ' ' A' ' 18' ' ' ILE . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.453 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.556 HD12 ' CZ ' ' A' ' 104' ' ' PHE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.03 -126.53 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.46 ' HA2' ' CD1' ' A' ' 52' ' ' ILE . . . 118.45 -67.24 0.36 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.438 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.44 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.23 151.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.6 t -176.46 -174.28 0.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -146.25 142.57 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 4.2 mt -105.76 148.24 10.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.65 139.64 36.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.921 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.2 ttp180 -89.54 10.32 23.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 8.6 mt -98.28 -36.36 10.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -167.86 173.67 8.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -116.83 162.34 17.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -126.64 137.29 9.93 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.26 0.58 37.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.856 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.59 176.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.895 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.609 ' CD1' ' CZ ' ' A' ' 53' ' ' PHE . 3.2 mm? -74.85 77.07 2.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.7 pttm -123.16 -14.15 7.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.44 -151.88 0.38 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.529 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 29.4 mm -114.47 133.71 59.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.609 ' CZ ' ' CD1' ' A' ' 49' ' ' LEU . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.455 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.419 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.419 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.538 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 68' ' ' ALA . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.459 ' CD1' HD13 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.409 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.455 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.455 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.447 HD21 ' CB ' ' A' ' 94' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.41 HG21 ' CD1' ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.447 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.436 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.7 m-20 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.518 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.455 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.481 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 2.6 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' SER . . . . . 0.456 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t -72.82 132.86 44.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.549 ' CD2' ' CD2' ' A' ' 13' ' ' TRP . 9.6 mt -71.55 158.99 35.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.1 t -61.21 75.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 109' ' ' LEU . 1.2 p -132.51 -1.54 3.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 6.3 p 58.33 151.12 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 0.0 111.151 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.669 2.246 . . . . 0.0 112.341 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 -130.18 -174.76 3.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.823 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.07 157.13 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.114 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.47 ' O ' ' CD1' ' A' ' 116' ' ' ILE . 1.5 pp -117.45 81.15 13.68 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.61 0.719 . . . . 0.0 111.105 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.187 0 C-N-CA 122.664 2.242 . . . . 0.0 112.336 179.858 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.9 t -76.3 -176.78 3.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -108.62 -74.4 0.66 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.49 58.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -95.36 26.63 3.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.832 0.349 . . . . 0.0 110.829 -179.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -107.45 135.87 48.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.861 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.84 66.31 1.13 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 171.5 14.31 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -77.3 160.51 28.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -133.78 -0.04 3.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.538 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 3.7 t -99.17 178.85 4.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.906 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -129.09 76.32 1.71 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.538 ' CD1' ' HB3' ' A' ' 11' ' ' SER . 56.1 m95 -91.02 114.85 27.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.35 -161.67 5.67 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.525 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.454 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.462 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.454 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 47.24 -142.98 5.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.41 ' C ' ' HB2' ' A' ' 88' ' ' HIS . . . 81.86 149.94 7.73 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.464 ' N ' ' H ' ' A' ' 88' ' ' HIS . 14.0 mt-30 62.86 54.87 2.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.888 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -124.4 -21.47 4.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 t -157.07 137.77 4.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.13 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 38.5 mt -117.54 -21.11 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.084 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.63 159.4 30.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.5 mmt85 -66.22 85.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 36.1 mt -105.95 -59.57 1.76 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.11 171.96 11.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.93 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.93 -70.61 0.79 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.2 176.56 14.59 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -103.57 -6.82 21.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.871 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -138.26 173.32 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.928 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -60.1 173.45 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 pttp -147.37 160.02 43.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 145.05 176.09 18.76 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.456 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 37.2 mm -79.67 107.93 12.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.413 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.465 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.44 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.44 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.46 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.454 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.457 ' O ' ' CG2' ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.457 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.404 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.446 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.418 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.456 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.451 HD21 ' CB ' ' A' ' 94' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.47 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.593 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.456 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.451 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.6 m-20 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.446 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t -74.54 127.82 34.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.516 HD21 ' CD2' ' A' ' 13' ' ' TRP . 9.5 mt -66.82 158.05 31.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -38.03 101.99 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.4 t -163.07 179.27 7.63 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.84 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 39.9 p -114.89 144.24 31.63 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.612 0.72 . . . . 0.0 111.129 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.81 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.736 2.29 . . . . 0.0 112.328 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.554 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 21.7 ttt180 -138.01 166.72 23.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.554 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 14.1 t -104.3 167.85 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 1.4 pp -117.15 159.3 41.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.618 0.723 . . . . 0.0 111.127 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.381 179.878 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m -154.04 149.02 26.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.852 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 74.9 p -139.34 -176.15 4.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.91 -172.26 13.88 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.514 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.436 ' O ' ' N ' ' A' ' 7' ' ' GLY . 46.1 m -107.73 -37.02 6.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.893 0.377 . . . . 0.0 110.899 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -39.23 95.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -134.92 -173.07 12.95 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 2.86 3.12 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.741 2.294 . . . . 0.0 112.374 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -71.45 79.77 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.84 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -82.16 -23.14 35.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.557 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 53.2 m -47.33 175.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -123.67 63.39 1.04 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.852 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.557 ' CD1' ' HB3' ' A' ' 11' ' ' SER . 51.0 m95 -88.46 118.04 27.82 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.958 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.55 -161.57 15.42 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.435 HG21 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.413 HG21 ' C ' ' A' ' 18' ' ' ILE . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.451 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.451 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.461 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.567 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.653 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.461 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.47 -143.85 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.03 -40.55 2.28 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.473 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.532 ' N ' HE21 ' A' ' 37' ' ' GLN . 0.0 OUTLIER -39.75 151.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.926 -179.929 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -138.18 -179.06 5.56 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.133 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -145.22 153.23 14.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 70.4 mt -78.37 -47.8 23.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.093 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -45.71 151.55 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.12 93.36 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -93.89 -175.38 3.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 pptp? -86.19 -2.28 58.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -80.03 165.45 22.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 132.81 74.5 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.513 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -131.57 -2.73 3.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.801 0.334 . . . . 0.0 110.847 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -98.98 177.06 5.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.523 ' HB3' ' CE1' ' A' ' 53' ' ' PHE . 3.8 mm? -76.32 108.77 9.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.913 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.12 -19.48 23.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.91 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.83 178.76 11.53 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.519 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 21.1 mm -91.92 140.24 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.523 ' CE1' ' HB3' ' A' ' 49' ' ' LEU . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.461 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.438 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.438 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.452 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.459 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.41 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.41 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.4 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.401 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.49 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.467 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.457 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.494 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.408 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.653 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.445 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.457 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 75.6 m-20 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.547 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.435 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CG ' HD12 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' SER . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -80.23 128.66 33.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.514 HD21 ' CG ' ' A' ' 13' ' ' TRP . 8.6 mt -64.71 159.68 21.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.898 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -45.24 100.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.867 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.0 p -169.72 176.41 4.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.863 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 72.8 p -131.59 144.15 52.13 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.57 0.7 . . . . 0.0 111.136 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.84 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.694 2.263 . . . . 0.0 112.374 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.7 -174.88 3.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 2.1 t -110.69 170.46 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 2.1 pt -113.63 158.64 38.23 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.647 0.736 . . . . 0.0 111.119 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.682 2.255 . . . . 0.0 112.358 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -135.37 -178.53 5.15 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.812 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -135.52 140.58 44.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.865 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.66 129.88 3.14 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 p -126.58 132.27 51.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.5 p -136.03 160.09 39.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.836 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.16 72.71 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 176.25 7.02 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.692 2.261 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 46.5 54.02 9.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.883 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' SER . 32.5 t80 -162.14 157.69 23.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 10' ' ' PHE . 2.4 p 35.22 50.68 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -86.08 94.55 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.833 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.447 ' CG ' HD23 ' A' ' 109' ' ' LEU . 76.5 m95 -85.13 110.92 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.946 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -69.7 -163.29 3.8 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.517 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.417 ' C ' HG22 ' A' ' 19' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.417 HG22 ' C ' ' A' ' 18' ' ' ILE . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.568 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.465 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.463 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.573 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 35' ' ' GLY . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 63.33 -170.89 14.74 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 38' ' ' THR . . . 170.52 -177.5 43.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.494 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' GLY . 13.9 pt20 34.22 35.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.922 0.392 . . . . 0.0 110.967 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 36' ' ' GLY . 5.4 p -44.65 169.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 t -96.89 147.5 6.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.105 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.429 ' CD1' ' N ' ' A' ' 40' ' ' ILE . 0.2 OUTLIER -130.97 90.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.123 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.448 ' HG2' ' N ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -178.68 147.22 0.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.895 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.448 ' N ' ' HG2' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -69.94 80.67 0.47 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.416 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 0.1 OUTLIER -99.51 141.82 31.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.416 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 37.7 mtpt -116.96 -43.89 2.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.949 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -81.41 93.18 6.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 143.88 80.54 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -86.28 114.82 23.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.415 ' HG3' ' N ' ' A' ' 49' ' ' LEU . 1.1 pt-20 -155.96 175.54 13.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD1' ' CZ ' ' A' ' 53' ' ' PHE . 0.3 OUTLIER -60.57 92.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.934 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.85 134.59 48.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.918 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.419 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 110.76 175.94 20.51 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 33.3 mm -93.28 156.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' A' ' 49' ' ' LEU . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.435 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.452 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.463 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.437 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.573 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.493 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.543 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.467 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.42 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.437 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.433 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.454 ' CD2' ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.474 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.494 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.437 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.474 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.494 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.8 m-20 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.437 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.515 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.467 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.42 ' CG ' HD13 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t -71.47 125.43 27.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.447 HD23 ' CG ' ' A' ' 13' ' ' TRP . 10.9 mt -63.54 175.8 0.98 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.874 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 16.7 t -40.96 -74.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.429 ' O ' ' CG2' ' A' ' 112' ' ' THR . 59.7 p -52.89 170.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' THR . . . . . 0.429 ' CG2' ' O ' ' A' ' 111' ' ' SER . 49.6 p -159.71 145.83 12.01 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.614 0.721 . . . . 0.0 111.129 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . 0.414 ' CG ' ' HG3' ' A' ' 70' ' ' LYS . 54.1 Cg_endo -69.79 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.551 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 4.2 ttm-85 -116.11 166.13 12.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.551 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 11.3 p -126.54 157.49 37.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 2.0 pt -79.33 156.25 76.27 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.635 0.731 . . . . 0.0 111.124 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--N 1.342 0.194 0 C-N-CA 122.669 2.246 . . . . 0.0 112.377 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -128.03 56.39 1.6 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.354 . . . . 0.0 110.846 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.4 t -93.25 145.48 24.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.68 157.73 28.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.485 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.5 t -125.19 -43.42 1.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.862 0.363 . . . . 0.0 110.881 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.6 p 42.24 29.49 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.911 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.95 176.35 1.83 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.505 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -164.53 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.651 2.234 . . . . 0.0 112.303 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -113.96 -174.64 2.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.931 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' O ' ' C ' ' A' ' 11' ' ' SER . 59.9 t80 -119.51 -39.36 2.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.47 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 33.0 p -34.55 147.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.5 t-80 -118.97 69.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.836 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.519 ' CG ' HD21 ' A' ' 109' ' ' LEU . 36.8 m95 -74.09 126.11 29.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.925 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.25 -163.31 30.5 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.448 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 HD13 ' CD1' ' A' ' 69' ' ' LEU . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.599 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.522 ' H ' ' ND2' ' A' ' 100' ' ' ASN . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.456 ' CD2' HG21 ' A' ' 21' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.468 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.459 ' N ' HG23 ' A' ' 34' ' ' VAL . . . 68.5 -159.73 51.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.436 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 148.26 -9.28 1.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.443 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.436 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.09 137.51 0.14 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 110.975 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.555 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.4 m -56.09 160.73 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.555 ' N ' ' CG2' ' A' ' 38' ' ' THR . 0.2 OUTLIER -130.99 157.58 43.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.525 ' N ' ' CG2' ' A' ' 39' ' ' VAL . 23.2 mm -149.54 147.38 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.452 ' C ' ' O ' ' A' ' 40' ' ' ILE . 0.0 OUTLIER -34.36 -44.11 0.18 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' CG ' ' O ' ' A' ' 41' ' ' LYS . 24.0 mtm180 -166.79 -175.54 3.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 59.93 45.27 12.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 9.1 tptp -115.69 131.6 56.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.71 171.79 9.11 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 169.71 118.83 0.47 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.445 ' CD ' ' O ' ' A' ' 47' ' ' GLU . 3.1 tp10 -73.02 -12.23 60.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.849 0.357 . . . . 0.0 110.898 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -126.6 -175.45 3.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.515 ' CD2' ' C ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -71.69 168.23 18.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.45 137.85 51.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.591 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 137.72 159.13 8.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.438 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.435 ' O ' ' N ' ' A' ' 75' ' ' ILE . 27.9 mm -81.25 138.68 19.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.415 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.47 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.437 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.437 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.447 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.44 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.568 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.454 ' O ' ' N ' ' A' ' 68' ' ' ALA . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.464 ' CD1' HD13 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.441 ' CE ' ' O ' ' A' ' 69' ' ' LEU . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.415 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.422 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.453 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.429 HG12 ' CB ' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.464 ' CD2' ' HA ' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.433 ' HB1' ' CB ' ' A' ' 90' ' ' GLU . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.45 ' NE2' ' O ' ' A' ' 33' ' ' ILE . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.433 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 83' ' ' LEU . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.47 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.429 ' CB ' HG12 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.453 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.599 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.2 t-20 -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.535 ' CZ ' HD12 ' A' ' 31' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.422 ' CG ' HD12 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p -76.1 125.62 29.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.519 HD21 ' CG ' ' A' ' 13' ' ' TRP . 11.9 mt -51.77 -176.67 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.7 t -74.63 61.26 0.95 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.409 ' O ' ' CG2' ' A' ' 112' ' ' THR . 11.6 p -176.79 159.62 1.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.843 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' THR . . . . . 0.409 ' CG2' ' O ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -172.17 144.37 1.42 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.6 0.714 . . . . 0.0 111.144 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -163.79 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.64 2.226 . . . . 0.0 112.361 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.468 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 5.3 tpm_? -114.81 149.66 36.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 116' ' ' ILE . 60.6 t -106.44 164.88 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.485 ' N ' ' CG1' ' A' ' 115' ' ' VAL . 4.2 pt -62.73 156.3 65.55 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.588 0.709 . . . . 0.0 111.156 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.641 2.227 . . . . 0.0 112.339 179.891 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.5 m -144.28 150.72 38.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.871 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -166.2 175.4 8.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.7 159.34 29.95 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.464 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.5 p -150.25 169.53 21.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.874 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -151.77 169.35 22.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.795 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.75 173.9 30.97 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -163.82 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.677 2.251 . . . . 0.0 112.348 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -174.17 152.47 1.85 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -124.58 -54.82 1.65 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.581 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.2 m -50.48 -177.86 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -119.3 51.67 1.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.871 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.581 ' CD1' ' CB ' ' A' ' 11' ' ' SER . 57.2 m95 -74.04 116.04 14.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -74.34 -162.74 9.06 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.487 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.413 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.41 HG21 ' C ' ' A' ' 18' ' ' ILE . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.447 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.45 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.579 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 35.84 -127.11 0.85 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.423 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 90.66 112.73 1.62 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.539 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.427 ' HG2' ' N ' ' A' ' 38' ' ' THR . 7.0 tt0 -163.64 158.92 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.865 0.364 . . . . 0.0 110.927 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.427 ' N ' ' HG2' ' A' ' 37' ' ' GLN . 1.6 t -66.46 161.09 23.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.16 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -60.51 -174.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.082 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.473 ' CG1' ' O ' ' A' ' 39' ' ' VAL . 32.6 mt -159.38 148.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -96.01 -70.34 0.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.915 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -135.15 1.24 2.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.861 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.599 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -94.16 41.35 1.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.93 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 17.9 pttm -97.34 162.98 13.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 22.8 m120 -120.35 20.94 11.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.02 178.62 27.8 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -123.74 125.63 45.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.816 0.341 . . . . 0.0 110.909 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -169.43 162.29 10.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.915 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -41.59 133.06 2.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 ptpt -112.72 -23.57 10.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.22 164.75 1.42 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 9.1 mm -87.78 108.27 18.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.439 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.435 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.454 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.45 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.462 ' CD1' HD13 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 53' ' ' PHE . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.452 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.454 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.455 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.434 HD21 ' CB ' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.407 ' HA ' ' N ' ' A' ' 37' ' ' GLN . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.488 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.455 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.488 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.4 m-20 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.413 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.654 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.452 ' CG ' HD13 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t -80.35 129.1 34.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.515 HD23 ' CG ' ' A' ' 13' ' ' TRP . 7.8 mt -66.03 159.68 25.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 25.2 p -51.44 102.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.837 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.8 t -156.03 170.57 21.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.0 p -99.77 150.88 37.22 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.579 0.704 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -163.86 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.687 2.258 . . . . 0.0 112.34 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.455 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 4.3 tpm_? -130.54 146.1 52.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.875 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' A' ' 116' ' ' ILE . 39.9 t -74.48 160.76 5.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.528 ' N ' ' CG1' ' A' ' 115' ' ' VAL . 44.6 mt -70.5 138.62 86.29 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.598 0.713 . . . . 0.0 111.164 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.175 0 C-N-CA 122.726 2.284 . . . . 0.0 112.359 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.5 m -81.07 129.29 34.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.368 . . . . 0.0 110.871 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.4 t -146.77 142.72 28.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.864 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.94 107.34 0.52 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.487 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.8 m -112.74 178.95 4.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 110.882 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 7' ' ' GLY . 54.2 p -114.41 -65.35 1.2 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' OG ' ' A' ' 6' ' ' SER . . . 154.86 150.7 5.61 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.483 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.75 2.3 . . . . 0.0 112.329 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -120.7 133.55 55.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.853 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.28 60.61 2.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.556 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.1 p -93.43 -175.31 3.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.0 m80 -125.97 66.98 1.19 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.811 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 11' ' ' SER . 57.7 m95 -93.66 113.51 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.29 -159.3 8.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.53 ' NH1' ' N ' ' A' ' 108' ' ' SER . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' C ' HG22 ' A' ' 19' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.418 HG22 ' C ' ' A' ' 18' ' ' ILE . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.593 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.464 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.456 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 66.13 -171.48 27.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.75 -36.69 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.466 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -65.95 130.74 44.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.87 0.367 . . . . 0.0 110.917 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 m -135.65 174.49 10.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.57 151.35 14.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.158 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 76.2 mt -118.47 -27.0 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.4 ttpm? -70.53 143.41 51.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 56.87 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.46 ' N ' HD21 ' A' ' 43' ' ' LEU . 0.6 OUTLIER -106.18 -7.71 17.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -145.2 113.93 6.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -105.09 116.11 31.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 136.16 76.84 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.442 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -146.76 142.56 27.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 110.859 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -47.39 172.91 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.91 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.428 ' CD2' ' CZ ' ' A' ' 53' ' ' PHE . 11.2 mp -44.51 133.63 5.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.474 ' NZ ' ' ND2' ' A' ' 85' ' ' ASN . 0.1 OUTLIER -128.72 -29.98 2.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.952 179.82 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -56.42 -161.22 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.515 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.449 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 31.1 mm -109.48 126.83 66.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CZ ' ' CD2' ' A' ' 49' ' ' LEU . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.47 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.419 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 68' ' ' ALA . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.468 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.447 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.437 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.456 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.46 HD21 ' CB ' ' A' ' 94' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . 0.474 ' ND2' ' NZ ' ' A' ' 50' ' ' LYS . 11.0 m120 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.449 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.595 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.423 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.45 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.46 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.45 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.418 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 12.7 t-20 -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.561 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.593 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.489 ' CG2' ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.437 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t -84.17 131.1 34.8 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.505 HD21 ' CG ' ' A' ' 13' ' ' TRP . 8.9 mt -61.64 160.46 11.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 45.4 p -57.7 95.1 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.5 t -125.48 16.24 8.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.86 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 55.07 163.46 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.609 0.719 . . . . 0.0 111.127 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -171.05 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.666 2.244 . . . . 0.0 112.318 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 0.6 OUTLIER -140.89 150.08 42.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.436 ' N ' ' HG2' ' A' ' 114' ' ' ARG . 5.5 p -115.0 143.61 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.4 pt -76.39 156.84 83.28 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.643 0.735 . . . . 0.0 111.14 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.657 2.238 . . . . 0.0 112.38 179.878 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.7 t -121.3 -9.35 9.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.859 0.361 . . . . 0.0 110.831 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -94.98 121.26 36.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.894 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.46 79.05 0.37 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.477 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.7 t -134.12 63.32 1.63 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.924 0.392 . . . . 0.0 110.878 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.8 p -66.52 167.31 11.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.877 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 171.32 45.61 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.47 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -46.68 1.12 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.54 160.73 15.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.589 ' CZ ' ' O ' ' A' ' 47' ' ' GLU . 5.4 t80 -175.11 -177.36 1.05 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PHE . 35.9 p -35.24 150.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.855 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -111.18 75.32 0.91 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.801 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.518 ' CG ' HD21 ' A' ' 109' ' ' LEU . 77.2 m95 -87.62 114.67 24.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.963 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.18 -162.96 10.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.463 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.683 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.448 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.445 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.547 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.462 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 46.68 -145.38 3.95 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 84.9 -22.54 9.19 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -34.37 -70.52 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 0.0 110.91 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.2 p -128.05 179.14 5.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -145.58 175.2 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.118 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.8 mt -150.94 140.63 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' CD ' ' O ' ' A' ' 41' ' ' LYS . 2.4 tmtp? -77.69 51.33 0.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -107.95 56.71 0.63 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.937 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.521 ' C ' ' CD1' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.05 19.51 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 20.81 13.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -171.82 158.49 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.07 139.52 6.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.589 ' O ' ' CZ ' ' A' ' 10' ' ' PHE . 3.7 mm-40 -114.32 -8.06 12.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.873 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 49' ' ' LEU . 29.8 mp0 -103.37 81.92 1.99 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.855 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.579 ' N ' ' CD1' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -34.55 128.78 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.925 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.36 179.56 7.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.881 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.594 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 138.9 157.63 7.4 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.477 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 42.9 mm -72.87 100.9 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.462 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.445 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.445 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.454 HD11 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.456 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.547 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.43 ' O ' ' N ' ' A' ' 68' ' ' ALA . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.407 ' CD2' HG23 ' A' ' 106' ' ' VAL . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.45 ' CE ' HD23 ' A' ' 49' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.434 ' CD2' ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.442 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.443 HG11 ' CB ' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.44 HD21 ' CB ' ' A' ' 94' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.454 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.596 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.443 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.6 m-80 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.442 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.566 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.683 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t -73.24 131.4 41.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.518 HD21 ' CG ' ' A' ' 13' ' ' TRP . 12.2 mt -68.38 166.45 16.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 m -56.02 87.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 109' ' ' LEU . 8.3 t -151.45 -178.6 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.859 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 52.5 p -125.11 144.1 46.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.583 0.706 . . . . 0.0 111.15 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.454 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 15.8 ttm-85 -149.45 150.39 32.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.454 ' N ' ' HG2' ' A' ' 114' ' ' ARG . 1.6 t -92.65 179.69 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.472 ' CG2' ' HD2' ' A' ' 117' ' ' PRO . 38.7 mt -85.21 138.64 36.56 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.621 0.724 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.364 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 63.6 52.78 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.943 0.401 . . . . 0.0 110.91 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.3 t -64.43 122.84 17.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -41.15 152.76 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.8 t -107.23 -4.81 18.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.813 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -92.69 135.76 33.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.24 178.19 34.2 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.438 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -163.89 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -113.95 177.46 4.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -175.28 -177.35 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.436 ' CB ' HD21 ' A' ' 109' ' ' LEU . 0.9 OUTLIER -39.92 160.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.889 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.2 m80 -110.04 84.93 2.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.518 ' CG ' HD22 ' A' ' 109' ' ' LEU . 55.0 m95 -81.0 118.06 22.15 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.38 -163.55 16.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.424 HG22 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.411 HG21 ' C ' ' A' ' 18' ' ' ILE . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.651 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.457 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.456 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.439 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.91 -127.68 4.16 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.436 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 86.02 -46.25 3.59 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.442 ' N ' ' HB2' ' A' ' 88' ' ' HIS . 16.7 tt0 -42.09 140.72 1.04 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.881 0.372 . . . . 0.0 110.913 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -44.64 158.4 0.05 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.446 ' C ' ' CD1' ' A' ' 40' ' ' ILE . 0.2 OUTLIER -168.87 151.84 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.168 179.9 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.559 ' CD1' ' N ' ' A' ' 40' ' ' ILE . 0.3 OUTLIER -148.86 135.46 12.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.145 179.948 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -139.94 143.22 36.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.904 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.0 ptt-85 -101.32 4.96 42.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.874 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 7.8 mp -69.52 155.8 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -127.66 10.68 6.64 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.902 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.447 ' O ' ' C ' ' A' ' 46' ' ' GLY . 15.6 t-20 -123.26 -55.45 1.76 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.905 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 45' ' ' ASN . . . -34.49 112.58 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 48' ' ' GLU . 12.0 tp10 -97.57 113.85 25.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.434 ' CG ' ' O ' ' A' ' 47' ' ' GLU . 62.8 mt-10 -161.11 173.99 14.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD2' ' CZ ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -122.41 154.79 37.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.923 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.87 -15.49 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.864 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . -41.81 164.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 9.0 mm -76.29 128.92 37.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.603 ' CZ ' ' CD2' ' A' ' 49' ' ' LEU . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.438 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.438 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.462 HD13 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.456 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.444 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.444 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.422 ' CD2' HG23 ' A' ' 106' ' ' VAL . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.412 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.422 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.485 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.461 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.441 HD23 ' CB ' ' A' ' 94' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . 0.443 ' N ' HD21 ' A' ' 85' ' ' ASN . 0.9 OUTLIER -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.429 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.429 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.447 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.443 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.447 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.4 m-20 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.4 ' CB ' HG11 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.4 HG11 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.424 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.651 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 69' ' ' LEU . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.422 ' CG ' HD13 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -74.58 129.64 38.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 13' ' ' TRP . 11.5 mt -60.63 178.62 0.21 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.0 t -52.68 -17.17 1.18 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.7 t -61.11 -174.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 66.8 p -138.4 144.08 41.27 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.55 0.69 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.486 ' NE ' ' H ' ' A' ' 115' ' ' VAL . 0.0 OUTLIER -121.3 163.43 18.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.486 ' H ' ' NE ' ' A' ' 114' ' ' ARG . 21.0 t -90.72 166.36 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.464 ' CG2' ' HD2' ' A' ' 117' ' ' PRO . 4.7 mp -62.17 138.63 96.05 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.617 0.722 . . . . 0.0 111.12 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.464 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.32 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -163.21 112.21 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.863 0.363 . . . . 0.0 110.842 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.2 p -62.8 159.46 16.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.847 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.7 83.38 0.75 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.474 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.3 p -69.98 178.92 2.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.0 m -98.05 -16.03 19.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 51.52 -164.73 1.08 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 159.11 54.63 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.657 2.238 . . . . 0.0 112.383 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 44.4 m-20 -78.16 126.24 30.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 68.1 m-85 -80.11 -178.01 6.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.548 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.9 p -34.56 150.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.91 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -126.69 74.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.548 ' CD1' ' HB2' ' A' ' 11' ' ' SER . 67.9 m95 -84.73 112.11 20.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.904 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.47 -161.42 5.66 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.407 ' C ' HG23 ' A' ' 19' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.407 HG23 ' C ' ' A' ' 18' ' ' ILE . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.617 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.569 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.444 ' HG2' ' CG2' ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.447 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.51 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.593 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.463 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.66 -129.41 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 155.0 -82.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.463 ' HB3' ' CB ' ' A' ' 87' ' ' SER . 4.3 tt0 -149.78 114.99 5.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 110.892 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.4 t -102.36 -176.87 3.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.42 ' C ' HG13 ' A' ' 40' ' ' ILE . 46.5 t -107.66 92.32 2.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.114 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.434 HG23 ' N ' ' A' ' 41' ' ' LYS . 77.1 mt -154.53 135.99 5.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 40' ' ' ILE . 2.8 ttpm? -37.01 145.49 0.05 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.937 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -79.58 50.85 1.18 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.889 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 12.4 tp -100.34 134.63 43.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.93 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -61.31 138.43 58.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.428 ' C ' ' OD1' ' A' ' 45' ' ' ASN . 26.9 t-20 -95.46 -72.49 0.62 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 163.12 -91.45 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -78.91 -6.65 56.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.787 0.327 . . . . 0.0 110.893 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -123.54 171.77 9.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' N ' ' CD1' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -161.91 158.9 26.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.2 tppp? -84.73 135.92 33.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 161.62 175.4 32.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.408 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 41.5 mm -90.06 125.8 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.463 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.464 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.51 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.402 ' C ' ' N ' ' A' ' 68' ' ' ALA . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.402 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.465 ' CD1' HD13 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.446 ' CB ' ' HG3' ' A' ' 113' ' ' PRO . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.407 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.407 ' CD2' ' HE3' ' A' ' 74' ' ' LYS . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.485 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.475 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.45 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 57.9 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.463 ' CB ' ' HB3' ' A' ' 37' ' ' GLN . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.457 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.452 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.45 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.457 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.7 m-80 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.459 ' CB ' HG23 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.512 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.459 HG23 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.617 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.406 ' CG ' HD13 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -73.12 133.07 44.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.494 HD21 ' CG ' ' A' ' 13' ' ' TRP . 12.4 mt -69.45 168.62 14.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.954 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 47.1 t -38.65 -59.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.889 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.9 t -73.76 173.53 9.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 25.0 p -151.62 145.21 17.61 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.573 0.702 . . . . 0.0 111.115 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . 0.446 ' HG3' ' CB ' ' A' ' 70' ' ' LYS . 53.5 Cg_endo -69.73 -168.3 0.27 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.697 2.265 . . . . 0.0 112.35 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.461 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 13.3 tpp180 -144.87 156.55 44.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.461 ' N ' ' HG3' ' A' ' 114' ' ' ARG . 47.8 t -150.2 148.6 15.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.48 ' C ' ' CD1' ' A' ' 116' ' ' ILE . 0.9 OUTLIER -49.11 151.28 2.44 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.591 0.71 . . . . 0.0 111.121 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.413 ' C ' HD13 ' A' ' 116' ' ' ILE . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.674 2.25 . . . . 0.0 112.336 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -141.71 166.91 23.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -158.67 117.18 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.08 162.83 23.01 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.497 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -160.52 160.06 31.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.9 t -154.29 -175.57 5.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.883 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.88 83.41 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -164.6 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.705 2.27 . . . . 0.0 112.353 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -140.45 -175.25 4.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.888 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -121.73 -64.42 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.563 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 21.5 p -40.4 161.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.841 -179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 20.0 t60 -120.79 68.55 0.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.828 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.563 ' CD1' ' HB2' ' A' ' 11' ' ' SER . 55.4 m95 -84.93 118.44 24.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.83 -163.72 18.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.409 ' C ' HG23 ' A' ' 19' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.409 HG23 ' C ' ' A' ' 18' ' ' ILE . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.592 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.569 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.451 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.455 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.566 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.445 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.97 -145.17 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.96 100.31 2.31 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.424 ' C ' ' HB2' ' A' ' 87' ' ' SER . 71.6 mt-30 -130.21 145.78 51.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.912 0.387 . . . . 0.0 110.852 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.1 m -105.47 109.31 21.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.13 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -175.01 149.7 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 60.8 mt -152.22 110.96 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.151 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.0 mtpt -144.73 129.59 18.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.913 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 49.5 mtt180 -81.69 68.0 7.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.906 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 42.7 mt -92.58 -71.66 0.64 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -135.52 124.65 24.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -57.4 151.18 16.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.77 133.34 5.53 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -171.54 142.29 1.61 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -53.58 176.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.868 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -47.1 125.94 8.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -116.67 -20.82 9.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.864 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.48 -175.04 3.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.484 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.498 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 27.3 mm -102.81 127.57 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.402 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.441 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.45 HD11 ' N ' ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.459 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.435 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.566 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 68' ' ' ALA . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.411 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.402 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.447 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.459 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.451 HG13 ' CB ' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.435 HD22 ' CB ' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.498 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.453 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HB2' ' N ' ' A' ' 87' ' ' SER . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.458 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.505 ' CG1' ' CE ' ' A' ' 96' ' ' LYS . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.451 ' CB ' HG13 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.487 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.507 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.451 ' CG2' ' HG3' ' A' ' 23' ' ' ARG . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.592 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.447 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t -81.88 138.35 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.519 HD22 ' CG ' ' A' ' 13' ' ' TRP . 12.1 mt -67.69 172.27 5.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.932 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 24.3 t -45.84 -21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.8 t -52.11 -176.48 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.844 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 76.6 p -145.25 148.59 38.41 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.537 0.684 . . . . 0.0 111.168 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 -163.84 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -130.15 -174.79 3.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.845 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 1.5 p -122.23 152.25 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -105.2 159.96 27.63 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.622 0.725 . . . . 0.0 111.13 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.673 2.248 . . . . 0.0 112.311 179.925 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.537 -0.225 . . . . 0.0 112.537 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -110.0 177.88 4.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.897 0.38 . . . . 0.0 110.864 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.4 p -154.8 161.47 41.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.837 -179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.3 -173.28 12.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 p -148.76 162.35 39.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.859 0.361 . . . . 0.0 110.862 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -112.14 -74.94 0.62 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.18 146.19 8.04 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.78 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -160.78 173.39 15.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 11.9 m-85 -83.16 -75.15 0.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PHE . 0.6 OUTLIER -34.85 151.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.853 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . 0.414 ' C ' HD23 ' A' ' 109' ' ' LEU . 11.3 t60 -132.83 95.37 3.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.524 ' CZ2' HD11 ' A' ' 109' ' ' LEU . 74.9 m95 -92.39 110.29 21.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.63 -163.23 4.7 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.462 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.41 ' C ' HG21 ' A' ' 19' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.41 HG21 ' C ' ' A' ' 18' ' ' ILE . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.599 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.47 ' CB ' HG11 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.47 HG11 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.55 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.623 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.73 -142.31 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.461 ' HA3' ' N ' ' A' ' 88' ' ' HIS . . . 115.33 77.83 0.73 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.51 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 tm0? -119.57 166.68 12.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 0.0 110.883 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 41.0 p -79.07 -179.19 6.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.192 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.39 132.09 14.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.435 ' CG2' ' N ' ' A' ' 41' ' ' LYS . 35.2 mt -93.62 164.52 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.435 ' N ' ' CG2' ' A' ' 40' ' ' ILE . 2.1 mmmp? -83.75 88.0 7.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.917 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.0 tpp180 -119.41 -27.24 5.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.891 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 31.6 mt 54.85 49.58 17.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.24 -39.5 3.87 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 46' ' ' GLY . 0.6 OUTLIER -59.91 161.57 6.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 45' ' ' ASN . . . 162.66 -33.36 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.23 7.3 14.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.779 0.323 . . . . 0.0 110.871 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -155.07 175.18 14.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.917 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.544 ' CD2' ' C ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -132.81 146.73 52.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.929 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.58 -177.61 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.489 ' CA ' ' O ' ' A' ' 84' ' ' GLN . . . 139.81 -123.63 2.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.439 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 33.3 mm -119.3 122.08 68.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.426 HG23 ' N ' ' A' ' 55' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.444 ' HB3' ' N ' ' A' ' 33' ' ' ILE . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.47 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.439 ' O ' ' N ' ' A' ' 68' ' ' ALA . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.5 ' HB2' ' CZ3' ' A' ' 13' ' ' TRP . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.458 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.45 HG11 ' CB ' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.429 HD21 ' CB ' ' A' ' 94' ' ' ALA . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.489 ' O ' ' CA ' ' A' ' 51' ' ' GLY . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.439 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.623 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.45 ' CB ' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.412 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.1 m-20 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.458 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.566 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.41 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.599 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -76.32 127.58 33.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.524 HD11 ' CZ2' ' A' ' 13' ' ' TRP . 9.5 mt -62.53 -178.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.3 p -34.55 150.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 67.4 m -37.9 156.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 6.8 p -157.74 144.26 13.02 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.607 0.718 . . . . 0.0 111.102 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 163.74 37.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.657 2.238 . . . . 0.0 112.4 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 16.6 ttm-85 -174.79 153.69 1.79 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.876 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.42 HG21 ' N ' ' A' ' 116' ' ' ILE . 13.4 p -145.71 166.51 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.47 ' CG2' ' HD2' ' A' ' 117' ' ' PRO . 0.9 OUTLIER -118.02 138.1 25.12 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.637 0.732 . . . . 0.0 111.086 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.175 0 C-N-CA 122.731 2.287 . . . . 0.0 112.349 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.6 m -64.5 144.22 57.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.92 0.391 . . . . 0.0 110.832 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 p -127.22 47.79 2.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.12 13.7 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t -168.73 165.38 11.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.89 0.376 . . . . 0.0 110.895 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -143.04 152.78 42.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.43 73.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.512 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.7 Cg_endo -69.76 2.45 3.52 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.677 2.251 . . . . 0.0 112.394 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 8' ' ' PRO . 8.1 m-80 -34.38 147.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -123.88 -19.8 5.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 32.4 m -49.14 179.24 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.917 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -125.11 62.5 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.857 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.555 ' CD1' ' HB3' ' A' ' 11' ' ' SER . 50.5 m95 -89.23 114.61 25.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.88 -160.68 5.65 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.423 ' C ' HG21 ' A' ' 19' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG21 ' C ' ' A' ' 18' ' ' ILE . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.443 HD23 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.593 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.61 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.06 -148.79 0.24 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.33 87.28 1.88 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.462 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -104.67 151.06 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 0.0 110.895 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.7 p -51.55 154.61 1.82 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -153.39 113.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.094 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.6 mt -104.96 -70.63 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.102 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' HE3' ' CD1' ' A' ' 43' ' ' LEU . 31.7 mtmt -106.75 171.3 7.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.884 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.403 ' HD3' ' N ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -101.18 35.56 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.41 ' CD1' ' HE3' ' A' ' 41' ' ' LYS . 41.5 mt -77.23 -58.38 3.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.55 93.11 6.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -138.55 172.24 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 104.13 78.29 1.24 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.06 175.33 8.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 0.0 110.908 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.45 ' O ' ' C ' ' A' ' 49' ' ' LEU . 17.5 mm-40 -43.89 167.87 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 48' ' ' GLU . 3.2 mm? -34.34 126.28 0.47 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.83 -15.16 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.916 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.39 -171.52 5.32 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.496 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 24.5 mm -98.63 133.55 40.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.473 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.485 ' O ' ' N ' ' A' ' 68' ' ' ALA . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.427 ' CD2' HG21 ' A' ' 106' ' ' VAL . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.409 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.492 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.462 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.455 HD21 ' CB ' ' A' ' 94' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.47 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.61 ' CD2' ' CD1' ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.428 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.447 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.473 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.455 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.447 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.473 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.1 m-20 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 19.3 t-20 -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.561 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.419 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 69' ' ' LEU . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.409 ' CG ' HD12 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m -81.62 117.76 22.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.515 HD22 ' CG ' ' A' ' 13' ' ' TRP . 10.2 mt -48.94 167.53 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.5 t -37.13 -29.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.487 ' N ' ' O ' ' A' ' 109' ' ' LEU . 45.2 t -41.56 163.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.8 p -127.25 149.22 69.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.558 0.694 . . . . 0.0 111.167 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.85 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.701 2.267 . . . . 0.0 112.327 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.463 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.3 tpp85 -137.52 158.0 45.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 114' ' ' ARG . 0.5 OUTLIER -92.0 -174.97 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.131 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.472 ' CG2' ' HD2' ' A' ' 117' ' ' PRO . 49.7 mt -101.47 138.67 19.96 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 0.0 111.117 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 54.5 Cg_endo . . . . . 0 C--O 1.231 0.143 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.483 -0.247 . . . . 0.0 112.483 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.3 m -155.38 177.81 10.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.4 p -93.17 89.47 6.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.85 -163.32 53.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.466 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 t -119.55 150.37 40.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.89 0.376 . . . . 0.0 110.865 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.9 t -95.14 159.16 15.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.82 146.25 16.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 9' ' ' ASN . 54.0 Cg_endo -69.76 -23.68 30.52 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.372 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 8' ' ' PRO . 31.6 m-80 -34.54 146.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -131.75 132.7 44.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.561 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 5.8 p -175.31 178.88 1.6 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -133.43 64.44 1.61 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.843 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.561 ' CD1' ' HB2' ' A' ' 11' ' ' SER . 60.1 m95 -88.77 111.46 22.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.18 -161.13 5.18 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.528 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.584 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.573 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.498 ' CG ' ' CG2' ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.458 ' CB ' HG12 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.458 HG12 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.452 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.603 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.447 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.421 ' O ' ' C ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . 35.35 -122.05 0.55 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.18 102.75 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -155.72 174.01 15.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.942 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.538 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.2 m -159.64 159.36 32.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.124 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.538 ' N ' ' CG2' ' A' ' 38' ' ' THR . 88.6 t -75.44 142.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.408 ' O ' ' C ' ' A' ' 41' ' ' LYS . 9.8 mt -105.99 -60.4 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 40' ' ' ILE . 34.7 ttpt -37.23 155.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.18 70.5 4.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.456 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 11.9 tp -135.57 155.08 51.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.456 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 6.5 mmpt? -87.78 114.51 24.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.878 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' ND2' ' OE2' ' A' ' 47' ' ' GLU . 6.2 t30 -175.06 168.36 3.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' C ' ' CD ' ' A' ' 47' ' ' GLU . . . -156.9 177.48 33.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.498 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.494 ' OE2' ' ND2' ' A' ' 45' ' ' ASN . 18.7 mp0 -153.03 165.25 36.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 0.0 110.892 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.442 ' O ' ' C ' ' A' ' 49' ' ' LEU . 4.4 mm-40 -101.58 172.65 6.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.893 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 48' ' ' GLU . 0.6 OUTLIER 34.46 49.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.9 -14.55 7.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.885 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.85 -145.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.515 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.497 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 30.6 mm -115.02 144.16 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.422 ' HB2' ' C ' ' A' ' 33' ' ' ILE . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.404 ' CD1' ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.479 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.468 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.448 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.467 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.451 HD23 ' CB ' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.497 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.446 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.452 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.454 ' CB ' HG12 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.452 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.7 m-20 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.448 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.527 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.498 ' CG2' ' CG ' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.584 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.45 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p -78.08 120.31 22.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.532 HD23 ' CD1' ' A' ' 13' ' ' TRP . 10.4 mt -49.83 173.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 109' ' ' LEU . 2.6 t -34.58 -74.37 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.5 m -109.47 -178.16 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -163.52 160.36 17.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.613 0.721 . . . . 0.0 111.116 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -173.4 0.71 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.696 2.264 . . . . 0.0 112.311 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.418 ' C ' HG23 ' A' ' 115' ' ' VAL . 19.3 ptt180 -143.28 177.55 8.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.418 HG23 ' C ' ' A' ' 114' ' ' ARG . 3.0 t -141.97 171.76 10.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.7 pt -47.74 150.84 1.72 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.582 0.706 . . . . 0.0 111.139 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.688 2.259 . . . . 0.0 112.344 179.876 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 1.4 t -78.52 -30.48 47.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.907 0.384 . . . . 0.0 110.88 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 22.7 p 35.86 39.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.87 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.56 97.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.8 p -89.98 75.55 7.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.895 0.379 . . . . 0.0 110.852 -179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.1 m 55.53 33.01 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.862 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.98 147.08 16.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 179.05 3.95 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.651 2.234 . . . . 0.0 112.384 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 36.3 t30 -86.36 179.82 6.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.9 t80 -166.75 152.51 8.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.537 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 51.6 m -40.72 160.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.3 t-80 -110.28 66.27 0.63 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.537 ' CD1' ' HB3' ' A' ' 11' ' ' SER . 70.6 m95 -84.94 109.14 17.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.923 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.21 -162.18 3.8 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.473 ' CD ' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.632 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.572 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.433 ' HG2' ' CG2' ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.5 m-80 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.452 HD22 ' CG2' ' A' ' 21' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.536 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.469 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 57.78 -150.31 31.78 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.422 ' O ' ' CG ' ' A' ' 37' ' ' GLN . . . 85.04 145.18 7.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.436 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.452 ' N ' ' H ' ' A' ' 88' ' ' HIS . 5.2 pt20 46.52 33.87 2.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.877 0.37 . . . . 0.0 110.931 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.1 p -102.83 113.8 27.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 82.2 t -130.24 117.1 38.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 4.5 mp -115.68 -64.31 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.088 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.47 175.3 9.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.409 ' HA ' ' NE ' ' A' ' 42' ' ' ARG . 7.9 tpm_? -54.92 98.41 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 19.4 mt -96.75 114.91 26.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.905 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 28.8 mmtp -76.94 170.03 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 33.1 p-10 -98.71 117.3 32.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.87 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.66 60.39 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 -150.27 176.75 10.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.805 0.336 . . . . 0.0 110.91 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -46.69 146.89 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.561 ' N ' ' CD1' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -37.53 129.91 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.938 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.484 ' CG ' ' N ' ' A' ' 51' ' ' GLY . 13.6 ttpt -115.06 163.09 16.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.484 ' N ' ' CG ' ' A' ' 50' ' ' LYS . . . 150.35 -161.75 29.04 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.491 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.435 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 42.5 mm -95.98 117.56 40.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.469 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.459 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.458 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.408 ' HD3' ' CD2' ' A' ' 76' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.43 HD13 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.427 HG12 ' CB ' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.458 HD23 ' CB ' ' A' ' 94' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.403 ' HB2' ' CA ' ' A' ' 37' ' ' GLN . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.6 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.446 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.446 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.492 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.458 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.446 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.492 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.9 m-80 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.489 ' CB ' ' CG1' ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.488 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.572 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.489 ' CG1' ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.473 ' CG2' ' CD ' ' A' ' 17' ' ' ARG . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.43 ' CG ' HD13 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t -74.9 131.5 40.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.516 HD22 ' CD2' ' A' ' 13' ' ' TRP . 8.7 mt -68.24 159.62 30.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -44.7 92.1 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.827 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.46 ' N ' ' O ' ' A' ' 109' ' ' LEU . 27.0 t -158.83 177.09 11.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.871 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 30.0 p -112.57 145.21 32.47 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.587 0.708 . . . . 0.0 111.149 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.711 2.274 . . . . 0.0 112.361 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -122.35 -174.32 2.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.845 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 1.9 t -106.32 164.96 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.469 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -119.49 158.66 48.51 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.62 0.724 . . . . 0.0 111.117 179.924 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.203 0 C-N-CA 122.685 2.256 . . . . 0.0 112.326 179.908 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -161.6 151.39 16.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.864 0.364 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.4 p -141.89 131.87 24.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.39 -101.31 2.43 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 t 45.52 45.52 10.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 110.877 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.0 t -70.33 -59.52 2.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.65 160.49 14.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.7 175.81 7.56 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.396 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -104.3 143.99 32.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -141.21 -175.11 4.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.524 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.8 m -48.93 178.64 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.848 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -116.34 55.83 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.524 ' CD1' ' CB ' ' A' ' 11' ' ' SER . 59.1 m95 -75.19 117.71 17.31 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.911 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -78.93 -161.6 20.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.495 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.443 HG22 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.443 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.642 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.45 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 28' ' ' SER . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.461 ' N ' HG22 ' A' ' 27' ' ' VAL . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.454 HD21 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.45 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.55 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 49.05 -134.65 22.74 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 95.85 96.27 1.77 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.438 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -152.84 -175.99 5.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.903 0.382 . . . . 0.0 110.89 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -46.55 173.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.144 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -129.58 140.83 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -118.68 -179.94 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.16 47.31 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.449 ' CG ' ' HG2' ' A' ' 44' ' ' LYS . 9.6 ttt180 -62.05 91.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.886 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.459 HD23 ' N ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -82.07 40.05 0.6 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.449 ' HG2' ' CG ' ' A' ' 42' ' ' ARG . 13.7 ptpt -130.65 -174.8 3.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.956 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 44' ' ' LYS . 26.2 m-80 -37.47 156.38 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -167.84 116.79 0.69 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.13 8.32 36.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.902 0.382 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -138.57 165.23 27.42 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.468 ' CD2' ' CZ ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -110.98 159.39 17.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.97 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.4 138.95 54.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 151.15 176.03 23.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 41.1 mm -86.4 124.05 40.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.468 ' CZ ' ' CD2' ' A' ' 49' ' ' LEU . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.441 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.461 HD13 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.45 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.443 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.471 ' O ' ' N ' ' A' ' 68' ' ' ALA . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.471 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.455 ' CD2' HG22 ' A' ' 106' ' ' VAL . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.416 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.488 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.461 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.454 HD21 ' CB ' ' A' ' 94' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.459 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.595 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.458 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.484 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.454 ' CB ' HD21 ' A' ' 83' ' ' LEU . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.484 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 68.8 m-20 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.412 ' O ' ' N ' ' A' ' 100' ' ' ASN . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.443 ' CG1' HG22 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.642 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 69' ' ' LEU . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.46 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.0 t -78.07 131.2 37.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.517 HD23 ' CD2' ' A' ' 13' ' ' TRP . 7.9 mt -66.34 159.78 26.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.5 t -44.71 101.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.834 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.9 p -151.67 -177.98 6.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.873 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.2 p -121.97 147.98 50.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.517 0.675 . . . . 0.0 111.175 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -163.8 0.12 Allowed 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.366 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.1 mtm180 -113.44 -174.41 2.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 1.9 t -87.4 177.74 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.142 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' N ' HD12 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -114.25 158.37 39.89 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.615 0.721 . . . . 0.0 111.143 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.14 0 C-N-CA 122.675 2.25 . . . . 0.0 112.366 179.868 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.6 t -94.78 9.83 37.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 0.0 110.853 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 m -133.49 148.49 51.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 165.45 77.27 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.425 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.9 p -140.88 178.9 7.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.916 0.388 . . . . 0.0 110.805 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.2 m -105.42 -176.1 2.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.842 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.71 82.85 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.515 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -50.72 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.695 2.263 . . . . 0.0 112.311 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.548 ' O ' ' CG ' ' A' ' 10' ' ' PHE . 41.8 t30 -95.6 112.77 24.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.866 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 9' ' ' ASN . 9.4 m-85 -174.24 166.51 4.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.7 m -47.4 175.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 9.1 m-70 -111.12 58.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.842 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.548 ' CD1' ' CB ' ' A' ' 11' ' ' SER . 67.4 m95 -80.44 114.28 19.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -76.09 -161.77 11.64 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.472 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.455 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.41 ' C ' HG22 ' A' ' 19' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.41 HG22 ' C ' ' A' ' 18' ' ' ILE . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.49 ' CD1' ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.553 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.442 ' CD ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 21' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.527 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.449 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.464 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.25 -132.86 2.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.35 92.75 1.81 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.463 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -156.74 172.7 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.919 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.405 ' CG2' ' HB3' ' A' ' 87' ' ' SER . 1.7 p -132.05 164.01 27.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.556 ' CG1' ' N ' ' A' ' 40' ' ' ILE . 0.3 OUTLIER -123.45 -168.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.104 179.895 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.556 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 14.8 mm -141.29 -47.12 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.149 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.8 mtpp -67.46 121.05 14.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.906 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 53.1 mmt-85 -81.29 -27.04 35.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.533 ' C ' ' CD1' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.52 13.24 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.931 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.5 tmtt? -133.67 125.25 28.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -144.66 160.5 41.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 47' ' ' GLU . . . -114.18 12.67 21.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 46' ' ' GLY . 20.5 pt-20 36.55 39.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.329 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -129.62 173.31 10.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.441 ' HB3' ' CZ ' ' A' ' 53' ' ' PHE . 3.3 mm? -59.0 118.09 5.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.972 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.407 ' C ' ' HD3' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -107.13 -18.11 13.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.02 -177.5 33.02 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 13.1 mm -93.17 152.38 3.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.48 ' CZ ' ' HG3' ' A' ' 74' ' ' LYS . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.464 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.462 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.527 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.406 ' C ' ' HG2' ' A' ' 70' ' ' LYS . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.406 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.48 ' HG3' ' CZ ' ' A' ' 53' ' ' PHE . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.463 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.462 ' CD2' ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.488 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.441 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.427 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.461 HD23 ' CB ' ' A' ' 94' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.456 ' HB2' ' CB ' ' A' ' 90' ' ' GLU . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.405 ' HB3' ' CG2' ' A' ' 38' ' ' THR . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.497 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.461 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.3 m-20 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.441 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.553 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.435 ' CG2' ' HG3' ' A' ' 23' ' ' ARG . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.49 ' CD2' ' CD1' ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.463 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t -79.45 125.37 29.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.518 HD21 ' CD2' ' A' ' 13' ' ' TRP . 8.6 mt -60.25 159.43 9.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 5.6 t -34.61 93.48 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 109' ' ' LEU . 4.9 p -79.9 -174.63 4.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.855 -179.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.8 160.67 52.49 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.59 0.71 . . . . 0.0 111.15 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 166.45 27.52 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.709 2.273 . . . . 0.0 112.393 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.42 165.03 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.404 HG13 ' N ' ' A' ' 116' ' ' ILE . 12.6 t -101.52 164.52 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.474 ' CG2' ' HD2' ' A' ' 117' ' ' PRO . 10.1 mm -78.63 138.7 58.47 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.568 0.699 . . . . 0.0 111.139 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . 0.474 ' HD2' ' CG2' ' A' ' 116' ' ' ILE . 53.6 Cg_endo . . . . . 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.355 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.1 p -146.28 148.92 32.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.861 0.362 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -72.47 175.47 6.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.75 -134.11 2.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.435 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -136.07 159.29 42.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.919 0.39 . . . . 0.0 110.861 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.1 m -137.08 168.07 20.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.06 74.24 1.11 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.432 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -38.88 7.26 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.404 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 53.52 52.35 13.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -119.8 -175.54 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.45 ' HB2' ' NE1' ' A' ' 13' ' ' TRP . 1.9 m -51.74 -174.8 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.851 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -121.27 81.98 1.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.846 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.513 ' CG ' HD23 ' A' ' 109' ' ' LEU . 54.7 m95 -87.07 112.97 22.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.894 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.31 -163.36 15.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.47 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.423 ' C ' HG22 ' A' ' 19' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG22 ' C ' ' A' ' 18' ' ' ILE . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.551 HD11 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.559 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.465 HD21 ' CG2' ' A' ' 21' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.463 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.458 HG12 ' CB ' ' A' ' 63' ' ' ALA . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.442 ' O ' ' NE2' ' A' ' 88' ' ' HIS . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 42.16 -156.65 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.494 ' O ' ' CG ' ' A' ' 37' ' ' GLN . . . 88.7 154.06 27.86 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.482 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.573 ' N ' ' H ' ' A' ' 88' ' ' HIS . 1.2 pt20 49.15 33.27 4.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.864 0.364 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -106.36 -12.51 15.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.471 ' CG1' ' N ' ' A' ' 40' ' ' ILE . 23.4 t -155.57 156.61 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.471 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 49.0 mt -109.36 -62.79 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 41.7 tttt -97.1 144.05 27.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.9 tpm_? -172.06 138.9 1.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.554 ' N ' ' CD2' ' A' ' 43' ' ' LEU . 0.3 OUTLIER -112.99 -177.41 3.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 20.3 mtmm -59.87 97.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.883 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -119.03 -24.37 6.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.23 169.52 35.03 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.518 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.04 29.31 7.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.787 0.327 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -56.43 -175.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.662 ' CB ' ' CZ ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -106.07 71.11 0.87 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.3 -12.37 15.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.73 -146.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.464 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 7.6 mm -99.03 107.51 20.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.662 ' CZ ' ' CB ' ' A' ' 49' ' ' LEU . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.436 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.443 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.443 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.451 ' N ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.481 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.46 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.4 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HB2' ' CD1' ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.5 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.466 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.423 HD12 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.491 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.459 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.457 HD23 ' CB ' ' A' ' 94' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.464 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.406 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.455 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.457 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.455 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.7 m-20 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.446 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.505 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.559 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.425 HG11 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.406 ' CG1' HG21 ' A' ' 18' ' ' ILE . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.466 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.423 ' CG ' HD12 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t -80.29 131.23 35.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.513 HD23 ' CG ' ' A' ' 13' ' ' TRP . 11.3 mt -62.31 165.88 5.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.96 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -34.52 -33.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.489 ' N ' ' O ' ' A' ' 109' ' ' LEU . 11.4 m -46.26 172.26 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.844 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 8.0 p -146.33 144.16 20.61 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.591 0.71 . . . . 0.0 111.167 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.721 2.281 . . . . 0.0 112.344 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.514 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 19.4 ttp180 -145.72 164.29 32.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.818 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.514 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 9.7 p -128.02 164.05 30.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.472 ' C ' ' CD1' ' A' ' 116' ' ' ILE . 1.2 pp -69.78 151.1 96.48 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 111.114 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.16 0 C-N-CA 122.721 2.281 . . . . 0.0 112.337 179.847 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.0 p -153.78 171.97 18.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.839 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.1 p -174.68 131.47 0.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.58 174.89 34.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -87.64 -71.83 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 m 62.4 54.83 2.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.828 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.544 ' N ' ' CD ' ' A' ' 8' ' ' PRO . . . -155.75 46.24 0.52 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.452 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 7' ' ' GLY . 53.8 Cg_endo -69.75 -13.57 34.87 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.625 2.217 . . . . 0.0 112.326 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.433 ' C ' ' O ' ' A' ' 8' ' ' PRO . 1.1 m120 -34.78 144.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.849 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.96 107.31 11.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.553 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 6.3 t -175.15 -174.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.11 77.15 1.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.849 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.553 ' CD1' ' HB3' ' A' ' 11' ' ' SER . 56.0 m95 -96.75 113.9 25.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -73.91 -159.6 6.18 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.409 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.42 ' C ' HG23 ' A' ' 19' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.42 HG23 ' C ' ' A' ' 18' ' ' ILE . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.635 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.564 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.465 ' NE ' ' HB2' ' A' ' 100' ' ' ASN . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.486 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.486 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' HG22 ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.575 ' CD1' ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.46 ' CG1' ' HA ' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 33.86 -143.56 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 126.87 -52.64 0.81 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.448 ' C ' ' O ' ' A' ' 36' ' ' GLY . 4.3 mm100 -34.16 113.65 0.18 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 9.6 t -59.62 179.63 0.11 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.5 155.67 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 77.3 mt -109.63 -53.57 5.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.419 ' C ' ' CG ' ' A' ' 42' ' ' ARG . 43.0 tttp -109.44 25.18 12.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.419 ' CG ' ' C ' ' A' ' 41' ' ' LYS . 6.8 ptm180 41.76 29.37 0.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.835 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 14.0 mt -72.53 -10.03 59.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 mmmm -94.63 -62.63 1.29 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -84.49 157.41 21.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.41 -75.73 0.83 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.503 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.08 -6.17 10.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.824 0.345 . . . . 0.0 110.88 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.4 mp0 -68.82 -177.46 1.0 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 5.2 mp -100.58 168.97 9.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.895 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -114.16 -28.23 7.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.915 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . -46.58 151.4 1.54 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.458 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.481 ' CD1' ' O ' ' A' ' 86' ' ' ALA . 13.4 mm -69.35 123.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.405 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.46 ' HA ' ' CG1' ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.472 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.47 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.405 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.433 ' HA ' ' CG1' ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.49 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.441 ' HB2' ' CB ' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.441 ' O ' ' CG1' ' A' ' 81' ' ' VAL . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.456 HD23 ' CB ' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.481 ' O ' ' CD1' ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' HIS . . . . . 0.593 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.451 ' O ' ' CD1' ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.456 ' CB ' HD23 ' A' ' 83' ' ' LEU . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.451 ' CD1' ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.5 m-20 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.441 ' CB ' ' HB2' ' A' ' 79' ' ' SER . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.486 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.564 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.635 ' CD1' ' CD1' ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.413 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' SER . . . . . 0.409 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t -77.45 119.4 21.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.532 ' CD2' ' CD2' ' A' ' 13' ' ' TRP . 9.0 mt -56.16 157.44 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.918 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 1.8 t -36.8 103.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.2 m -175.36 163.23 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 65.0 p -117.06 144.17 33.09 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.571 0.701 . . . . 0.0 111.129 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 -163.8 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.663 2.242 . . . . 0.0 112.376 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -124.53 -174.79 3.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 10.2 p -80.16 165.69 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.157 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.26 145.2 68.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.617 0.723 . . . . 0.0 111.149 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.39 179.865 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.329 0 CA-C-O 121.421 0.456 . . . . 0.0 112.475 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.717 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.518 HG21 ' HB1' ' A' ' 68' ' ' ALA . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.909 HD11 HD11 ' A' ' 69' ' ' LEU . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.428 ' CG ' HD22 ' A' ' 100' ' ' ASN . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.548 ' HB2' HG13 ' A' ' 27' ' ' VAL . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.548 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.41 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.651 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.473 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 21' ' ' ILE . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.473 HD11 HG23 ' A' ' 92' ' ' VAL . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 1.008 HD11 ' O ' ' A' ' 86' ' ' ALA . 8.5 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.618 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.634 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.518 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.909 HD11 HD11 ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.5 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.535 ' HE3' HD23 ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.731 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.844 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.682 HD22 ' HA ' ' A' ' 91' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 1.008 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.42 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.715 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.473 HG23 HD11 ' A' ' 33' ' ' ILE . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.844 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.715 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.535 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.44 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.717 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.831 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.417 0.454 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.512 HG23 ' CG1' ' A' ' 103' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.409 HG21 ' HB1' ' A' ' 68' ' ' ALA . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.856 HD12 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.94 HD11 HG11 ' A' ' 102' ' ' VAL . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.818 HD11 HD13 ' A' ' 21' ' ' ILE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.888 HD11 HG23 ' A' ' 92' ' ' VAL . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.897 HD11 ' O ' ' A' ' 86' ' ' ALA . 29.4 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.542 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.432 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.432 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.711 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.559 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.693 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.512 ' HA ' HG22 ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.987 ' HA ' HG12 ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.401 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.538 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.814 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.546 HD22 ' HA ' ' A' ' 91' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.897 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.458 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.658 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.888 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.447 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.814 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.658 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.447 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.53 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.94 HG11 HD11 ' A' ' 29' ' ' LEU . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.512 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.856 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.987 HG12 ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CG ' HD11 ' A' ' 76' ' ' LEU . 7.1 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' SER . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.431 0.462 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.872 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.796 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.466 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.507 HG21 ' CG2' ' A' ' 52' ' ' ILE . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.94 HD11 ' O ' ' A' ' 86' ' ' ALA . 37.2 mm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.583 HD12 ' O ' ' A' ' 70' ' ' LYS . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.466 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.583 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.95 ' HA ' HG12 ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.612 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.664 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.618 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.94 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.687 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.4 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.791 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 88' ' ' HIS . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.404 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.796 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.404 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.872 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.95 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.612 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 CA-C-O 121.399 0.444 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.686 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.49 HG21 ' CB ' ' A' ' 68' ' ' ALA . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.839 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.477 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 95' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.061 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.561 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.91 HD11 ' O ' ' A' ' 86' ' ' ALA . 21.1 mm . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.506 HD12 ' HB2' ' A' ' 73' ' ' ASP . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.561 ' HB2' HG12 ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.448 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.448 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.597 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.49 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.556 ' HE2' HD21 ' A' ' 76' ' ' LEU . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.769 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.619 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.828 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.541 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.91 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 1.061 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.52 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.758 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.729 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.828 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.744 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.555 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.744 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.686 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.839 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 75' ' ' ILE . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.619 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' SER . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 CA-C-O 121.422 0.457 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.427 HG23 ' CG1' ' A' ' 103' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.407 ' HG3' HG22 ' A' ' 103' ' ' VAL . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.921 HD11 HD11 ' A' ' 69' ' ' LEU . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.513 ' HB2' HG13 ' A' ' 27' ' ' VAL . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.402 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.862 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.767 HD11 HD13 ' A' ' 21' ' ' ILE . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HG23 ' A' ' 92' ' ' VAL . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.549 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.948 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CE2' ' HG3' ' A' ' 74' ' ' LYS . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.48 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.474 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.653 ' O ' HG23 ' A' ' 66' ' ' THR . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.586 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.653 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.921 HD11 HD11 ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.48 ' O ' HD12 ' A' ' 54' ' ' ILE . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.528 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 1.031 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.579 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.752 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.853 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.738 HD22 ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.948 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.506 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.738 ' HA ' HD22 ' A' ' 83' ' ' LEU . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 33' ' ' ILE . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.853 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.862 HG23 HD12 ' A' ' 29' ' ' LEU . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.752 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.526 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.596 HG13 ' CB ' ' A' ' 98' ' ' ALA . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.427 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.848 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 1.031 HG12 ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.579 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 CA-C-O 121.44 0.466 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.578 HG23 ' CG1' ' A' ' 103' ' ' VAL . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' HG3' HG22 ' A' ' 103' ' ' VAL . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.864 HD12 ' CD2' ' A' ' 104' ' ' PHE . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.744 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.873 HD12 HG23 ' A' ' 95' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.478 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.488 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' N ' HG23 ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.847 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.9 mm . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 70' ' ' LYS . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.478 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.461 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.576 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t30 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.782 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.518 ' O ' HD12 ' A' ' 54' ' ' ILE . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.983 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.608 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.579 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.77 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.788 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.812 HD13 ' HB1' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.847 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.624 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.509 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.474 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.788 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.873 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.474 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.77 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.744 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 29' ' ' LEU . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.578 ' CG1' HG23 ' A' ' 18' ' ' ILE . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.864 ' CD2' HD12 ' A' ' 21' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.983 HG12 ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.608 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 CA-C-O 121.431 0.462 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.65 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 68' ' ' ALA . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.889 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG23 ' A' ' 92' ' ' VAL . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.594 HG23 ' N ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' N ' HG23 ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.721 HG22 HD12 ' A' ' 75' ' ' ILE . 9.1 mm . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.445 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.621 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.677 ' O ' HG23 ' A' ' 66' ' ' THR . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.677 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.669 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.469 ' NZ ' HD21 ' A' ' 76' ' ' LEU . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.721 HD12 HG22 ' A' ' 52' ' ' ILE . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.844 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.557 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.739 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.869 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.458 HD21 ' HB2' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.692 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.62 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.716 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.616 HG23 HD11 ' A' ' 33' ' ' ILE . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.869 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 29' ' ' LEU . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.785 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.785 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.65 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.889 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.844 ' CG ' HD11 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 CA-C-O 121.41 0.45 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 1.012 ' NH1' HG23 ' A' ' 106' ' ' VAL . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.768 HG23 ' CG1' ' A' ' 103' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.574 HG21 ' CB ' ' A' ' 68' ' ' ALA . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.506 ' HG3' HG22 ' A' ' 103' ' ' VAL . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.838 HD12 ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.743 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.736 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.468 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.448 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.572 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.926 HD11 ' O ' ' A' ' 86' ' ' ALA . 31.1 mm . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.401 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.572 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.461 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.461 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.468 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.527 ' O ' HG23 ' A' ' 66' ' ' THR . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 62' ' ' PRO . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.574 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.771 HD11 HD11 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.946 ' HA ' HG12 ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.822 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.692 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.926 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.67 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.593 ' HB3' ' HB1' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.801 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.67 HG23 ' O ' ' A' ' 88' ' ' HIS . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.822 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.801 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.741 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.743 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.4 OUTLIER -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.741 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.768 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.838 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 1.012 HG23 ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 CA-C-O 121.459 0.477 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.561 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.934 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.681 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.669 HD11 HD13 ' A' ' 21' ' ' ILE . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.798 HD12 ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.559 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.968 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.9 mm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' LYS . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.559 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.455 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.624 ' N ' HD12 ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.464 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.585 ' O ' HG23 ' A' ' 66' ' ' THR . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.612 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.585 HG23 ' O ' ' A' ' 62' ' ' PRO . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.603 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.409 ' O ' HD12 ' A' ' 54' ' ' ILE . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.581 ' HD3' HD21 ' A' ' 76' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.977 ' HA ' HG12 ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.581 HD21 ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.581 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.741 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.841 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.848 HD13 ' HB1' ' A' ' 91' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.968 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.798 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.848 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 88' ' ' HIS . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.841 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.781 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.741 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.74 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.561 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.934 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.977 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.54 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 CA-C-O 121.421 0.456 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG21 ' CB ' ' A' ' 68' ' ' ALA . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.883 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.778 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.603 HD11 HD13 ' A' ' 21' ' ' ILE . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 92' ' ' VAL . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.751 HD11 ' O ' ' A' ' 86' ' ' ALA . 9.0 mm . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.637 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.449 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.449 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.629 ' N ' HD12 ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' O ' HG23 ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.483 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.637 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.923 ' HA ' HG12 ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.632 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.543 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.817 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.592 HD13 ' HB1' ' A' ' 91' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.751 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.487 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.748 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.529 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.817 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.778 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.794 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.883 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.923 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.632 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.432 0.462 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.649 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.532 HG21 ' HB1' ' A' ' 68' ' ' ALA . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.924 HD11 HD11 ' A' ' 69' ' ' LEU . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.519 ' HG2' HG23 ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.72 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.469 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.69 HD11 HD13 ' A' ' 21' ' ' ILE . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.897 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.555 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.863 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.5 mm . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HB2' HG12 ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.623 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.679 ' O ' HG23 ' A' ' 66' ' ' THR . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.532 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.924 HD11 HD11 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.401 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 1.026 ' HA ' HG12 ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.649 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.544 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.785 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.664 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.863 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.897 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.739 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.846 HG23 HD11 ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.785 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.739 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.679 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.584 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.679 HG13 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.649 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 1.026 HG12 ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.649 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 CA-C-O 121.43 0.461 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.406 ' NH1' ' HB3' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.712 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.441 HG21 ' CB ' ' A' ' 68' ' ' ALA . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.843 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.62 ' HG3' HG23 ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' HG13 ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.49 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.677 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 21' ' ' ILE . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.565 HD11 HG23 ' A' ' 92' ' ' VAL . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.93 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.3 mm . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.419 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.56 ' HB2' HG12 ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.454 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.454 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.62 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.706 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.706 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.649 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.907 ' HA ' HG12 ' A' ' 106' ' ' VAL . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.798 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.598 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.799 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.888 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.587 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.93 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' SER . . . . . 0.458 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.596 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.806 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.565 HG23 HD11 ' A' ' 33' ' ' ILE . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 92' ' ' VAL . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.888 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.806 HD12 ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.586 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.712 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.843 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.907 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.798 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 CA-C-O 121.421 0.456 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.696 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.993 HD12 ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' HG13 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.483 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.692 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.511 ' HA2' HD12 ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 21' ' ' ILE . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.412 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.996 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.567 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.74 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.567 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.511 HD12 ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.599 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.744 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.598 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.423 ' HZ3' HD23 ' A' ' 76' ' ' LEU . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.6 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.772 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.838 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.458 ' HG ' HG13 ' A' ' 81' ' ' VAL . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 83' ' ' LEU . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.74 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.996 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.766 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.746 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.422 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.838 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.766 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.422 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.41 ' N ' ' O ' ' A' ' 93' ' ' GLU . 18.1 m120 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.772 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.602 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.696 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.993 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.6 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 CA-C-O 121.424 0.458 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.489 ' HG3' HG22 ' A' ' 103' ' ' VAL . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.91 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.741 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.839 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.668 HD11 ' HB2' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.997 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.92 HD11 ' O ' ' A' ' 86' ' ' ALA . 24.5 mm . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 70' ' ' LYS . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.607 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.482 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.646 ' O ' HG23 ' A' ' 66' ' ' THR . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.646 HG23 ' O ' ' A' ' 62' ' ' PRO . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.568 ' O ' HD12 ' A' ' 54' ' ' ILE . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.857 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.685 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.562 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.642 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.799 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.696 HD13 ' HB1' ' A' ' 91' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.92 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.997 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.445 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.811 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.732 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.799 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.839 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.726 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.741 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.8 OUTLIER -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.726 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.91 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.857 HG12 ' HA ' ' A' ' 75' ' ' ILE . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.685 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.298 0 CA-C-O 121.378 0.432 . . . . 0.0 112.528 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.948 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.577 ' HG2' HG21 ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.491 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.491 HG13 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.712 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.522 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.909 HD11 HD13 ' A' ' 21' ' ' ILE . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.626 HD11 HG23 ' A' ' 92' ' ' VAL . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.869 HD11 ' O ' ' A' ' 86' ' ' ALA . 30.6 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.619 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.553 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.474 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.531 HG22 HG23 ' A' ' 31' ' ' ILE . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.603 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.487 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.487 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 62' ' ' PRO . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.671 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.619 ' O ' HD12 ' A' ' 54' ' ' ILE . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.982 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.663 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.553 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.744 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.86 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 ' HB2' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.869 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.466 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.734 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.626 HG23 HD11 ' A' ' 33' ' ' ILE . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.86 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.734 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.744 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.54 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.585 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.577 HG21 ' HG2' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.948 ' CD1' HD12 ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.982 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.663 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 CA-C-O 121.416 0.453 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.484 ' HD3' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.803 HG23 ' CG1' ' A' ' 103' ' ' VAL . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 1.061 HD12 ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.601 ' HG2' HG21 ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.819 HD12 HG23 ' A' ' 95' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.735 HD11 HD13 ' A' ' 21' ' ' ILE . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.447 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.552 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.85 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.5 mm . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.41 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.456 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.624 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.686 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.573 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.686 HG23 ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.736 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.41 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.561 ' HD3' HD21 ' A' ' 76' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.632 ' HA ' HG12 ' A' ' 106' ' ' VAL . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.679 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.589 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.7 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.843 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.788 HD13 ' HB1' ' A' ' 91' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.85 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.739 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.477 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.788 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.843 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.819 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.971 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.971 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.803 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 1.061 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.632 HG12 ' HA ' ' A' ' 75' ' ' ILE . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.679 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.332 0 CA-C-O 121.458 0.477 . . . . 0.0 112.495 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.816 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.865 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.481 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.481 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.732 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.556 HD11 HD13 ' A' ' 21' ' ' ILE . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.501 HD11 HG23 ' A' ' 92' ' ' VAL . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.543 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.1 mm . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.431 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.551 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.543 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.684 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.678 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.601 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.551 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.915 ' HA ' HG12 ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.586 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.679 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.807 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.593 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.793 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.603 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.579 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.764 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 88' ' ' HIS . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.807 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.733 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.733 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.816 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.865 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.586 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' SER . . . . . 0.419 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 29.0 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.277 0 CA-C-O 121.444 0.469 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.576 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.928 HD12 ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.562 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.448 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.82 HD12 HG23 ' A' ' 95' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.513 HD11 HG23 ' A' ' 92' ' ' VAL . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.556 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.95 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.1 mm . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HG3' ' A' ' 74' ' ' LYS . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.556 ' HB2' HG12 ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.612 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.557 ' O ' HG23 ' A' ' 66' ' ' THR . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.571 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 21' ' ' ILE . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.585 ' HE3' HD21 ' A' ' 76' ' ' LEU . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 1.02 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.585 HD21 ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.585 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.722 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.821 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.95 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.507 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.78 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.513 HG23 HD11 ' A' ' 33' ' ' ILE . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.821 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.82 HG23 HD12 ' A' ' 29' ' ' LEU . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.722 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.562 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.697 HG13 ' CB ' ' A' ' 98' ' ' ALA . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.576 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.928 ' CD2' HD12 ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 1.02 HG12 ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.507 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.494 0.497 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.737 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.503 HG21 ' HB1' ' A' ' 68' ' ' ALA . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.758 ' HG3' HG22 ' A' ' 103' ' ' VAL . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 1.079 HD11 HD11 ' A' ' 69' ' ' LEU . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HB2' HG13 ' A' ' 27' ' ' VAL . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 24' ' ' GLU . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.765 HD12 HG23 ' A' ' 95' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.475 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 57' ' ' VAL . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.537 HD11 HG23 ' A' ' 92' ' ' VAL . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.949 HD11 ' O ' ' A' ' 86' ' ' ALA . 7.6 mm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.495 ' CE1' ' HG3' ' A' ' 74' ' ' LYS . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.728 HG22 HG23 ' A' ' 31' ' ' ILE . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.494 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.494 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.584 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.3 m-20 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 1.079 HD11 HD11 ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 54' ' ' ILE . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.552 ' HB2' HD12 ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.495 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 1.016 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.729 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.473 ' OE1' HD12 ' A' ' 105' ' ' ILE . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.55 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.753 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.847 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.949 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.411 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.724 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.537 HG23 HD11 ' A' ' 33' ' ' ILE . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.847 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.765 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.753 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.626 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.758 HG22 ' HG3' ' A' ' 20' ' ' GLU . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.756 ' CD1' HD12 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.473 HD12 ' OE1' ' A' ' 77' ' ' GLU . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 1.016 HG12 ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.729 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-O 121.449 0.472 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.43 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.62 HG23 ' CG1' ' A' ' 103' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.403 ' HG3' HG22 ' A' ' 103' ' ' VAL . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.724 HD13 HD11 ' A' ' 31' ' ' ILE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.488 ' H ' ' CD ' ' A' ' 23' ' ' ARG . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.487 ' CB ' HG13 ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD2' ' CD ' ' A' ' 24' ' ' GLU . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.487 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.656 HD22 ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.488 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.724 HD11 HD13 ' A' ' 21' ' ' ILE . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.942 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.877 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.4 mm . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 73' ' ' ASP . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.488 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.575 ' HG2' HD23 ' A' ' 29' ' ' LEU . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.405 ' H ' HG23 ' A' ' 66' ' ' THR . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.528 ' HB2' HD12 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.921 ' HA ' HG12 ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.621 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.685 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.829 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.464 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.877 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' SER . . . . . 0.4 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' HIS . . . . . 0.942 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.476 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.699 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.742 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.829 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.699 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.718 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.497 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.718 HG13 ' CB ' ' A' ' 98' ' ' ALA . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.62 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.706 ' CE1' HD12 ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.921 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.621 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' SER . . . . . 0.43 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -48.11 -22.35 0.61 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.919 0.39 . . . . 0.0 110.869 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.9 t -121.24 -40.88 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.841 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.68 152.39 26.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 t -140.92 136.71 32.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.838 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 p -137.33 110.02 7.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.99 78.11 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 71.2 1.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.701 2.268 . . . . 0.0 112.354 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.91 44.82 3.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.895 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -117.34 116.13 26.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.595 ' O ' ' CD1' ' A' ' 13' ' ' TRP . 7.5 t 50.76 45.31 27.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.857 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -66.66 107.25 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.727 ' CE2' HD21 ' A' ' 109' ' ' LEU . 65.8 m95 -88.2 108.61 19.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -66.31 -162.71 1.26 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.475 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.717 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.518 HG21 ' HB1' ' A' ' 68' ' ' ALA . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.909 HD11 HD11 ' A' ' 69' ' ' LEU . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.428 ' CG ' HD22 ' A' ' 100' ' ' ASN . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.548 ' HB2' HG13 ' A' ' 27' ' ' VAL . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.548 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.41 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.651 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.473 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 21' ' ' ILE . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.473 HD11 HG23 ' A' ' 92' ' ' VAL . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 37.94 -121.3 0.97 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.38 83.74 1.71 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.52 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.8 mt-30 -123.03 155.06 37.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.853 0.359 . . . . 0.0 110.887 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 6.0 t -127.03 -10.84 5.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.09 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 t -142.68 128.2 16.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.132 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 41' ' ' LYS . 15.5 mt -143.52 163.56 15.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 40' ' ' ILE . 0.7 OUTLIER -51.26 132.24 28.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' A' ' 44' ' ' LYS . 14.0 tpp180 -70.12 -67.79 0.47 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 42' ' ' ARG . 3.9 mp -34.53 -32.91 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 42' ' ' ARG . 19.7 ttpt -43.18 134.79 3.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.865 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -146.18 120.69 9.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.927 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -164.01 -153.28 7.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -128.54 -6.75 5.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.893 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -61.94 175.95 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.911 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.863 ' N ' HD13 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -123.15 153.47 39.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.918 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -15.29 6.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -49.26 179.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 1.008 HD11 ' O ' ' A' ' 86' ' ' ALA . 8.5 mm -86.89 131.85 33.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.618 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.634 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.518 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.909 HD11 HD11 ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.5 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.535 ' HE3' HD23 ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.731 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.844 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.682 HD22 ' HA ' ' A' ' 91' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 1.008 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.42 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.715 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.473 HG23 HD11 ' A' ' 33' ' ' ILE . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.844 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.715 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.535 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.44 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.717 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.831 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -73.3 123.66 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.727 HD21 ' CE2' ' A' ' 13' ' ' TRP . 12.5 mt -62.37 169.97 2.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.8 t -52.87 86.72 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 109' ' ' LEU . 26.9 t -154.37 -176.84 6.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.809 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.448 ' N ' ' OG ' ' A' ' 111' ' ' SER . 34.5 p -131.39 144.14 52.17 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.548 0.689 . . . . 0.0 111.144 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -163.8 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.676 2.25 . . . . 0.0 112.296 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.432 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.8 tpt180 -131.51 157.51 43.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.846 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 116' ' ' ILE . 9.2 p -98.6 163.34 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.14 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.551 HD12 ' C ' ' A' ' 117' ' ' PRO . 0.7 OUTLIER -80.44 151.75 72.3 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.635 0.731 . . . . 0.0 111.139 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.551 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.743 2.296 . . . . 0.0 112.317 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.3 t -70.87 144.43 50.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.2 m -74.82 154.08 38.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.829 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.22 -18.69 0.26 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.2 t -81.89 130.87 35.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.816 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.7 t -149.51 126.55 11.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.52 80.57 0.19 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.6 Cg_endo -69.76 0.51 5.54 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.68 2.253 . . . . 0.0 112.352 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.434 ' C ' ' O ' ' A' ' 8' ' ' PRO . 26.0 m-20 -34.4 146.96 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -134.85 118.69 17.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.871 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.549 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 18.4 p -157.32 163.04 39.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.58 69.68 1.47 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.826 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.754 ' CD1' HD21 ' A' ' 109' ' ' LEU . 50.9 m95 -85.95 116.42 24.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.913 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.46 -158.1 6.9 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.489 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.512 HG23 ' CG1' ' A' ' 103' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.409 HG21 ' HB1' ' A' ' 68' ' ' ALA . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.856 HD12 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.94 HD11 HG11 ' A' ' 102' ' ' VAL . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.818 HD11 HD13 ' A' ' 21' ' ' ILE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.888 HD11 HG23 ' A' ' 92' ' ' VAL . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.03 -126.53 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 52' ' ' ILE . . . 118.45 -67.24 0.36 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.438 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.44 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.23 151.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.6 t -176.46 -174.28 0.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -146.25 142.57 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 4.2 mt -105.76 148.24 10.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.65 139.64 36.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.921 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.2 ttp180 -89.54 10.32 23.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 8.6 mt -98.28 -36.36 10.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -167.86 173.67 8.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -116.83 162.34 17.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -126.64 137.29 9.93 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.26 0.58 37.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.856 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.59 176.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.895 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.873 HD13 ' CZ ' ' A' ' 53' ' ' PHE . 3.2 mm? -74.85 77.07 2.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.7 pttm -123.16 -14.15 7.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.44 -151.88 0.38 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.529 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.897 HD11 ' O ' ' A' ' 86' ' ' ALA . 29.4 mm -114.47 133.71 59.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.873 ' CZ ' HD13 ' A' ' 49' ' ' LEU . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.542 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.432 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.432 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.711 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.559 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.693 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.512 ' HA ' HG22 ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.987 ' HA ' HG12 ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.401 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.538 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.814 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.546 HD22 ' HA ' ' A' ' 91' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.897 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.458 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.658 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.888 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.447 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.814 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.658 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.447 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.53 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.94 HG11 HD11 ' A' ' 29' ' ' LEU . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.512 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.856 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.987 HG12 ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CG ' HD11 ' A' ' 76' ' ' LEU . 7.1 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t -72.82 132.86 44.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.754 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.6 mt -71.55 158.99 35.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.1 t -61.21 75.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 109' ' ' LEU . 1.2 p -132.51 -1.54 3.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 6.3 p 58.33 151.12 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 0.0 111.151 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.669 2.246 . . . . 0.0 112.341 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 -130.18 -174.76 3.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.823 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.559 HG13 ' HD3' ' A' ' 117' ' ' PRO . 12.5 p -70.07 157.13 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.114 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.51 ' O ' HD12 ' A' ' 116' ' ' ILE . 1.5 pp -117.45 81.15 13.68 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.61 0.719 . . . . 0.0 111.105 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HD3' HG13 ' A' ' 115' ' ' VAL . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.187 0 C-N-CA 122.664 2.242 . . . . 0.0 112.336 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.9 t -76.3 -176.78 3.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -108.62 -74.4 0.66 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.49 58.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -95.36 26.63 3.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.832 0.349 . . . . 0.0 110.829 -179.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -107.45 135.87 48.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.861 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.84 66.31 1.13 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 171.5 14.31 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -77.3 160.51 28.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -133.78 -0.04 3.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 3.7 t -99.17 178.85 4.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.906 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -129.09 76.32 1.71 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.749 ' CD1' HD21 ' A' ' 109' ' ' LEU . 56.1 m95 -91.02 114.85 27.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.35 -161.67 5.67 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.525 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.872 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.796 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.466 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.507 HG21 ' CG2' ' A' ' 52' ' ' ILE . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 47.24 -142.98 5.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.42 ' C ' ' HB2' ' A' ' 88' ' ' HIS . . . 81.86 149.94 7.73 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.482 ' N ' ' H ' ' A' ' 88' ' ' HIS . 14.0 mt-30 62.86 54.87 2.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.888 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -124.4 -21.47 4.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 38' ' ' THR . 12.7 t -157.07 137.77 4.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.13 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 38.5 mt -117.54 -21.11 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.084 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.63 159.4 30.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.5 mmt85 -66.22 85.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 36.1 mt -105.95 -59.57 1.76 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.11 171.96 11.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.93 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -114.93 -70.61 0.79 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.2 176.56 14.59 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -103.57 -6.82 21.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.871 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -138.26 173.32 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.928 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -60.1 173.45 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 pttp -147.37 160.02 43.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 145.05 176.09 18.76 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.456 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.94 HD11 ' O ' ' A' ' 86' ' ' ALA . 37.2 mm -79.67 107.93 12.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.413 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.583 HD12 ' O ' ' A' ' 70' ' ' LYS . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.466 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.583 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.95 ' HA ' HG12 ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.612 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.664 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.618 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.94 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.687 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.4 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.791 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 88' ' ' HIS . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.404 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.796 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.404 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.872 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.95 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.612 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t -74.54 127.82 34.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.749 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.5 mt -66.82 158.05 31.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -38.03 101.99 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.4 t -163.07 179.27 7.63 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.84 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 39.9 p -114.89 144.24 31.63 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.612 0.72 . . . . 0.0 111.129 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.81 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.736 2.29 . . . . 0.0 112.328 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.554 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 21.7 ttt180 -138.01 166.72 23.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 116' ' ' ILE . 14.1 t -104.3 167.85 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.582 ' N ' HG12 ' A' ' 115' ' ' VAL . 1.4 pp -117.15 159.3 41.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.618 0.723 . . . . 0.0 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.381 179.878 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m -154.04 149.02 26.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.852 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 74.9 p -139.34 -176.15 4.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.91 -172.26 13.88 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.514 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.436 ' O ' ' N ' ' A' ' 7' ' ' GLY . 46.1 m -107.73 -37.02 6.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.893 0.377 . . . . 0.0 110.899 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -39.23 95.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -134.92 -173.07 12.95 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 2.86 3.12 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.741 2.294 . . . . 0.0 112.374 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -71.45 79.77 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.84 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -82.16 -23.14 35.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.582 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 53.2 m -47.33 175.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -123.67 63.39 1.04 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.852 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.738 ' CD1' HD21 ' A' ' 109' ' ' LEU . 51.0 m95 -88.46 118.04 27.82 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.958 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.55 -161.57 15.42 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.686 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.49 HG21 ' CB ' ' A' ' 68' ' ' ALA . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.839 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.477 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 95' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.061 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.561 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.47 -143.85 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.03 -40.55 2.28 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.473 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 4.8 mp0 -39.75 151.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.926 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.739 HG22 ' H ' ' A' ' 39' ' ' VAL . 0.6 OUTLIER -138.18 -179.06 5.56 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.133 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.739 ' H ' HG22 ' A' ' 38' ' ' THR . 0.8 OUTLIER -145.22 153.23 14.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.14 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 70.4 mt -78.37 -47.8 23.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.093 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -45.71 151.55 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.12 93.36 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -93.89 -175.38 3.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 pptp? -86.19 -2.28 58.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -80.03 165.45 22.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 132.81 74.5 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.513 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -131.57 -2.73 3.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.801 0.334 . . . . 0.0 110.847 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -98.98 177.06 5.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.538 ' HB3' ' CE1' ' A' ' 53' ' ' PHE . 3.8 mm? -76.32 108.77 9.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.913 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.12 -19.48 23.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.91 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.83 178.76 11.53 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.519 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.91 HD11 ' O ' ' A' ' 86' ' ' ALA . 21.1 mm -91.92 140.24 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 49' ' ' LEU . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.506 HD12 ' HB2' ' A' ' 73' ' ' ASP . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.561 ' HB2' HG12 ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.448 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.448 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.597 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.49 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.556 ' HE2' HD21 ' A' ' 76' ' ' LEU . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.769 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.619 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.828 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.541 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.91 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 1.061 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.52 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.758 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.729 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.828 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.744 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.555 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.744 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.686 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.839 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 75' ' ' ILE . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.619 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -80.23 128.66 33.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.738 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.6 mt -64.71 159.68 21.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.898 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -45.24 100.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.867 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.0 p -169.72 176.41 4.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.863 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 72.8 p -131.59 144.15 52.13 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.57 0.7 . . . . 0.0 111.136 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.84 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.694 2.263 . . . . 0.0 112.374 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.7 -174.88 3.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.581 HG12 ' H ' ' A' ' 116' ' ' ILE . 2.1 t -110.69 170.46 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.581 ' H ' HG12 ' A' ' 115' ' ' VAL . 2.1 pt -113.63 158.64 38.23 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.647 0.736 . . . . 0.0 111.119 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.682 2.255 . . . . 0.0 112.358 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -135.37 -178.53 5.15 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.812 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -135.52 140.58 44.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.865 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.66 129.88 3.14 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 p -126.58 132.27 51.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.5 p -136.03 160.09 39.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.836 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.16 72.71 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 176.25 7.02 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.692 2.261 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 46.5 54.02 9.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.883 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' SER . 32.5 t80 -162.14 157.69 23.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 10' ' ' PHE . 2.4 p 35.22 50.68 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -86.08 94.55 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.833 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.658 ' CD1' HD21 ' A' ' 109' ' ' LEU . 76.5 m95 -85.13 110.92 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.946 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -69.7 -163.29 3.8 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.517 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.427 HG23 ' CG1' ' A' ' 103' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.407 ' HG3' HG22 ' A' ' 103' ' ' VAL . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.921 HD11 HD11 ' A' ' 69' ' ' LEU . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.513 ' HB2' HG13 ' A' ' 27' ' ' VAL . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.402 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.862 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.767 HD11 HD13 ' A' ' 21' ' ' ILE . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HG23 ' A' ' 92' ' ' VAL . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.549 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 63.33 -170.89 14.74 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 38' ' ' THR . . . 170.52 -177.5 43.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.494 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' GLY . 13.9 pt20 34.22 35.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.922 0.392 . . . . 0.0 110.967 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 36' ' ' GLY . 5.4 p -44.65 169.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 t -96.89 147.5 6.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.105 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.614 HD12 ' N ' ' A' ' 40' ' ' ILE . 0.2 OUTLIER -130.97 90.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.123 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HG2' ' N ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -178.68 147.22 0.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.895 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.441 ' H ' ' CD ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -69.94 80.67 0.47 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.43 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 0.1 OUTLIER -99.51 141.82 31.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.43 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 37.7 mtpt -116.96 -43.89 2.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.949 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -81.41 93.18 6.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 143.88 80.54 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -86.28 114.82 23.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.427 ' HG3' ' N ' ' A' ' 49' ' ' LEU . 1.1 pt-20 -155.96 175.54 13.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD1' ' CZ ' ' A' ' 53' ' ' PHE . 0.3 OUTLIER -60.57 92.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.934 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.85 134.59 48.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.918 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.419 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 110.76 175.94 20.51 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.948 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm -93.28 156.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' A' ' 49' ' ' LEU . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.48 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.474 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.653 ' O ' HG23 ' A' ' 66' ' ' THR . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.586 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.653 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.503 ' OD1' HG23 ' A' ' 115' ' ' VAL . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.921 HD11 HD11 ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.48 ' O ' HD12 ' A' ' 54' ' ' ILE . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.528 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 1.031 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.579 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.752 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.853 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.738 HD22 ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.948 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.506 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.738 ' HA ' HD22 ' A' ' 83' ' ' LEU . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 33' ' ' ILE . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.853 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.862 HG23 HD12 ' A' ' 29' ' ' LEU . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.752 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.526 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.596 HG13 ' CB ' ' A' ' 98' ' ' ALA . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.427 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.848 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 1.031 HG12 ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.579 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t -71.47 125.43 27.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.658 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.9 mt -63.54 175.8 0.98 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.874 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 16.7 t -40.96 -74.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 112' ' ' THR . 59.7 p -52.89 170.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.501 HG23 ' O ' ' A' ' 111' ' ' SER . 49.6 p -159.71 145.83 12.01 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.614 0.721 . . . . 0.0 111.129 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PRO . . . . . 0.402 ' CG ' ' HG3' ' A' ' 70' ' ' LYS . 54.1 Cg_endo -69.79 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.551 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 4.2 ttm-85 -116.11 166.13 12.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.551 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 11.3 p -126.54 157.49 37.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.446 ' N ' HG22 ' A' ' 115' ' ' VAL . 2.0 pt -79.33 156.25 76.27 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.635 0.731 . . . . 0.0 111.124 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--N 1.342 0.194 0 C-N-CA 122.669 2.246 . . . . 0.0 112.377 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -128.03 56.39 1.6 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.354 . . . . 0.0 110.846 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.4 t -93.25 145.48 24.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.68 157.73 28.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.485 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.5 t -125.19 -43.42 1.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.862 0.363 . . . . 0.0 110.881 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.6 p 42.24 29.49 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.911 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.95 176.35 1.83 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.505 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -164.53 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.651 2.234 . . . . 0.0 112.303 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -113.96 -174.64 2.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.931 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' O ' ' C ' ' A' ' 11' ' ' SER . 59.9 t80 -119.51 -39.36 2.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.462 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 33.0 p -34.55 147.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.5 t-80 -118.97 69.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.836 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.67 ' CD1' HD21 ' A' ' 109' ' ' LEU . 36.8 m95 -74.09 126.11 29.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.925 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.25 -163.31 30.5 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.578 HG23 ' CG1' ' A' ' 103' ' ' VAL . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' HG3' HG22 ' A' ' 103' ' ' VAL . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.864 HD12 ' CD2' ' A' ' 104' ' ' PHE . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.744 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.873 HD12 HG23 ' A' ' 95' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.478 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.488 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' N ' HG23 ' A' ' 34' ' ' VAL . . . 68.5 -159.73 51.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.436 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 148.26 -9.28 1.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.443 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.436 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.09 137.51 0.14 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 110.975 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.555 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.4 m -56.09 160.73 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HD13 ' A' ' 40' ' ' ILE . 0.2 OUTLIER -130.99 157.58 43.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.598 HD13 ' O ' ' A' ' 39' ' ' VAL . 23.2 mm -149.54 147.38 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 40' ' ' ILE . 0.0 OUTLIER -34.36 -44.11 0.18 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' CG ' ' O ' ' A' ' 41' ' ' LYS . 24.0 mtm180 -166.79 -175.54 3.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 59.93 45.27 12.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 9.1 tptp -115.69 131.6 56.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.71 171.79 9.11 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 169.71 118.83 0.47 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.445 ' CD ' ' O ' ' A' ' 47' ' ' GLU . 3.1 tp10 -73.02 -12.23 60.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.849 0.357 . . . . 0.0 110.898 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -126.6 -175.45 3.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.721 HD13 ' H ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -71.69 168.23 18.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.45 137.85 51.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.591 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 137.72 159.13 8.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.438 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.847 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.9 mm -81.25 138.68 19.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 70' ' ' LYS . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.478 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.461 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.576 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.782 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.518 ' O ' HD12 ' A' ' 54' ' ' ILE . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.983 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.608 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.579 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.77 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.788 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.812 HD13 ' HB1' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASN . . . . . 0.448 ' O ' HG11 ' A' ' 39' ' ' VAL . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.847 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.624 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.509 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.474 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.788 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.873 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.474 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.77 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.744 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 29' ' ' LEU . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.578 ' CG1' HG23 ' A' ' 18' ' ' ILE . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.864 ' CD2' HD12 ' A' ' 21' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.983 HG12 ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.608 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p -76.1 125.62 29.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.67 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.9 mt -51.77 -176.67 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.7 t -74.63 61.26 0.95 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.79 ' O ' HG23 ' A' ' 112' ' ' THR . 11.6 p -176.79 159.62 1.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.843 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -172.17 144.37 1.42 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.6 0.714 . . . . 0.0 111.144 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -163.79 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.64 2.226 . . . . 0.0 112.361 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.461 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 5.3 tpm_? -114.81 149.66 36.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.631 HG12 ' N ' ' A' ' 116' ' ' ILE . 60.6 t -106.44 164.88 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.631 ' N ' HG12 ' A' ' 115' ' ' VAL . 4.2 pt -62.73 156.3 65.55 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.588 0.709 . . . . 0.0 111.156 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.641 2.227 . . . . 0.0 112.339 179.891 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.5 m -144.28 150.72 38.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.871 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -166.2 175.4 8.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.7 159.34 29.95 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.464 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.5 p -150.25 169.53 21.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.874 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -151.77 169.35 22.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.795 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.75 173.9 30.97 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -163.82 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.677 2.251 . . . . 0.0 112.348 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -174.17 152.47 1.85 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -124.58 -54.82 1.65 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.589 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 3.2 m -50.48 -177.86 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -119.3 51.67 1.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.871 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 57.2 m95 -74.04 116.04 14.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -74.34 -162.74 9.06 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.487 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.65 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 68' ' ' ALA . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.889 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG23 ' A' ' 92' ' ' VAL . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.594 HG23 ' N ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' N ' HG23 ' A' ' 34' ' ' VAL . . . 35.84 -127.11 0.85 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 90.66 112.73 1.62 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.539 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.441 ' HG2' ' N ' ' A' ' 38' ' ' THR . 46.5 tt0 -163.64 158.92 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.865 0.364 . . . . 0.0 110.927 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.441 ' N ' ' HG2' ' A' ' 37' ' ' GLN . 1.6 t -66.46 161.09 23.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.16 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.72 HG22 ' H ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -60.51 -174.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.082 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.72 ' H ' HG22 ' A' ' 39' ' ' VAL . 32.6 mt -159.38 148.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -96.01 -70.34 0.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.915 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -135.15 1.24 2.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.861 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.599 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -94.16 41.35 1.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.93 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 17.9 pttm -97.34 162.98 13.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 22.8 m120 -120.35 20.94 11.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.02 178.62 27.8 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -123.74 125.63 45.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.816 0.341 . . . . 0.0 110.909 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -169.43 162.29 10.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.915 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.409 HD13 ' HA ' ' A' ' 49' ' ' LEU . 4.2 mm? -41.59 133.06 2.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 ptpt -112.72 -23.57 10.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.22 164.75 1.42 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.721 HG22 HD12 ' A' ' 75' ' ' ILE . 9.1 mm -87.78 108.27 18.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.445 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.621 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.677 ' O ' HG23 ' A' ' 66' ' ' THR . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.677 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.669 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.469 ' NZ ' HD21 ' A' ' 76' ' ' LEU . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.721 HD12 HG22 ' A' ' 52' ' ' ILE . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.844 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.557 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.739 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.869 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.458 HD21 ' HB2' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.692 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.416 ' HA ' ' N ' ' A' ' 37' ' ' GLN . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.62 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.716 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.616 HG23 HD11 ' A' ' 33' ' ' ILE . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.869 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 29' ' ' LEU . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.785 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.785 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.65 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.889 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.844 ' CG ' HD11 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t -80.35 129.1 34.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 7.8 mt -66.03 159.68 25.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 25.2 p -51.44 102.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.837 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.8 t -156.03 170.57 21.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.0 p -99.77 150.88 37.22 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.579 0.704 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -163.86 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.687 2.258 . . . . 0.0 112.34 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 4.3 tpm_? -130.54 146.1 52.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.875 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' A' ' 116' ' ' ILE . 39.9 t -74.48 160.76 5.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 117' ' ' PRO . 44.6 mt -70.5 138.62 86.29 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.598 0.713 . . . . 0.0 111.164 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.175 0 C-N-CA 122.726 2.284 . . . . 0.0 112.359 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.5 m -81.07 129.29 34.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.368 . . . . 0.0 110.871 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.4 t -146.77 142.72 28.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.864 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.94 107.34 0.52 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.487 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.8 m -112.74 178.95 4.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 110.882 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 7' ' ' GLY . 54.2 p -114.41 -65.35 1.2 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' OG ' ' A' ' 6' ' ' SER . . . 154.86 150.7 5.61 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.483 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.75 2.3 . . . . 0.0 112.329 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -120.7 133.55 55.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.853 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.28 60.61 2.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.546 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.1 p -93.43 -175.31 3.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.0 m80 -125.97 66.98 1.19 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.811 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.702 ' CD1' HD21 ' A' ' 109' ' ' LEU . 57.7 m95 -93.66 113.51 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.29 -159.3 8.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 1.012 ' NH1' HG23 ' A' ' 106' ' ' VAL . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.768 HG23 ' CG1' ' A' ' 103' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.574 HG21 ' CB ' ' A' ' 68' ' ' ALA . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.506 ' HG3' HG22 ' A' ' 103' ' ' VAL . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.838 HD12 ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.743 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.736 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.468 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.448 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.572 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 66.13 -171.48 27.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.75 -36.69 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.466 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -65.95 130.74 44.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.87 0.367 . . . . 0.0 110.917 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.669 HG22 ' H ' ' A' ' 39' ' ' VAL . 1.3 m -135.65 174.49 10.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.669 ' H ' HG22 ' A' ' 38' ' ' THR . 0.9 OUTLIER -145.57 151.35 14.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.158 179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 76.2 mt -118.47 -27.0 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.4 ttpm? -70.53 143.41 51.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 56.87 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.18 -7.71 17.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -145.2 113.93 6.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -105.09 116.11 31.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 136.16 76.84 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.442 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -146.76 142.56 27.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 110.859 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -47.39 172.91 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.91 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.687 HD23 ' CZ ' ' A' ' 53' ' ' PHE . 11.2 mp -44.51 133.63 5.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.72 -29.98 2.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.952 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -56.42 -161.22 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.515 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.926 HD11 ' O ' ' A' ' 86' ' ' ALA . 31.1 mm -109.48 126.83 66.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.687 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.572 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.461 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.461 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.468 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.527 ' O ' HG23 ' A' ' 66' ' ' THR . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 62' ' ' PRO . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.574 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.771 HD11 HD11 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.946 ' HA ' HG12 ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.822 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.692 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASN . . . . . 0.666 ' C ' HG21 ' A' ' 38' ' ' THR . 55.7 m-20 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.926 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.67 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.593 ' HB3' ' HB1' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.801 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.67 HG23 ' O ' ' A' ' 88' ' ' HIS . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.822 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.801 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.741 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.743 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.4 OUTLIER -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.741 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.768 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.838 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 1.012 HG23 ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t -84.17 131.1 34.8 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.702 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.9 mt -61.64 160.46 11.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 45.4 p -57.7 95.1 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.5 t -125.48 16.24 8.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.86 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 55.07 163.46 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.609 0.719 . . . . 0.0 111.127 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -171.05 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.666 2.244 . . . . 0.0 112.318 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 0.6 OUTLIER -140.89 150.08 42.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.436 ' N ' ' HG2' ' A' ' 114' ' ' ARG . 5.5 p -115.0 143.61 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.4 pt -76.39 156.84 83.28 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.643 0.735 . . . . 0.0 111.14 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.657 2.238 . . . . 0.0 112.38 179.878 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.7 t -121.3 -9.35 9.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.859 0.361 . . . . 0.0 110.831 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -94.98 121.26 36.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.894 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.46 79.05 0.37 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.477 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.7 t -134.12 63.32 1.63 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.924 0.392 . . . . 0.0 110.878 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.8 p -66.52 167.31 11.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.877 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 171.32 45.61 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.47 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -46.68 1.12 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -166.54 160.73 15.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.922 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.589 ' CZ ' ' O ' ' A' ' 47' ' ' GLU . 5.4 t80 -175.11 -177.36 1.05 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PHE . 35.9 p -35.24 150.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.855 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -111.18 75.32 0.91 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.801 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.692 ' CD1' HD21 ' A' ' 109' ' ' LEU . 77.2 m95 -87.62 114.67 24.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.963 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.18 -162.96 10.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.463 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.561 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.934 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.681 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.669 HD11 HD13 ' A' ' 21' ' ' ILE . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.798 HD12 ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.559 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 46.68 -145.38 3.95 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 84.9 -22.54 9.19 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -34.37 -70.52 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 0.0 110.91 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.2 p -128.05 179.14 5.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -145.58 175.2 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.118 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.461 ' N ' HG23 ' A' ' 39' ' ' VAL . 22.8 mt -150.94 140.63 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' CD ' ' O ' ' A' ' 41' ' ' LYS . 2.4 tmtp? -77.69 51.33 0.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -107.95 56.71 0.63 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.937 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.521 ' C ' ' CD1' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.05 19.51 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 20.81 13.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 31.1 t30 -171.82 158.49 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.07 139.52 6.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.589 ' O ' ' CZ ' ' A' ' 10' ' ' PHE . 3.7 mm-40 -114.32 -8.06 12.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.873 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 49' ' ' LEU . 29.8 mp0 -103.37 81.92 1.99 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.855 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.92 ' O ' HD22 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -34.55 128.78 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.925 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.36 179.56 7.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.881 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.594 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 138.9 157.63 7.4 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.968 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.9 mm -72.87 100.9 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' LYS . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.559 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.455 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.624 ' N ' HD12 ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.464 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.585 ' O ' HG23 ' A' ' 66' ' ' THR . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.612 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.585 HG23 ' O ' ' A' ' 62' ' ' PRO . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.603 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.409 ' O ' HD12 ' A' ' 54' ' ' ILE . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.743 ' CE ' HD23 ' A' ' 49' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.977 ' HA ' HG12 ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.581 HD21 ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.581 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.741 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.841 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.848 HD13 ' HB1' ' A' ' 91' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.968 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.798 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.848 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 88' ' ' HIS . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.841 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.781 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.741 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.74 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.561 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.934 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.977 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.54 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t -73.24 131.4 41.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.692 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.2 mt -68.38 166.45 16.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 m -56.02 87.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 109' ' ' LEU . 8.3 t -151.45 -178.6 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.859 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 52.5 p -125.11 144.1 46.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.583 0.706 . . . . 0.0 111.15 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.457 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 15.8 ttm-85 -149.45 150.39 32.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.6 t -92.65 179.69 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.734 ' H ' HG12 ' A' ' 115' ' ' VAL . 38.7 mt -85.21 138.64 36.56 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.621 0.724 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.682 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.364 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 63.6 52.78 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.943 0.401 . . . . 0.0 110.91 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.3 t -64.43 122.84 17.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -41.15 152.76 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.8 t -107.23 -4.81 18.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.813 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -92.69 135.76 33.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.24 178.19 34.2 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.438 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -163.89 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -113.95 177.46 4.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -175.28 -177.35 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.438 ' HB2' ' NE1' ' A' ' 13' ' ' TRP . 0.9 OUTLIER -39.92 160.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.889 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.2 m80 -110.04 84.93 2.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.677 ' CD1' HD21 ' A' ' 109' ' ' LEU . 55.0 m95 -81.0 118.06 22.15 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.38 -163.55 16.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG21 ' CB ' ' A' ' 68' ' ' ALA . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.883 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.778 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.603 HD11 HD13 ' A' ' 21' ' ' ILE . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 92' ' ' VAL . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.91 -127.68 4.16 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 86.02 -46.25 3.59 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.455 ' N ' ' HB2' ' A' ' 88' ' ' HIS . 16.7 tt0 -42.09 140.72 1.04 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.881 0.372 . . . . 0.0 110.913 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -44.64 158.4 0.05 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.727 ' C ' HD12 ' A' ' 40' ' ' ILE . 0.2 OUTLIER -168.87 151.84 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.168 179.9 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.821 HD12 ' N ' ' A' ' 40' ' ' ILE . 0.3 OUTLIER -148.86 135.46 12.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.145 179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -139.94 143.22 36.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.904 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.0 ptt-85 -101.32 4.96 42.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.874 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 7.8 mp -69.52 155.8 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -127.66 10.68 6.64 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.902 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.447 ' O ' ' C ' ' A' ' 46' ' ' GLY . 15.6 t-20 -123.26 -55.45 1.76 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.905 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 45' ' ' ASN . . . -34.49 112.58 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 48' ' ' GLU . 12.0 tp10 -97.57 113.85 25.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.434 ' CG ' ' O ' ' A' ' 47' ' ' GLU . 62.8 mt-10 -161.11 173.99 14.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.908 HD23 ' CZ ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -122.41 154.79 37.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.923 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.87 -15.49 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.864 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . -41.81 164.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.751 HD11 ' O ' ' A' ' 86' ' ' ALA . 9.0 mm -76.29 128.92 37.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.908 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.637 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.449 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.449 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.629 ' N ' HD12 ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' O ' HG23 ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.483 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.637 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.923 ' HA ' HG12 ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.632 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.543 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.817 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.592 HD13 ' HB1' ' A' ' 91' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.751 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.487 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.748 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.529 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.817 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.778 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.794 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.883 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.923 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.632 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -74.58 129.64 38.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.677 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.5 mt -60.63 178.62 0.21 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.0 t -52.68 -17.17 1.18 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.7 t -61.11 -174.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 66.8 p -138.4 144.08 41.27 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.55 0.69 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.504 ' NE ' ' H ' ' A' ' 115' ' ' VAL . 0.0 OUTLIER -121.3 163.43 18.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.604 HG12 ' N ' ' A' ' 116' ' ' ILE . 21.0 t -90.72 166.36 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.707 ' H ' HD12 ' A' ' 116' ' ' ILE . 4.7 mp -62.17 138.63 96.05 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.617 0.722 . . . . 0.0 111.12 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.666 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.32 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -163.21 112.21 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.863 0.363 . . . . 0.0 110.842 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.2 p -62.8 159.46 16.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.847 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.7 83.38 0.75 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.474 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.3 p -69.98 178.92 2.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.0 m -98.05 -16.03 19.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 51.52 -164.73 1.08 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 159.11 54.63 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.657 2.238 . . . . 0.0 112.383 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 44.4 m-20 -78.16 126.24 30.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 68.1 m-85 -80.11 -178.01 6.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.9 p -34.56 150.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.91 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -126.69 74.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.7 ' CD1' HD21 ' A' ' 109' ' ' LEU . 67.9 m95 -84.73 112.11 20.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.904 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.47 -161.42 5.66 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.649 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.532 HG21 ' HB1' ' A' ' 68' ' ' ALA . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.924 HD11 HD11 ' A' ' 69' ' ' LEU . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.519 ' HG2' HG23 ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.72 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.469 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.69 HD11 HD13 ' A' ' 21' ' ' ILE . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.897 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.555 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.66 -129.41 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 155.0 -82.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.483 ' HB3' ' CB ' ' A' ' 87' ' ' SER . 4.3 tt0 -149.78 114.99 5.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 110.892 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.4 t -102.36 -176.87 3.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.441 ' C ' HG13 ' A' ' 40' ' ' ILE . 46.5 t -107.66 92.32 2.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.114 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.441 HG13 ' C ' ' A' ' 39' ' ' VAL . 77.1 mt -154.53 135.99 5.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.412 ' C ' ' O ' ' A' ' 40' ' ' ILE . 2.8 ttpm? -37.01 145.49 0.05 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.937 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -79.58 50.85 1.18 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.889 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 12.4 tp -100.34 134.63 43.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.93 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -61.31 138.43 58.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.428 ' C ' ' OD1' ' A' ' 45' ' ' ASN . 26.9 t-20 -95.46 -72.49 0.62 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 163.12 -91.45 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -78.91 -6.65 56.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.787 0.327 . . . . 0.0 110.893 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -123.54 171.77 9.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' N ' ' CD1' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -161.91 158.9 26.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.2 tppp? -84.73 135.92 33.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 161.62 175.4 32.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.863 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.5 mm -90.06 125.8 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HB2' HG12 ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.623 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.648 ' OE2' HD11 ' A' ' 116' ' ' ILE . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.679 ' O ' HG23 ' A' ' 66' ' ' THR . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.532 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.924 HD11 HD11 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.48 ' CB ' ' HG3' ' A' ' 113' ' ' PRO . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.401 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 1.026 ' HA ' HG12 ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.649 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.544 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.785 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.664 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.863 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.483 ' CB ' ' HB3' ' A' ' 37' ' ' GLN . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.897 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.739 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.846 HG23 HD11 ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.785 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.739 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.679 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.584 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.679 HG13 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.649 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 1.026 HG12 ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.649 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -73.12 133.07 44.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.7 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.4 mt -69.45 168.62 14.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.954 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 47.1 t -38.65 -59.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.889 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.9 t -73.76 173.53 9.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 25.0 p -151.62 145.21 17.61 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.573 0.702 . . . . 0.0 111.115 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' PRO . . . . . 0.48 ' HG3' ' CB ' ' A' ' 70' ' ' LYS . 53.5 Cg_endo -69.73 -168.3 0.27 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.697 2.265 . . . . 0.0 112.35 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 13.3 tpp180 -144.87 156.55 44.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.443 ' N ' ' HG3' ' A' ' 114' ' ' ARG . 47.8 t -150.2 148.6 15.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.689 ' C ' HD12 ' A' ' 116' ' ' ILE . 0.9 OUTLIER -49.11 151.28 2.44 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.591 0.71 . . . . 0.0 111.121 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.585 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.674 2.25 . . . . 0.0 112.336 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -141.71 166.91 23.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -158.67 117.18 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.08 162.83 23.01 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.497 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -160.52 160.06 31.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.9 t -154.29 -175.57 5.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.883 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.88 83.41 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -164.6 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.705 2.27 . . . . 0.0 112.353 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -140.45 -175.25 4.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.888 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -121.73 -64.42 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 21.5 p -40.4 161.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.841 -179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 20.0 t60 -120.79 68.55 0.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.828 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.667 ' CD1' HD21 ' A' ' 109' ' ' LEU . 55.4 m95 -84.93 118.44 24.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.83 -163.72 18.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.406 ' NH1' ' HB3' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.712 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.441 HG21 ' CB ' ' A' ' 68' ' ' ALA . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.843 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.62 ' HG3' HG23 ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' HG13 ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.49 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.677 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 21' ' ' ILE . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.565 HD11 HG23 ' A' ' 92' ' ' VAL . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.97 -145.17 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.96 100.31 2.31 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' C ' ' HB2' ' A' ' 87' ' ' SER . 71.6 mt-30 -130.21 145.78 51.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.912 0.387 . . . . 0.0 110.852 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.1 m -105.47 109.31 21.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.13 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -175.01 149.7 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 60.8 mt -152.22 110.96 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.151 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.0 mtpt -144.73 129.59 18.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.913 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 49.5 mtt180 -81.69 68.0 7.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.906 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 42.7 mt -92.58 -71.66 0.64 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -135.52 124.65 24.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -57.4 151.18 16.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.77 133.34 5.53 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -171.54 142.29 1.61 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -53.58 176.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.868 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.553 HD12 ' HZ ' ' A' ' 53' ' ' PHE . 1.8 mm? -47.1 125.94 8.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -116.67 -20.82 9.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.864 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.48 -175.04 3.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.484 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.93 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.3 mm -102.81 127.57 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 49' ' ' LEU . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.419 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.56 ' HB2' HG12 ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.454 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.454 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.62 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.706 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.706 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.649 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.907 ' HA ' HG12 ' A' ' 106' ' ' VAL . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.798 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.598 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.799 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.888 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.587 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.93 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.458 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.596 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.806 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.565 HG23 HD11 ' A' ' 33' ' ' ILE . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 92' ' ' VAL . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.888 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.806 HD12 ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.586 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.712 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.843 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.907 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.798 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t -81.88 138.35 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.667 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.1 mt -67.69 172.27 5.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.932 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 24.3 t -45.84 -21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.8 t -52.11 -176.48 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.844 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 76.6 p -145.25 148.59 38.41 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.537 0.684 . . . . 0.0 111.168 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 -163.84 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -130.15 -174.79 3.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.845 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 1.5 p -122.23 152.25 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.56 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -105.2 159.96 27.63 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.622 0.725 . . . . 0.0 111.13 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.673 2.248 . . . . 0.0 112.311 179.925 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.537 -0.225 . . . . 0.0 112.537 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -110.0 177.88 4.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.897 0.38 . . . . 0.0 110.864 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.4 p -154.8 161.47 41.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.837 -179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.3 -173.28 12.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 p -148.76 162.35 39.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.859 0.361 . . . . 0.0 110.862 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -112.14 -74.94 0.62 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.18 146.19 8.04 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.78 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -160.78 173.39 15.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 11.9 m-85 -83.16 -75.15 0.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PHE . 0.6 OUTLIER -34.85 151.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.853 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' HIS . . . . . 0.462 ' C ' HD23 ' A' ' 109' ' ' LEU . 11.3 t60 -132.83 95.37 3.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.647 ' CD1' HD21 ' A' ' 109' ' ' LEU . 74.9 m95 -92.39 110.29 21.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.63 -163.23 4.7 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.462 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.696 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.993 HD12 ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' HG13 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.483 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.692 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.511 ' HA2' HD12 ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 21' ' ' ILE . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.412 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.996 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.567 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.73 -142.31 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 88' ' ' HIS . . . 115.33 77.83 0.73 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.51 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 tm0? -119.57 166.68 12.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 0.0 110.883 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 41.0 p -79.07 -179.19 6.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.192 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.39 132.09 14.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.609 HG22 ' N ' ' A' ' 41' ' ' LYS . 35.2 mt -93.62 164.52 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.609 ' N ' HG22 ' A' ' 40' ' ' ILE . 2.1 mmmp? -83.75 88.0 7.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.917 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.0 tpp180 -119.41 -27.24 5.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.891 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 31.6 mt 54.85 49.58 17.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.24 -39.5 3.87 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 46' ' ' GLY . 0.7 OUTLIER -59.91 161.57 6.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 45' ' ' ASN . . . 162.66 -33.36 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.23 7.3 14.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.779 0.323 . . . . 0.0 110.871 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -155.07 175.18 14.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.917 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.827 HD22 ' C ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -132.81 146.73 52.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.929 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.58 -177.61 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.489 ' CA ' ' O ' ' A' ' 84' ' ' GLN . . . 139.81 -123.63 2.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.74 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm -119.3 122.08 68.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.567 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.511 HD12 ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.599 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.744 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.598 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.646 ' CE ' HD23 ' A' ' 49' ' ' LEU . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.6 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.772 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.838 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.458 ' HG ' HG13 ' A' ' 81' ' ' VAL . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.489 ' O ' ' CA ' ' A' ' 51' ' ' GLY . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.74 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.996 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.766 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.746 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.422 ' HA ' ' CD ' ' A' ' 96' ' ' LYS . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.838 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.766 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.422 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.41 ' N ' ' O ' ' A' ' 93' ' ' GLU . 18.1 m120 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.772 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.602 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.696 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.993 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.6 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -76.32 127.58 33.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.647 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.5 mt -62.53 -178.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.3 p -34.55 150.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 112' ' ' THR . 67.4 m -37.9 156.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 111' ' ' SER . 6.8 p -157.74 144.26 13.02 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.607 0.718 . . . . 0.0 111.102 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 163.74 37.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.657 2.238 . . . . 0.0 112.4 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 16.6 ttm-85 -174.79 153.69 1.79 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.876 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 116' ' ' ILE . 13.4 p -145.71 166.51 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.631 HG22 ' HD2' ' A' ' 117' ' ' PRO . 0.9 OUTLIER -118.02 138.1 25.12 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.637 0.732 . . . . 0.0 111.086 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.631 ' HD2' HG22 ' A' ' 116' ' ' ILE . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.175 0 C-N-CA 122.731 2.287 . . . . 0.0 112.349 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.6 m -64.5 144.22 57.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.92 0.391 . . . . 0.0 110.832 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 p -127.22 47.79 2.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.12 13.7 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t -168.73 165.38 11.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.89 0.376 . . . . 0.0 110.895 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -143.04 152.78 42.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.43 73.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.512 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.7 Cg_endo -69.76 2.45 3.52 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.677 2.251 . . . . 0.0 112.394 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 8' ' ' PRO . 8.1 m-80 -34.38 147.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -123.88 -19.8 5.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.578 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 32.4 m -49.14 179.24 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.917 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -125.11 62.5 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.857 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.729 ' CD1' HD21 ' A' ' 109' ' ' LEU . 50.5 m95 -89.23 114.61 25.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.88 -160.68 5.65 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.489 ' HG3' HG22 ' A' ' 103' ' ' VAL . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.91 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.741 ' CE2' ' ND2' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.839 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.668 HD11 ' HB2' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.997 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.06 -148.79 0.24 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.33 87.28 1.88 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.462 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -104.67 151.06 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 0.0 110.895 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.7 p -51.55 154.61 1.82 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 39' ' ' VAL . 2.2 t -153.39 113.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.094 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.6 mt -104.96 -70.63 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.102 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.425 ' HE3' HD12 ' A' ' 43' ' ' LEU . 31.7 mtmt -106.75 171.3 7.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.884 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.4 ' HD3' ' N ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -101.18 35.56 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.425 HD12 ' HE3' ' A' ' 41' ' ' LYS . 41.5 mt -77.23 -58.38 3.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.55 93.11 6.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -138.55 172.24 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 104.13 78.29 1.24 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.06 175.33 8.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 0.0 110.908 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.45 ' O ' ' C ' ' A' ' 49' ' ' LEU . 17.5 mm-40 -43.89 167.87 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 48' ' ' GLU . 3.2 mm? -34.34 126.28 0.47 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.83 -15.16 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.916 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.39 -171.52 5.32 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.496 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.92 HD11 ' O ' ' A' ' 86' ' ' ALA . 24.5 mm -98.63 133.55 40.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 70' ' ' LYS . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.607 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.482 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.646 ' O ' HG23 ' A' ' 66' ' ' THR . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.646 HG23 ' O ' ' A' ' 62' ' ' PRO . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.568 ' O ' HD12 ' A' ' 54' ' ' ILE . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.857 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.685 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.562 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.642 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.799 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.696 HD13 ' HB1' ' A' ' 91' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.92 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.997 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.445 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.811 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.732 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.799 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.839 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.726 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.741 ' ND2' ' CE2' ' A' ' 22' ' ' PHE . 0.8 OUTLIER -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.726 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.91 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.857 HG12 ' HA ' ' A' ' 75' ' ' ILE . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.685 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m -81.62 117.76 22.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.729 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.2 mt -48.94 167.53 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.5 t -37.13 -29.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.487 ' N ' ' O ' ' A' ' 109' ' ' LEU . 45.2 t -41.56 163.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.8 p -127.25 149.22 69.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.558 0.694 . . . . 0.0 111.167 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.85 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.701 2.267 . . . . 0.0 112.327 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.448 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.3 tpp85 -137.52 158.0 45.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.674 HG22 ' H ' ' A' ' 116' ' ' ILE . 0.5 OUTLIER -92.0 -174.97 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.131 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.674 ' H ' HG22 ' A' ' 115' ' ' VAL . 49.7 mt -101.47 138.67 19.96 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 0.0 111.117 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.664 ' HD2' HG23 ' A' ' 116' ' ' ILE . 54.5 Cg_endo . . . . . 0 C--O 1.231 0.143 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.483 -0.247 . . . . 0.0 112.483 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.3 m -155.38 177.81 10.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.4 p -93.17 89.47 6.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.85 -163.32 53.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.466 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 t -119.55 150.37 40.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.89 0.376 . . . . 0.0 110.865 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.9 t -95.14 159.16 15.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.82 146.25 16.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 9' ' ' ASN . 54.0 Cg_endo -69.76 -23.68 30.52 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.372 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 8' ' ' PRO . 9.1 m120 -34.54 146.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -131.75 132.7 44.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 5.8 p -175.31 178.88 1.6 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -133.43 64.44 1.61 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.843 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 60.1 m95 -88.77 111.46 22.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.18 -161.13 5.18 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.528 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.948 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.577 ' HG2' HG21 ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.491 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.491 HG13 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.712 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.522 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.909 HD11 HD13 ' A' ' 21' ' ' ILE . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.626 HD11 HG23 ' A' ' 92' ' ' VAL . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . 35.35 -122.05 0.55 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' HG3' ' A' ' 37' ' ' GLN . . . 94.18 102.75 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.427 ' HG3' ' C ' ' A' ' 36' ' ' GLY . 30.1 mt-30 -155.72 174.01 15.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.942 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.538 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.2 m -159.64 159.36 32.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.124 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.538 ' N ' ' CG2' ' A' ' 38' ' ' THR . 88.6 t -75.44 142.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.408 ' O ' ' C ' ' A' ' 41' ' ' LYS . 9.8 mt -105.99 -60.4 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 40' ' ' ILE . 34.7 ttpt -37.23 155.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.18 70.5 4.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 11.9 tp -135.57 155.08 51.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.469 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 6.5 mmpt? -87.78 114.51 24.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.878 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -175.06 168.36 3.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' C ' ' CD ' ' A' ' 47' ' ' GLU . . . -156.9 177.48 33.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.498 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.475 ' CD ' ' C ' ' A' ' 46' ' ' GLY . 18.7 mp0 -153.03 165.25 36.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 0.0 110.892 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.442 ' O ' ' C ' ' A' ' 49' ' ' LEU . 4.4 mm-40 -101.58 172.65 6.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.893 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 48' ' ' GLU . 0.6 OUTLIER 34.46 49.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.9 -14.55 7.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.885 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.85 -145.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.515 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.869 HD11 ' O ' ' A' ' 86' ' ' ALA . 30.6 mm -115.02 144.16 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.619 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.553 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.474 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.531 HG22 HG23 ' A' ' 31' ' ' ILE . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.603 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.487 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.487 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 62' ' ' PRO . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.671 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.619 ' O ' HD12 ' A' ' 54' ' ' ILE . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.982 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.663 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.553 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.744 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.86 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 ' HB2' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.869 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.466 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.734 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.626 HG23 HD11 ' A' ' 33' ' ' ILE . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.86 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.734 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.744 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.54 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.585 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.577 HG21 ' HG2' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.948 ' CD1' HD12 ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.982 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.663 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p -78.08 120.31 22.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.4 mt -49.83 173.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 109' ' ' LEU . 2.6 t -34.58 -74.37 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.577 ' O ' HG23 ' A' ' 112' ' ' THR . 10.5 m -109.47 -178.16 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.577 HG23 ' O ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -163.52 160.36 17.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.613 0.721 . . . . 0.0 111.116 -179.929 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -173.4 0.71 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.696 2.264 . . . . 0.0 112.311 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -143.28 177.55 8.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.646 HG12 ' H ' ' A' ' 116' ' ' ILE . 3.0 t -141.97 171.76 10.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.646 ' H ' HG12 ' A' ' 115' ' ' VAL . 3.7 pt -47.74 150.84 1.72 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.582 0.706 . . . . 0.0 111.139 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.688 2.259 . . . . 0.0 112.344 179.876 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 1.4 t -78.52 -30.48 47.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.907 0.384 . . . . 0.0 110.88 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 22.7 p 35.86 39.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.87 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.56 97.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.8 p -89.98 75.55 7.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.895 0.379 . . . . 0.0 110.852 -179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.1 m 55.53 33.01 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.862 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.98 147.08 16.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 179.05 3.95 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.651 2.234 . . . . 0.0 112.384 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 36.3 t30 -86.36 179.82 6.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.9 t80 -166.75 152.51 8.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.562 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 51.6 m -40.72 160.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.3 t-80 -110.28 66.27 0.63 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.719 ' CD1' HD21 ' A' ' 109' ' ' LEU . 70.6 m95 -84.94 109.14 17.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.923 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.21 -162.18 3.8 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.484 ' HD3' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.803 HG23 ' CG1' ' A' ' 103' ' ' VAL . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 1.061 HD12 ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.601 ' HG2' HG21 ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.819 HD12 HG23 ' A' ' 95' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.735 HD11 HD13 ' A' ' 21' ' ' ILE . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.447 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.552 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 57.78 -150.31 31.78 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' HB2' ' A' ' 88' ' ' HIS . . . 85.04 145.18 7.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.436 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.468 ' N ' ' H ' ' A' ' 88' ' ' HIS . 5.2 pt20 46.52 33.87 2.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.877 0.37 . . . . 0.0 110.931 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.1 p -102.83 113.8 27.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 82.2 t -130.24 117.1 38.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.407 HD12 ' N ' ' A' ' 40' ' ' ILE . 4.5 mp -115.68 -64.31 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.088 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.47 175.3 9.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.416 ' HA ' ' NE ' ' A' ' 42' ' ' ARG . 7.9 tpm_? -54.92 98.41 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 19.4 mt -96.75 114.91 26.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.905 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 28.8 mmtp -76.94 170.03 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 33.1 p-10 -98.71 117.3 32.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.87 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.66 60.39 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 -150.27 176.75 10.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.805 0.336 . . . . 0.0 110.91 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -46.69 146.89 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.907 ' O ' HD22 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -37.53 129.91 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.938 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.484 ' CG ' ' N ' ' A' ' 51' ' ' GLY . 13.6 ttpt -115.06 163.09 16.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.484 ' N ' ' CG ' ' A' ' 50' ' ' LYS . . . 150.35 -161.75 29.04 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.491 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.85 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.5 mm -95.98 117.56 40.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.41 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.456 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.624 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.686 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.573 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.686 HG23 ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.736 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.41 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.704 ' CE ' HD23 ' A' ' 49' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.632 ' HA ' HG12 ' A' ' 106' ' ' VAL . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.679 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.589 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.7 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.843 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.788 HD13 ' HB1' ' A' ' 91' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.85 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.416 ' HB2' ' CA ' ' A' ' 37' ' ' GLN . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.739 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.477 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.788 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.843 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.819 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.971 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.971 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.803 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 1.061 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.632 HG12 ' HA ' ' A' ' 75' ' ' ILE . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.679 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t -74.9 131.5 40.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.719 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.7 mt -68.24 159.62 30.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -44.7 92.1 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.827 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.46 ' N ' ' O ' ' A' ' 109' ' ' LEU . 27.0 t -158.83 177.09 11.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.871 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 30.0 p -112.57 145.21 32.47 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.587 0.708 . . . . 0.0 111.149 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.711 2.274 . . . . 0.0 112.361 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -122.35 -174.32 2.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.845 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.9 t -106.32 164.96 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.598 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -119.49 158.66 48.51 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.62 0.724 . . . . 0.0 111.117 179.924 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.203 0 C-N-CA 122.685 2.256 . . . . 0.0 112.326 179.908 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -161.6 151.39 16.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.864 0.364 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.4 p -141.89 131.87 24.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.39 -101.31 2.43 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 t 45.52 45.52 10.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 110.877 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.0 t -70.33 -59.52 2.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.65 160.49 14.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.7 175.81 7.56 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.396 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -104.3 143.99 32.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -141.21 -175.11 4.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.524 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.8 m -48.93 178.64 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.848 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -116.34 55.83 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.744 ' CD1' HD21 ' A' ' 109' ' ' LEU . 59.1 m95 -75.19 117.71 17.31 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.911 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -78.93 -161.6 20.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.495 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.816 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.865 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.481 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.481 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.732 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.556 HD11 HD13 ' A' ' 21' ' ' ILE . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.501 HD11 HG23 ' A' ' 92' ' ' VAL . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.543 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 49.05 -134.65 22.74 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 95.85 96.27 1.77 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.438 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -152.84 -175.99 5.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.903 0.382 . . . . 0.0 110.89 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -46.55 173.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.144 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -129.58 140.83 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 41' ' ' LYS . 0.3 OUTLIER -118.68 -179.94 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.728 ' H ' HG22 ' A' ' 40' ' ' ILE . 0.0 OUTLIER -127.16 47.31 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.815 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.473 ' CG ' ' HG2' ' A' ' 44' ' ' LYS . 9.6 ttt180 -62.05 91.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.886 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.471 ' CD2' ' H ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -82.07 40.05 0.6 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.473 ' HG2' ' CG ' ' A' ' 42' ' ' ARG . 13.7 ptpt -130.65 -174.8 3.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.956 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 44' ' ' LYS . 26.2 m-80 -37.47 156.38 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -167.84 116.79 0.69 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.13 8.32 36.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.902 0.382 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -138.57 165.23 27.42 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.784 HD13 ' H ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -110.98 159.39 17.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.97 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.4 138.95 54.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 151.15 176.03 23.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.1 mm -86.4 124.05 40.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.678 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.551 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.543 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.625 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.684 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.678 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.601 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.551 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.915 ' HA ' HG12 ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.586 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.679 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.807 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.593 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.793 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.603 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.579 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.764 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 88' ' ' HIS . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.807 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.733 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.733 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.816 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.865 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.586 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.419 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 29.0 t -78.07 131.2 37.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.744 HD21 ' CD1' ' A' ' 13' ' ' TRP . 7.9 mt -66.34 159.78 26.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.5 t -44.71 101.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.834 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.9 p -151.67 -177.98 6.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.873 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.2 p -121.97 147.98 50.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.517 0.675 . . . . 0.0 111.175 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -163.8 0.12 Allowed 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.366 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.1 mtm180 -113.44 -174.41 2.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.726 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.9 t -87.4 177.74 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.142 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.726 ' H ' HG12 ' A' ' 115' ' ' VAL . 0.0 OUTLIER -114.25 158.37 39.89 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.615 0.721 . . . . 0.0 111.143 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.14 0 C-N-CA 122.675 2.25 . . . . 0.0 112.366 179.868 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.6 t -94.78 9.83 37.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 0.0 110.853 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 m -133.49 148.49 51.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 165.45 77.27 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.425 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.9 p -140.88 178.9 7.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.916 0.388 . . . . 0.0 110.805 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.2 m -105.42 -176.1 2.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.842 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.71 82.85 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.515 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -50.72 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.695 2.263 . . . . 0.0 112.311 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.548 ' O ' ' CG ' ' A' ' 10' ' ' PHE . 41.8 t30 -95.6 112.77 24.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.866 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 9' ' ' ASN . 9.4 m-85 -174.24 166.51 4.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.7 m -47.4 175.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 9.1 m-70 -111.12 58.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.842 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 67.4 m95 -80.44 114.28 19.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -76.09 -161.77 11.64 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.472 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.576 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.928 HD12 ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.562 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.448 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.82 HD12 HG23 ' A' ' 95' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.513 HD11 HG23 ' A' ' 92' ' ' VAL . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.556 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.25 -132.86 2.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.35 92.75 1.81 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.463 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -156.74 172.7 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.919 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.613 HG23 ' HB3' ' A' ' 87' ' ' SER . 1.7 p -132.05 164.01 27.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.806 HG13 ' N ' ' A' ' 40' ' ' ILE . 0.3 OUTLIER -123.45 -168.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.104 179.895 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.806 ' N ' HG13 ' A' ' 39' ' ' VAL . 14.8 mm -141.29 -47.12 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.149 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.8 mtpp -67.46 121.05 14.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.906 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 53.1 mmt-85 -81.29 -27.04 35.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.533 ' C ' ' CD1' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.52 13.24 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.931 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.5 tmtt? -133.67 125.25 28.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -144.66 160.5 41.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 47' ' ' GLU . . . -114.18 12.67 21.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 46' ' ' GLY . 20.5 pt-20 36.55 39.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.329 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -129.62 173.31 10.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.533 HD12 ' HZ ' ' A' ' 53' ' ' PHE . 3.3 mm? -59.0 118.09 5.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.972 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.4 ' C ' ' HD3' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -107.13 -18.11 13.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.02 -177.5 33.02 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.95 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.1 mm -93.17 152.38 3.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.533 ' HZ ' HD12 ' A' ' 49' ' ' LEU . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.556 ' HB2' HG12 ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.612 ' N ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.557 ' O ' HG23 ' A' ' 66' ' ' THR . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.571 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 21' ' ' ILE . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.585 ' HE3' HD21 ' A' ' 76' ' ' LEU . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 1.02 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.585 HD21 ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.585 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.722 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.821 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.95 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.613 ' HB3' HG23 ' A' ' 38' ' ' THR . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.507 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.78 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.513 HG23 HD11 ' A' ' 33' ' ' ILE . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.821 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.82 HG23 HD12 ' A' ' 29' ' ' LEU . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.722 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.562 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.697 HG13 ' CB ' ' A' ' 98' ' ' ALA . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.576 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.928 ' CD2' HD12 ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 1.02 HG12 ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.507 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t -79.45 125.37 29.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.6 mt -60.25 159.43 9.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 5.6 t -34.61 93.48 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 109' ' ' LEU . 4.9 p -79.9 -174.63 4.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.855 -179.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.8 160.67 52.49 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.59 0.71 . . . . 0.0 111.15 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 166.45 27.52 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.709 2.273 . . . . 0.0 112.393 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.42 165.03 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.542 HG12 ' N ' ' A' ' 116' ' ' ILE . 12.6 t -101.52 164.52 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.68 HG23 ' HD2' ' A' ' 117' ' ' PRO . 10.1 mm -78.63 138.7 58.47 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.568 0.699 . . . . 0.0 111.139 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.68 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.6 Cg_endo . . . . . 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.355 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.1 p -146.28 148.92 32.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.861 0.362 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -72.47 175.47 6.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.75 -134.11 2.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.435 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -136.07 159.29 42.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.919 0.39 . . . . 0.0 110.861 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.1 m -137.08 168.07 20.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.06 74.24 1.11 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.432 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -38.88 7.26 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.404 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 53.52 52.35 13.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.437 ' HZ ' HD11 ' A' ' 49' ' ' LEU . 2.5 t80 -119.8 -175.54 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.458 ' HB2' ' NE1' ' A' ' 13' ' ' TRP . 1.9 m -51.74 -174.8 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.851 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -121.27 81.98 1.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.846 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.743 ' CD1' HD21 ' A' ' 109' ' ' LEU . 54.7 m95 -87.07 112.97 22.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.894 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.31 -163.36 15.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.47 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.737 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.503 HG21 ' HB1' ' A' ' 68' ' ' ALA . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.758 ' HG3' HG22 ' A' ' 103' ' ' VAL . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 1.079 HD11 HD11 ' A' ' 69' ' ' LEU . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HB2' HG13 ' A' ' 27' ' ' VAL . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 24' ' ' GLU . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.765 HD12 HG23 ' A' ' 95' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.475 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 57' ' ' VAL . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.537 HD11 HG23 ' A' ' 92' ' ' VAL . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 42.16 -156.65 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.494 ' O ' ' CG ' ' A' ' 37' ' ' GLN . . . 88.7 154.06 27.86 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.482 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.589 ' N ' ' H ' ' A' ' 88' ' ' HIS . 1.2 pt20 49.15 33.27 4.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.864 0.364 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -106.36 -12.51 15.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 -179.932 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.471 ' CG1' ' N ' ' A' ' 40' ' ' ILE . 23.4 t -155.57 156.61 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.471 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 49.0 mt -109.36 -62.79 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 41.7 tttt -97.1 144.05 27.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' C ' HD22 ' A' ' 43' ' ' LEU . 3.9 tpm_? -172.06 138.9 1.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.8 ' N ' HD22 ' A' ' 43' ' ' LEU . 0.3 OUTLIER -112.99 -177.41 3.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 20.3 mtmm -59.87 97.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.883 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -119.03 -24.37 6.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.23 169.52 35.03 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.518 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.04 29.31 7.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.787 0.327 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -56.43 -175.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.762 ' N ' HD13 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -106.07 71.11 0.87 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.3 -12.37 15.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.73 -146.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.949 HD11 ' O ' ' A' ' 86' ' ' ALA . 7.6 mm -99.03 107.51 20.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.662 ' CZ ' ' CB ' ' A' ' 49' ' ' LEU . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.728 HG22 HG23 ' A' ' 31' ' ' ILE . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.494 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.494 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.584 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.3 m-20 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 1.079 HD11 HD11 ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 54' ' ' ILE . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.552 ' HB2' HD12 ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.495 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 1.016 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.729 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.473 ' OE1' HD12 ' A' ' 105' ' ' ILE . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.55 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.753 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.847 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.949 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.45 ' CB ' ' H ' ' A' ' 37' ' ' GLN . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.411 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.724 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.537 HG23 HD11 ' A' ' 33' ' ' ILE . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.847 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.765 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.753 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.626 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.758 HG22 ' HG3' ' A' ' 20' ' ' GLU . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.756 ' CD1' HD12 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.473 HD12 ' OE1' ' A' ' 77' ' ' GLU . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 1.016 HG12 ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.729 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t -80.29 131.23 35.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.743 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.3 mt -62.31 165.88 5.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.96 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -34.52 -33.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.489 ' N ' ' O ' ' A' ' 109' ' ' LEU . 11.4 m -46.26 172.26 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.844 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 8.0 p -146.33 144.16 20.61 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.591 0.71 . . . . 0.0 111.167 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.721 2.281 . . . . 0.0 112.344 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.514 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 19.4 ttp180 -145.72 164.29 32.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.818 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.514 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 9.7 p -128.02 164.05 30.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.703 ' C ' HD12 ' A' ' 116' ' ' ILE . 1.2 pp -69.78 151.1 96.48 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 111.114 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.437 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.16 0 C-N-CA 122.721 2.281 . . . . 0.0 112.337 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.0 p -153.78 171.97 18.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.839 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.1 p -174.68 131.47 0.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.58 174.89 34.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -87.64 -71.83 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 m 62.4 54.83 2.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.828 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.544 ' N ' ' CD ' ' A' ' 8' ' ' PRO . . . -155.75 46.24 0.52 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.452 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 7' ' ' GLY . 53.8 Cg_endo -69.75 -13.57 34.87 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.625 2.217 . . . . 0.0 112.326 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.433 ' C ' ' O ' ' A' ' 8' ' ' PRO . 1.7 m-20 -34.78 144.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.849 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.96 107.31 11.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.549 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 6.3 t -175.15 -174.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.11 77.15 1.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.849 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 56.0 m95 -96.75 113.9 25.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -73.91 -159.6 6.18 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.43 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.62 HG23 ' CG1' ' A' ' 103' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.403 ' HG3' HG22 ' A' ' 103' ' ' VAL . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.724 HD13 HD11 ' A' ' 31' ' ' ILE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.488 ' H ' ' CD ' ' A' ' 23' ' ' ARG . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.487 ' CB ' HG13 ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD2' ' CD ' ' A' ' 24' ' ' GLU . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.487 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.656 HD22 ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.488 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.724 HD11 HD13 ' A' ' 21' ' ' ILE . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.942 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 33.86 -143.56 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 126.87 -52.64 0.81 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.448 ' C ' ' O ' ' A' ' 36' ' ' GLY . 4.3 mm100 -34.16 113.65 0.18 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 9.6 t -59.62 179.63 0.11 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.5 155.67 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 77.3 mt -109.63 -53.57 5.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.419 ' C ' ' CG ' ' A' ' 42' ' ' ARG . 43.0 tttp -109.44 25.18 12.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.419 ' CG ' ' C ' ' A' ' 41' ' ' LYS . 6.8 ptm180 41.76 29.37 0.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.835 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 14.0 mt -72.53 -10.03 59.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 mmmm -94.63 -62.63 1.29 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -84.49 157.41 21.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.41 -75.73 0.83 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.503 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.08 -6.17 10.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.824 0.345 . . . . 0.0 110.88 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.4 mp0 -68.82 -177.46 1.0 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.488 HD22 ' HZ ' ' A' ' 53' ' ' PHE . 5.2 mp -100.58 168.97 9.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.895 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -114.16 -28.23 7.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.915 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . -46.58 151.4 1.54 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.458 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.877 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.4 mm -69.35 123.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 73' ' ' ASP . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.488 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.575 ' HG2' HD23 ' A' ' 29' ' ' LEU . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.405 ' H ' HG23 ' A' ' 66' ' ' THR . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.528 ' HB2' HD12 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.921 ' HA ' HG12 ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.621 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.685 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.829 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.464 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.877 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.4 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' HIS . . . . . 0.942 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.476 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.699 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.742 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.829 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.699 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.8 m120 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.718 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.497 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.718 HG13 ' CB ' ' A' ' 98' ' ' ALA . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.62 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.706 ' CE1' HD12 ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.921 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.621 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.43 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t -77.45 119.4 21.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.0 mt -56.16 157.44 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.918 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 1.8 t -36.8 103.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.2 m -175.36 163.23 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 65.0 p -117.06 144.17 33.09 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.571 0.701 . . . . 0.0 111.129 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 -163.8 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.663 2.242 . . . . 0.0 112.376 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -124.53 -174.79 3.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.564 HG22 ' N ' ' A' ' 116' ' ' ILE . 10.2 p -80.16 165.69 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.157 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.564 ' N ' HG22 ' A' ' 115' ' ' VAL . 0.7 OUTLIER -78.26 145.2 68.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.617 0.723 . . . . 0.0 111.149 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.39 179.865 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.329 0 CA-C-O 121.421 0.456 . . . . 0.0 112.475 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.717 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.518 HG21 ' HB1' ' A' ' 68' ' ' ALA . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.909 HD11 HD11 ' A' ' 69' ' ' LEU . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.428 ' CG ' HD22 ' A' ' 100' ' ' ASN . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.548 ' HB2' HG13 ' A' ' 27' ' ' VAL . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.548 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.41 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.651 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.473 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 21' ' ' ILE . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.473 HD11 HG23 ' A' ' 92' ' ' VAL . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 1.008 HD11 ' O ' ' A' ' 86' ' ' ALA . 8.5 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.618 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.634 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.518 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.909 HD11 HD11 ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.5 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.535 ' HE3' HD23 ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.731 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.844 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.682 HD22 ' HA ' ' A' ' 91' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 1.008 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.42 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.715 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.473 HG23 HD11 ' A' ' 33' ' ' ILE . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.491 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.844 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.715 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.8 m-20 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.535 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.44 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.717 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.831 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.481 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.417 0.454 . . . . 0.0 112.489 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.512 HG23 ' CG1' ' A' ' 103' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.409 HG21 ' HB1' ' A' ' 68' ' ' ALA . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.856 HD12 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.94 HD11 HG11 ' A' ' 102' ' ' VAL . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.818 HD11 HD13 ' A' ' 21' ' ' ILE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.888 HD11 HG23 ' A' ' 92' ' ' VAL . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.897 HD11 ' O ' ' A' ' 86' ' ' ALA . 29.4 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.542 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.432 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.432 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.609 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.711 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.559 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.693 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.512 ' HA ' HG22 ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.987 ' HA ' HG12 ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.401 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.538 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.814 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.546 HD22 ' HA ' ' A' ' 91' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.897 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.458 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.658 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.888 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.814 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.658 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.447 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.7 m-20 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.53 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.94 HG11 HD11 ' A' ' 29' ' ' LEU . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.512 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.856 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.987 HG12 ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.481 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 2.6 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.431 0.462 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.872 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.796 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.466 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.507 HG21 ' CG2' ' A' ' 52' ' ' ILE . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.94 HD11 ' O ' ' A' ' 86' ' ' ALA . 37.2 mm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.583 HD12 ' O ' ' A' ' 70' ' ' LYS . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.466 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.583 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.95 ' HA ' HG12 ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.612 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.664 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.618 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.94 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.687 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.4 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.791 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 88' ' ' HIS . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.796 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.404 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.6 m-20 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.872 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.95 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.612 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 CA-C-O 121.399 0.444 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.686 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.49 HG21 ' CB ' ' A' ' 68' ' ' ALA . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.839 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.477 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 95' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.061 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.561 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.91 HD11 ' O ' ' A' ' 86' ' ' ALA . 21.1 mm . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.506 HD12 ' HB2' ' A' ' 73' ' ' ASP . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.561 ' HB2' HG12 ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.448 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.448 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.597 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.49 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.556 ' HE2' HD21 ' A' ' 76' ' ' LEU . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.769 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.619 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.828 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.541 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.91 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 1.061 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.52 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.758 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.729 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.828 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 75.6 m-20 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.744 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.555 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.744 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.686 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.839 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 75' ' ' ILE . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.619 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 CA-C-O 121.422 0.457 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.427 HG23 ' CG1' ' A' ' 103' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.407 ' HG3' HG22 ' A' ' 103' ' ' VAL . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.921 HD11 HD11 ' A' ' 69' ' ' LEU . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.513 ' HB2' HG13 ' A' ' 27' ' ' VAL . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.402 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.862 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.767 HD11 HD13 ' A' ' 21' ' ' ILE . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HG23 ' A' ' 92' ' ' VAL . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.549 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.948 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CE2' ' HG3' ' A' ' 74' ' ' LYS . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.48 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.474 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.653 ' O ' HG23 ' A' ' 66' ' ' THR . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.586 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.653 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.921 HD11 HD11 ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.48 ' O ' HD12 ' A' ' 54' ' ' ILE . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.528 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 1.031 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.579 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.752 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.853 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.738 HD22 ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.948 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.506 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.738 ' HA ' HD22 ' A' ' 83' ' ' LEU . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 33' ' ' ILE . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.494 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.853 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.862 HG23 HD12 ' A' ' 29' ' ' LEU . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.494 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.8 m-20 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.752 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.526 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.596 HG13 ' CB ' ' A' ' 98' ' ' ALA . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.427 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.848 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 1.031 HG12 ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.579 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 CA-C-O 121.44 0.466 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.578 HG23 ' CG1' ' A' ' 103' ' ' VAL . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' HG3' HG22 ' A' ' 103' ' ' VAL . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.864 HD12 ' CD2' ' A' ' 104' ' ' PHE . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.599 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.548 ' H ' ' ND2' ' A' ' 100' ' ' ASN . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.873 HD12 HG23 ' A' ' 95' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.478 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.488 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' N ' HG23 ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.847 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.9 mm . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 70' ' ' LYS . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.478 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.461 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.576 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.782 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.518 ' O ' HD12 ' A' ' 54' ' ' ILE . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.983 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.608 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.579 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.77 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.788 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.812 HD13 ' HB1' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.847 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.624 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.509 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.474 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.788 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.873 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.474 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.77 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.599 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.2 t-20 -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 29' ' ' LEU . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.578 ' CG1' HG23 ' A' ' 18' ' ' ILE . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.864 ' CD2' HD12 ' A' ' 21' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.983 HG12 ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.608 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 CA-C-O 121.431 0.462 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.65 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 68' ' ' ALA . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.889 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG23 ' A' ' 92' ' ' VAL . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.594 HG23 ' N ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' N ' HG23 ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.721 HG22 HD12 ' A' ' 75' ' ' ILE . 9.1 mm . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.445 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.677 ' O ' HG23 ' A' ' 66' ' ' THR . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.677 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.669 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.469 ' NZ ' HD21 ' A' ' 76' ' ' LEU . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.721 HD12 HG22 ' A' ' 52' ' ' ILE . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.844 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.557 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.739 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.869 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.458 HD21 ' HB2' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.692 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.62 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.716 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.616 HG23 HD11 ' A' ' 33' ' ' ILE . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.488 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.869 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 29' ' ' LEU . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.488 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.4 m-20 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.785 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.785 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.65 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.889 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.844 ' CG ' HD11 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 CA-C-O 121.41 0.45 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 1.012 ' NH1' HG23 ' A' ' 106' ' ' VAL . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.768 HG23 ' CG1' ' A' ' 103' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.574 HG21 ' CB ' ' A' ' 68' ' ' ALA . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.506 ' HG3' HG22 ' A' ' 103' ' ' VAL . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.838 HD12 ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.736 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.468 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.448 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.572 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.926 HD11 ' O ' ' A' ' 86' ' ' ALA . 31.1 mm . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.401 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.572 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.461 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.461 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.468 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.527 ' O ' HG23 ' A' ' 66' ' ' THR . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 62' ' ' PRO . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.574 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.771 HD11 HD11 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.946 ' HA ' HG12 ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.822 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.692 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.926 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.67 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.593 ' HB3' ' HB1' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.801 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.67 HG23 ' O ' ' A' ' 88' ' ' HIS . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.822 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.801 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.741 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 12.7 t-20 -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.741 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.768 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.838 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 1.012 HG23 ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 CA-C-O 121.459 0.477 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.561 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.934 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.681 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.669 HD11 HD13 ' A' ' 21' ' ' ILE . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.798 HD12 ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.559 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.968 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.9 mm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' LYS . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.559 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.455 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.464 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.585 ' O ' HG23 ' A' ' 66' ' ' THR . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.612 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.585 HG23 ' O ' ' A' ' 62' ' ' PRO . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.603 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.409 ' O ' HD12 ' A' ' 54' ' ' ILE . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.581 ' HD3' HD21 ' A' ' 76' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.977 ' HA ' HG12 ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.581 HD21 ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.581 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.741 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.841 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.848 HD13 ' HB1' ' A' ' 91' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.968 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.798 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.848 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 88' ' ' HIS . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.841 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.781 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.6 m-80 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.741 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.74 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.561 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.934 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.977 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.54 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 CA-C-O 121.421 0.456 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG21 ' CB ' ' A' ' 68' ' ' ALA . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.883 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.778 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.603 HD11 HD13 ' A' ' 21' ' ' ILE . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 92' ' ' VAL . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.751 HD11 ' O ' ' A' ' 86' ' ' ALA . 9.0 mm . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.637 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.449 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.449 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.629 HD12 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' O ' HG23 ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.483 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.637 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.923 ' HA ' HG12 ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.632 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.543 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.817 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.592 HD13 ' HB1' ' A' ' 91' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . 0.454 HD22 ' N ' ' A' ' 85' ' ' ASN . 0.9 OUTLIER -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.751 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.487 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.748 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.529 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.817 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.778 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.4 m-20 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.794 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.883 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.923 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.632 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 CA-C-O 121.432 0.462 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.649 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.532 HG21 ' HB1' ' A' ' 68' ' ' ALA . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.924 HD11 HD11 ' A' ' 69' ' ' LEU . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.519 ' HG2' HG23 ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.72 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.469 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.69 HD11 HD13 ' A' ' 21' ' ' ILE . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.897 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.555 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.863 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.5 mm . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HB2' HG12 ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.623 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.679 ' O ' HG23 ' A' ' 66' ' ' THR . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.532 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.924 HD11 HD11 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.401 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 1.026 ' HA ' HG12 ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.649 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.544 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.785 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.664 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 57.9 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.863 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.897 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.739 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.846 HG23 HD11 ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.452 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.785 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.739 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.7 m-80 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.679 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.584 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.679 HG13 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.649 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 1.026 HG12 ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.649 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 CA-C-O 121.43 0.461 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.406 ' NH1' ' HB3' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.712 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.441 HG21 ' CB ' ' A' ' 68' ' ' ALA . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.843 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.62 ' HG3' HG23 ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.677 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 21' ' ' ILE . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.565 HD11 HG23 ' A' ' 92' ' ' VAL . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.93 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.3 mm . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.419 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.56 ' HB2' HG12 ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.454 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.454 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.62 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.706 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.706 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.649 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.907 ' HA ' HG12 ' A' ' 106' ' ' VAL . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.798 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.598 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.799 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.888 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.587 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.93 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . 0.458 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.596 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.806 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.565 HG23 HD11 ' A' ' 33' ' ' ILE . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 92' ' ' VAL . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.888 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.806 HD12 ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.586 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.712 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.843 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.907 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.798 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 CA-C-O 121.421 0.456 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.696 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.993 HD12 ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' HG13 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.483 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.692 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.511 ' HA2' HD12 ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 21' ' ' ILE . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.412 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.996 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.567 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.74 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.567 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.511 HD12 ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.599 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.744 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.598 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.423 ' HZ3' HD23 ' A' ' 76' ' ' LEU . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.6 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.772 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.838 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.458 ' HG ' HG13 ' A' ' 81' ' ' VAL . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.422 ' C ' ' O ' ' A' ' 83' ' ' LEU . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.74 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.996 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.766 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.746 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.838 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.766 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.422 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.1 m-20 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.772 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.602 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.696 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.993 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.6 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 CA-C-O 121.424 0.458 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.489 ' HG3' HG22 ' A' ' 103' ' ' VAL . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.91 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.839 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.668 HD11 ' HB2' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.997 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.92 HD11 ' O ' ' A' ' 86' ' ' ALA . 24.5 mm . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 70' ' ' LYS . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.607 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.482 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.646 ' O ' HG23 ' A' ' 66' ' ' THR . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.646 HG23 ' O ' ' A' ' 62' ' ' PRO . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.568 ' O ' HD12 ' A' ' 54' ' ' ILE . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.857 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.685 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.562 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.642 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.799 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.696 HD13 ' HB1' ' A' ' 91' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.92 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.997 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.445 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.811 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.732 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.477 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.799 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.839 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 72.1 m-20 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.726 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 19.3 t-20 -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.726 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.91 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.857 HG12 ' HA ' ' A' ' 75' ' ' ILE . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.685 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.298 0 CA-C-O 121.378 0.432 . . . . 0.0 112.528 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.948 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.577 ' HG2' HG21 ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.491 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.491 HG13 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.712 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.522 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.909 HD11 HD13 ' A' ' 21' ' ' ILE . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.626 HD11 HG23 ' A' ' 92' ' ' VAL . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.869 HD11 ' O ' ' A' ' 86' ' ' ALA . 30.6 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.619 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.553 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.474 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.531 HG22 HG23 ' A' ' 31' ' ' ILE . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.487 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.487 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 62' ' ' PRO . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.671 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.619 ' O ' HD12 ' A' ' 54' ' ' ILE . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.982 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.663 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.553 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.744 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.86 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 ' HB2' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.869 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.466 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.734 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.626 HG23 HD11 ' A' ' 33' ' ' ILE . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.86 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.734 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.7 m-20 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.744 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.54 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.585 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.577 HG21 ' HG2' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.948 ' CD1' HD12 ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.982 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.663 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 CA-C-O 121.416 0.453 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.484 ' HD3' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.803 HG23 ' CG1' ' A' ' 103' ' ' VAL . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 1.061 HD12 ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.601 ' HG2' HG21 ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.5 m-80 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.819 HD12 HG23 ' A' ' 95' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.735 HD11 HD13 ' A' ' 21' ' ' ILE . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.447 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.552 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.85 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.5 mm . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.41 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.456 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.686 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.573 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.686 HG23 ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.736 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.41 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.561 ' HD3' HD21 ' A' ' 76' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.632 ' HA ' HG12 ' A' ' 106' ' ' VAL . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.679 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.589 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.7 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.843 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.788 HD13 ' HB1' ' A' ' 91' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.85 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.739 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.477 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.788 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.492 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.843 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.819 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.492 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.9 m-80 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.971 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.971 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.803 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 1.061 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.632 HG12 ' HA ' ' A' ' 75' ' ' ILE . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.679 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.451 -0.332 0 CA-C-O 121.458 0.477 . . . . 0.0 112.495 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.816 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.865 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.481 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.481 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.732 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.556 HD11 HD13 ' A' ' 21' ' ' ILE . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.501 HD11 HG23 ' A' ' 92' ' ' VAL . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.543 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.1 mm . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.431 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.551 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.543 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.684 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.678 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.601 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.551 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.915 ' HA ' HG12 ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.586 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.679 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.807 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.593 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.793 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.603 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.579 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.764 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 88' ' ' HIS . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.484 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.807 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.484 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 68.8 m-20 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.733 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.733 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.816 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.865 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.586 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . 0.419 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 29.0 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.277 0 CA-C-O 121.444 0.469 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.576 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.928 HD12 ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.562 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.448 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.82 HD12 HG23 ' A' ' 95' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.513 HD11 HG23 ' A' ' 92' ' ' VAL . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.556 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.95 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.1 mm . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.469 ' CZ ' ' HG3' ' A' ' 74' ' ' LYS . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.556 ' HB2' HG12 ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.612 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.557 ' O ' HG23 ' A' ' 66' ' ' THR . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.571 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 21' ' ' ILE . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.585 ' HE3' HD21 ' A' ' 76' ' ' LEU . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 1.02 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.585 HD21 ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.585 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.722 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.821 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.95 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.507 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.78 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.513 HG23 HD11 ' A' ' 33' ' ' ILE . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.497 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.821 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.82 HG23 HD12 ' A' ' 29' ' ' LEU . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.3 m-20 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.722 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.562 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.697 HG13 ' CB ' ' A' ' 98' ' ' ALA . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.576 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.928 ' CD2' HD12 ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 1.02 HG12 ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.507 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 CA-C-O 121.494 0.497 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.737 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.503 HG21 ' HB1' ' A' ' 68' ' ' ALA . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.758 ' HG3' HG22 ' A' ' 103' ' ' VAL . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 1.079 HD11 HD11 ' A' ' 69' ' ' LEU . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HB2' HG13 ' A' ' 27' ' ' VAL . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 24' ' ' GLU . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.765 HD12 HG23 ' A' ' 95' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.475 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 57' ' ' VAL . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.537 HD11 HG23 ' A' ' 92' ' ' VAL . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.949 HD11 ' O ' ' A' ' 86' ' ' ALA . 7.6 mm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.495 ' CE1' ' HG3' ' A' ' 74' ' ' LYS . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.728 HG22 HG23 ' A' ' 31' ' ' ILE . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.494 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.494 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.584 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 1.079 HD11 HD11 ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 54' ' ' ILE . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.552 ' HB2' HD12 ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.495 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 1.016 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.729 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.473 ' OE1' HD12 ' A' ' 105' ' ' ILE . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.55 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.753 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.847 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.949 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.411 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.724 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.537 HG23 HD11 ' A' ' 33' ' ' ILE . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.847 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.765 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.7 m-20 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.753 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.626 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.758 HG22 ' HG3' ' A' ' 20' ' ' GLU . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.756 ' CD1' HD12 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.473 HD12 ' OE1' ' A' ' 77' ' ' GLU . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 1.016 HG12 ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.729 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-O 121.449 0.472 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.43 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.62 HG23 ' CG1' ' A' ' 103' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.403 ' HG3' HG22 ' A' ' 103' ' ' VAL . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.724 HD13 HD11 ' A' ' 31' ' ' ILE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.488 ' CD ' ' H ' ' A' ' 23' ' ' ARG . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.487 ' CB ' HG13 ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD2' ' CD ' ' A' ' 24' ' ' GLU . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.487 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.656 HD22 ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.488 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.724 HD11 HD13 ' A' ' 21' ' ' ILE . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.942 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.877 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.4 mm . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 73' ' ' ASP . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.488 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.575 ' HG2' HD23 ' A' ' 29' ' ' LEU . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.405 ' H ' HG23 ' A' ' 66' ' ' THR . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.528 ' HB2' HD12 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.921 ' HA ' HG12 ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.621 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.685 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.829 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.464 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.877 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' SER . . . . . 0.4 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' HIS . . . . . 0.942 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.476 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.699 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.742 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.829 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.699 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.5 m-20 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.718 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.497 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.718 HG13 ' CB ' ' A' ' 98' ' ' ALA . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.62 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.706 ' CE1' HD12 ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.921 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.621 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . 0.43 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -48.11 -22.35 0.61 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.919 0.39 . . . . 0.0 110.869 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.9 t -121.24 -40.88 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.841 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.68 152.39 26.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.47 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 t -140.92 136.71 32.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.838 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 p -137.33 110.02 7.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.99 78.11 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 71.2 1.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.701 2.268 . . . . 0.0 112.354 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 64.91 44.82 3.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -117.34 116.13 26.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.595 ' O ' ' CD1' ' A' ' 13' ' ' TRP . 7.5 t 50.76 45.31 27.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.857 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.8 t60 -66.66 107.25 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.727 ' CE2' HD21 ' A' ' 109' ' ' LEU . 65.8 m95 -88.2 108.61 19.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -66.31 -162.71 1.26 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.475 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 159.7 52.41 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 165.62 30.33 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.645 2.23 . . . . 0.0 112.345 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -140.92 131.32 25.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.717 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.4 mt -99.94 130.98 48.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.144 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.518 HG21 ' HB1' ' A' ' 68' ' ' ALA . 24.4 t -139.88 125.94 22.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.147 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.65 119.65 28.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.909 HD11 HD11 ' A' ' 69' ' ' LEU . 3.2 mt -117.67 120.96 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.556 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -86.2 118.87 25.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.428 ' CG ' HD22 ' A' ' 100' ' ' ASN . 19.0 ptt85 -61.3 149.73 37.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.548 ' HB2' HG13 ' A' ' 27' ' ' VAL . 13.9 mm-40 -112.11 155.8 42.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.667 0.746 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -90.89 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.677 2.252 . . . . 0.0 112.309 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -46.93 -41.41 16.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.924 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.548 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.9 p -108.53 153.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.41 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.33 -168.77 2.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.826 -179.849 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.651 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.9 mt -60.55 -24.39 65.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.93 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.473 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.32 11.54 77.89 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.444 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 21' ' ' ILE . 11.8 mt -111.79 148.76 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 111.139 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.0 m -132.16 170.49 14.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.473 HD11 HG23 ' A' ' 92' ' ' VAL . 15.5 pt -141.34 148.42 21.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.6 173.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.137 179.872 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 37.94 -121.3 0.97 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.518 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.38 83.74 1.71 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.52 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.8 mt-30 -123.03 155.06 37.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.853 0.359 . . . . 0.0 110.887 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 6.0 t -127.03 -10.84 5.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.09 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 t -142.68 128.2 16.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.132 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 41' ' ' LYS . 15.5 mt -143.52 163.56 15.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.526 ' N ' HG22 ' A' ' 40' ' ' ILE . 0.7 OUTLIER -51.26 132.24 28.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' A' ' 44' ' ' LYS . 14.0 tpp180 -70.12 -67.79 0.47 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 42' ' ' ARG . 3.9 mp -34.53 -32.91 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 42' ' ' ARG . 19.7 ttpt -43.18 134.79 3.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.865 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -146.18 120.69 9.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.927 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -164.01 -153.28 7.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -128.54 -6.75 5.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.893 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -61.94 175.95 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.911 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.863 HD13 ' N ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -123.15 153.47 39.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.918 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -15.29 6.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -49.26 179.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 1.008 HD11 ' O ' ' A' ' 86' ' ' ALA . 8.5 mm -86.89 131.85 33.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.848 0.356 . . . . 0.0 111.123 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -124.88 145.08 49.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.884 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.0 mt -58.07 116.88 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 7.7 tptp -76.15 -48.42 20.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.442 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.89 149.03 5.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.442 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.1 t -130.16 126.1 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.091 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.618 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -71.71 176.53 4.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -101.94 -44.23 5.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -82.51 39.13 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.807 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.473 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.89 167.21 18.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.697 0.76 . . . . 0.0 110.872 -179.812 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.76 -18.81 36.77 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.643 2.229 . . . . 0.0 112.378 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -94.17 -24.88 17.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.5 -20.56 63.89 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.523 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 27.5 mttm -84.01 -30.7 25.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.895 0.379 . . . . 0.0 110.935 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.634 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.0 p -68.09 -14.31 62.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 43.62 23.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.518 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -109.15 3.56 22.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.909 HD11 HD11 ' A' ' 21' ' ' ILE . 9.5 mt -141.45 134.3 28.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HG2' ' C ' ' A' ' 69' ' ' LEU . 11.2 mmmt -149.04 160.23 43.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -57.3 135.57 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 111.0 -30.95 7.61 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.502 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.5 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -54.55 167.74 0.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.873 0.368 . . . . 0.0 110.932 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.535 ' HE3' HD23 ' A' ' 76' ' ' LEU . 35.6 tttp -120.78 107.57 12.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.5 mt -75.94 118.36 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -102.37 -23.14 13.99 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 179.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.89 151.44 7.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.12 125.99 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.125 179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.731 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.79 17.24 6.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.06 33.03 8.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.844 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.82 124.81 59.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 111.111 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -67.43 111.8 4.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.682 HD22 ' HA ' ' A' ' 91' ' ' ALA . 38.0 mt -113.21 -0.02 14.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.93 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 52.4 mt-30 -48.21 -65.72 0.52 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -87.47 15.53 6.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 1.008 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -86.73 138.75 31.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 10.7 p -67.46 -175.44 0.5 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.817 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -62.09 -42.36 99.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.819 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 37.7 m -77.52 -39.75 45.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.42 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 14.5 mm-40 -55.4 -35.92 65.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.715 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -39.92 24.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.134 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.473 HG23 HD11 ' A' ' 33' ' ' ILE . 4.2 t -54.18 -56.31 10.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.098 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.491 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 10.3 mt-10 -54.17 -32.98 56.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.844 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.56 -47.14 82.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.116 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.715 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.8 mp -66.82 -37.8 80.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.092 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -79.88 -26.42 40.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.8 m-20 -106.0 19.2 20.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.882 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -80.62 115.49 20.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.099 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.08 96.62 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.477 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.535 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 26.7 t-20 -39.42 136.75 1.08 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.596 0.712 . . . . 0.0 110.916 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.556 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.85 171.0 56.16 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.66 -1.808 . . . . 0.0 112.306 0.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.44 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.5 t -105.03 97.14 5.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.717 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -76.36 146.64 8.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.831 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.3 m-85 -126.85 129.7 48.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.41 90.08 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 18.1 m -121.41 179.14 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.065 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.4 mt-30 -137.93 106.64 5.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -73.3 123.66 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.827 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.727 HD21 ' CE2' ' A' ' 13' ' ' TRP . 12.5 mt -62.37 169.97 2.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.8 t -52.87 86.72 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 109' ' ' LEU . 26.9 t -154.37 -176.84 6.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.809 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.448 ' N ' ' OG ' ' A' ' 111' ' ' SER . 34.5 p -131.39 144.14 52.17 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.548 0.689 . . . . 0.0 111.144 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -163.8 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.676 2.25 . . . . 0.0 112.296 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.432 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.8 tpt180 -131.51 157.51 43.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.846 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.526 HG22 ' N ' ' A' ' 116' ' ' ILE . 9.2 p -98.6 163.34 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.14 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.551 HD12 ' C ' ' A' ' 117' ' ' PRO . 0.7 OUTLIER -80.44 151.75 72.3 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.635 0.731 . . . . 0.0 111.139 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.551 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.743 2.296 . . . . 0.0 112.317 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.3 t -70.87 144.43 50.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.2 m -74.82 154.08 38.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.829 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.22 -18.69 0.26 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.2 t -81.89 130.87 35.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.816 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.7 t -149.51 126.55 11.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.52 80.57 0.19 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.6 Cg_endo -69.76 0.51 5.54 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.68 2.253 . . . . 0.0 112.352 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.434 ' C ' ' O ' ' A' ' 8' ' ' PRO . 26.0 m-20 -34.4 146.96 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -134.85 118.69 17.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.871 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.549 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 18.4 p -157.32 163.04 39.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.58 69.68 1.47 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.826 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.754 ' CD1' HD21 ' A' ' 109' ' ' LEU . 50.9 m95 -85.95 116.42 24.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.913 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.481 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -75.46 -158.1 6.9 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.489 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.76 159.87 51.8 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.702 2.268 . . . . 0.0 112.299 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 157.51 60.13 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.657 2.238 . . . . 0.0 112.366 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.475 ' CZ ' ' HB3' ' A' ' 108' ' ' SER . 7.2 ptp180 -132.48 117.97 18.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.512 HG23 ' CG1' ' A' ' 103' ' ' VAL . 21.8 mt -90.39 131.94 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.409 HG21 ' HB1' ' A' ' 68' ' ' ALA . 47.8 t -140.75 128.72 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.171 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.09 125.76 35.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.885 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.856 HD12 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -121.41 106.37 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 1.9 m-85 -71.83 126.01 28.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 11.1 mmm-85 -55.67 162.52 1.67 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.494 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.3 mm-40 -122.76 150.78 59.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.613 0.721 . . . . 0.0 110.868 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -90.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -52.06 -33.0 37.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.494 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 5.9 p -117.39 157.78 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.145 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -89.16 -164.3 1.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.94 HD11 HG11 ' A' ' 102' ' ' VAL . 6.6 mt -58.33 -31.16 67.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.874 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 86.83 14.65 64.66 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.52 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.818 HD11 HD13 ' A' ' 21' ' ' ILE . 16.4 mt -112.9 150.11 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 111.121 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.4 m -132.19 173.63 11.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.888 HD11 HG23 ' A' ' 92' ' ' VAL . 23.9 pt -144.0 150.18 17.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -103.86 176.69 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.868 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.592 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.03 -126.53 0.48 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.485 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 52' ' ' ILE . . . 118.45 -67.24 0.36 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.438 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.44 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.23 151.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.6 t -176.46 -174.28 0.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -146.25 142.57 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 4.2 mt -105.76 148.24 10.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.133 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.65 139.64 36.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.921 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.2 ttp180 -89.54 10.32 23.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 8.6 mt -98.28 -36.36 10.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -167.86 173.67 8.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -116.83 162.34 17.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -126.64 137.29 9.93 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.26 0.58 37.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.856 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -59.59 176.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.895 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.873 HD13 ' CZ ' ' A' ' 53' ' ' PHE . 3.2 mm? -74.85 77.07 2.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.7 pttm -123.16 -14.15 7.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -68.44 -151.88 0.38 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.529 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.897 HD11 ' O ' ' A' ' 86' ' ' ALA . 29.4 mm -114.47 133.71 59.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.843 0.354 . . . . 0.0 111.136 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.873 ' CZ ' HD13 ' A' ' 49' ' ' LEU . 65.2 m-85 -131.32 141.42 49.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 71' ' ' THR . 7.5 mt -55.47 138.96 15.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.093 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.542 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -97.42 -47.2 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.906 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.432 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.7 OUTLIER -170.17 150.15 3.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.432 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.0 t -129.44 125.93 62.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.14 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.609 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.49 174.41 4.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -99.78 -43.84 6.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -82.56 38.95 0.58 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.864 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.0 168.21 16.1 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.713 0.768 . . . . 0.0 110.833 -179.784 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.711 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.78 -22.62 31.74 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.689 2.259 . . . . 0.0 112.32 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.559 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -88.58 -29.38 20.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.65 -27.96 68.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.7 mttt -76.89 -40.48 47.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 110.872 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.2 p -56.57 -20.67 21.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.188 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 40.79 25.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.863 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -108.1 0.28 21.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.693 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -144.28 136.22 26.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.947 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 mmtp -148.31 156.26 42.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.883 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.512 ' HA ' HG22 ' A' ' 54' ' ' ILE . 13.3 t -45.67 137.43 5.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.08 -33.29 6.37 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.09 147.3 24.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.905 0.384 . . . . 0.0 110.882 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -95.75 114.36 26.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.987 ' HA ' HG12 ' A' ' 106' ' ' VAL . 7.9 mt -84.44 119.74 33.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.118 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.401 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.42 -26.7 13.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.942 179.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -164.94 151.2 10.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.907 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.538 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.82 125.77 11.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.2 t 59.58 18.14 6.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.24 33.39 8.8 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.447 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.814 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.8 123.44 56.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 111.115 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -66.46 110.62 3.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.546 HD22 ' HA ' ' A' ' 91' ' ' ALA . 36.9 mt -112.43 -2.94 14.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -42.28 -70.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.967 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 -90.81 35.01 0.89 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.897 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.15 141.39 35.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.107 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 88.0 p -72.09 175.15 6.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.822 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.4 t-160 -51.89 -42.55 62.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 50.2 m -73.95 -48.96 26.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.821 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.458 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.7 mm-40 -51.25 -32.72 25.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.903 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.658 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -89.91 -37.75 14.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.08 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.888 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -58.46 -43.15 86.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 8.2 mt-10 -67.48 -34.43 77.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.814 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.65 -46.68 84.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.087 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.658 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.5 mp -69.95 -35.51 64.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.447 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 10.0 ptmt -80.69 -25.83 37.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.897 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.7 m-20 -107.11 11.34 29.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.888 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -62.59 113.78 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.071 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.424 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -57.25 95.4 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.53 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.1 OUTLIER -36.39 133.23 0.61 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.91 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.567 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.2 Cg_endo -69.8 175.19 37.66 Favored 'Cis proline' 0 C--N 1.342 0.2 0 C-N-CA 122.634 -1.819 . . . . 0.0 112.349 -0.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.94 HG11 HD11 ' A' ' 29' ' ' LEU . 7.8 t -111.73 95.15 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.512 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -76.26 143.17 13.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.131 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.856 ' CD1' HD12 ' A' ' 21' ' ' ILE . 6.6 m-85 -124.77 129.15 49.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -118.12 89.71 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.08 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.987 HG12 ' HA ' ' A' ' 75' ' ' ILE . 3.8 m -125.75 -177.9 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.481 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 2.6 mt-30 -139.1 107.21 5.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.475 ' HB3' ' CZ ' ' A' ' 17' ' ' ARG . 2.7 t -72.82 132.86 44.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.865 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.754 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.6 mt -71.55 158.99 35.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.1 t -61.21 75.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 109' ' ' LEU . 1.2 p -132.51 -1.54 3.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 6.3 p 58.33 151.12 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 0.0 111.151 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.669 2.246 . . . . 0.0 112.341 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 mtm180 -130.18 -174.76 3.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.823 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.559 HG13 ' HD3' ' A' ' 117' ' ' PRO . 12.5 p -70.07 157.13 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.114 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.51 HD12 ' O ' ' A' ' 116' ' ' ILE . 1.5 pp -117.45 81.15 13.68 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.61 0.719 . . . . 0.0 111.105 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HD3' HG13 ' A' ' 115' ' ' VAL . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.187 0 C-N-CA 122.664 2.242 . . . . 0.0 112.336 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.9 t -76.3 -176.78 3.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -108.62 -74.4 0.66 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 168.49 58.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -95.36 26.63 3.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.832 0.349 . . . . 0.0 110.829 -179.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -107.45 135.87 48.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.861 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.84 66.31 1.13 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 171.5 14.31 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -77.3 160.51 28.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -133.78 -0.04 3.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 3.7 t -99.17 178.85 4.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.906 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -129.09 76.32 1.71 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.749 ' CD1' HD21 ' A' ' 109' ' ' LEU . 56.1 m95 -91.02 114.85 27.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.444 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.35 -161.67 5.67 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.525 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 158.4 57.11 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.642 2.228 . . . . 0.0 112.4 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 157.34 60.82 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.243 . . . . 0.0 112.387 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -131.75 122.53 25.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 24.2 mt -89.06 133.06 32.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.137 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.3 t -143.06 123.15 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -85.21 124.3 31.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.872 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -122.73 115.99 47.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.66 127.98 33.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.2 mtm180 -64.37 150.56 46.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.498 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 8.5 mm-40 -115.37 150.55 44.7 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.638 0.732 . . . . 0.0 110.891 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -90.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.682 2.255 . . . . 0.0 112.364 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -48.0 -36.21 12.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.498 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 10.6 p -115.6 146.65 19.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.154 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -79.65 -166.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.796 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.6 mt -61.72 -29.47 70.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.928 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.466 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.85 12.83 63.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.52 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.574 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.0 mt -112.55 149.38 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.43 171.59 13.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.507 HG21 ' CG2' ' A' ' 52' ' ' ILE . 23.5 pt -143.99 148.88 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.36 178.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.122 179.856 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 47.24 -142.98 5.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.441 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.42 ' C ' ' HB2' ' A' ' 88' ' ' HIS . . . 81.86 149.94 7.73 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.482 ' N ' ' H ' ' A' ' 88' ' ' HIS . 14.0 mt-30 62.86 54.87 2.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.888 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -124.4 -21.47 4.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 38' ' ' THR . 12.7 t -157.07 137.77 4.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.13 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 38.5 mt -117.54 -21.11 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.084 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -124.63 159.4 30.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.5 mmt85 -66.22 85.8 0.1 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 36.1 mt -105.95 -59.57 1.76 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.11 171.96 11.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.93 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.93 -70.61 0.79 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.2 176.56 14.59 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -103.57 -6.82 21.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.871 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -138.26 173.32 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.928 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -60.1 173.45 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 pttp -147.37 160.02 43.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 145.05 176.09 18.76 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.456 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.94 HD11 ' O ' ' A' ' 86' ' ' ALA . 37.2 mm -79.67 107.93 12.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 111.168 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.413 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 57.4 m-85 -101.28 137.36 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.863 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.583 HD12 ' O ' ' A' ' 70' ' ' LYS . 16.0 mt -54.53 122.54 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.7 tptm -80.65 -47.66 13.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -169.89 149.67 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.888 179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.4 t -130.32 126.9 62.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.153 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.59 172.92 9.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.925 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -98.82 -43.62 6.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -83.01 38.77 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.466 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.68 167.12 18.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.634 0.73 . . . . 0.0 110.832 -179.723 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.82 -19.58 35.67 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.681 2.254 . . . . 0.0 112.335 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.574 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.6 -26.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.096 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.17 -38.4 34.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.3 mttt -64.17 -38.72 92.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.58 -22.5 22.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 42.95 23.66 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.07 -3.97 19.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.156 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.1 mt -136.29 135.22 38.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.948 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.583 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.93 170.46 14.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.3 t -71.59 136.59 47.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.204 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.12 -26.65 16.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.518 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.09 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 71.2 tttt -123.62 101.84 7.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.916 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.95 ' HA ' HG12 ' A' ' 106' ' ' VAL . 22.9 mt -71.05 117.61 14.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.108 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.612 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -101.09 -25.08 14.16 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.944 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -166.74 152.08 7.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.822 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.74 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.102 179.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.664 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.75 16.0 6.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.862 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.83 33.17 8.0 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.469 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -130.15 124.62 58.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.355 . . . . 0.0 111.099 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -67.18 111.17 3.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.618 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.1 mt -111.75 -5.91 14.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.945 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -39.17 -68.35 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -92.86 34.26 1.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.917 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.94 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.45 135.25 41.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.09 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -60.4 -175.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.687 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.5 t-160 -65.42 -36.44 83.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -83.73 -39.96 19.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.4 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 5.4 mm-40 -52.68 -36.26 56.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.938 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.791 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -84.82 -39.2 18.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.125 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 88' ' ' HIS . 10.4 t -53.68 -46.96 62.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.1 mt-10 -64.77 -31.8 73.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.52 -51.39 60.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.096 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.796 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.4 mp -65.32 -34.99 74.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.123 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.404 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 21.3 pttt -80.81 -29.12 36.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.6 m-20 -105.47 17.33 24.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -71.27 110.41 5.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.408 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.38 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.586 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 25.7 t-20 -37.58 132.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.624 0.726 . . . . 0.0 110.911 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.75 177.74 27.8 Favored 'Cis proline' 0 C--N 1.341 0.16 0 C-N-CA 122.686 -1.797 . . . . 0.0 112.323 -0.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.3 t -112.2 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.061 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -74.7 143.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.872 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.1 m-85 -124.38 130.89 53.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.87 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.8 89.98 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.95 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.7 m -121.17 179.36 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.139 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.612 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.4 mt-30 -140.67 107.68 5.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.4 t -74.54 127.82 34.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.855 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.749 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.5 mt -66.82 158.05 31.46 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -38.03 101.99 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 14.4 t -163.07 179.27 7.63 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.84 -179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 39.9 p -114.89 144.24 31.63 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.612 0.72 . . . . 0.0 111.129 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.81 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.736 2.29 . . . . 0.0 112.328 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.554 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 21.7 ttt180 -138.01 166.72 23.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 116' ' ' ILE . 14.1 t -104.3 167.85 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.582 ' N ' HG12 ' A' ' 115' ' ' VAL . 1.4 pp -117.15 159.3 41.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.618 0.723 . . . . 0.0 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.381 179.878 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m -154.04 149.02 26.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.852 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 74.9 p -139.34 -176.15 4.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.888 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.91 -172.26 13.88 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.514 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.436 ' O ' ' N ' ' A' ' 7' ' ' GLY . 46.1 m -107.73 -37.02 6.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.893 0.377 . . . . 0.0 110.899 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -39.23 95.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -134.92 -173.07 12.95 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 2.86 3.12 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.741 2.294 . . . . 0.0 112.374 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -71.45 79.77 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.84 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -82.16 -23.14 35.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.582 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 53.2 m -47.33 175.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -123.67 63.39 1.04 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.852 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.738 ' CD1' HD21 ' A' ' 109' ' ' LEU . 51.0 m95 -88.46 118.04 27.82 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.958 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.55 -161.57 15.42 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.49 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 159.15 54.47 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.652 2.235 . . . . 0.0 112.338 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 159.27 54.02 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.672 2.248 . . . . 0.0 112.329 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.464 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.0 ptt180 -131.06 117.79 19.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.686 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.2 mt -86.25 130.81 35.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.108 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.49 HG21 ' CB ' ' A' ' 68' ' ' ALA . 61.2 t -142.03 123.22 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -84.63 123.71 30.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.839 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.3 mt -120.67 116.67 50.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -82.66 127.76 33.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.902 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -64.57 151.56 44.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -117.16 151.09 47.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.695 0.76 . . . . 0.0 110.85 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -90.77 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.324 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -47.41 -37.09 10.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.477 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.9 p -114.82 147.81 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.44 -167.8 1.62 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.854 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 95' ' ' ILE . 6.3 mt -60.19 -30.2 69.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.66 12.49 62.5 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.506 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 63' ' ' ALA . 11.1 mt -113.26 148.72 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.868 0.366 . . . . 0.0 111.105 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.6 m -131.88 170.13 15.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.835 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.061 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.6 pt -138.37 154.28 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.561 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.01 165.52 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.105 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.47 -143.85 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.531 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.03 -40.55 2.28 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.473 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.531 HE21 ' N ' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -39.75 151.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.926 -179.929 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.739 HG22 ' H ' ' A' ' 39' ' ' VAL . 0.6 OUTLIER -138.18 -179.06 5.56 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.133 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.739 ' H ' HG22 ' A' ' 38' ' ' THR . 0.8 OUTLIER -145.22 153.23 14.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.14 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 70.4 mt -78.37 -47.8 23.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.093 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -45.71 151.55 0.41 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? -126.12 93.36 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -93.89 -175.38 3.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 pptp? -86.19 -2.28 58.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -80.03 165.45 22.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 132.81 74.5 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.513 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -131.57 -2.73 3.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.801 0.334 . . . . 0.0 110.847 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -98.98 177.06 5.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.538 ' HB3' ' CE1' ' A' ' 53' ' ' PHE . 3.8 mm? -76.32 108.77 9.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.913 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.12 -19.48 23.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.91 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.83 178.76 11.53 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.519 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.91 HD11 ' O ' ' A' ' 86' ' ' ALA . 21.1 mm -91.92 140.24 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.144 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 49' ' ' LEU . 16.6 m-85 -130.34 148.87 52.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.506 HD12 ' HB2' ' A' ' 73' ' ' ASP . 16.2 mt -65.45 119.94 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.561 ' HB2' HG12 ' A' ' 34' ' ' VAL . 18.0 tptt -78.07 -49.68 13.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.448 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -166.45 149.99 7.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.877 179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.448 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.6 t -131.31 126.87 59.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.31 173.84 8.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.894 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 -99.59 -44.36 6.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -82.91 38.62 0.59 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.49 167.36 16.74 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.674 0.75 . . . . 0.0 110.85 -179.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.471 ' O ' ' CG2' ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.72 -19.68 35.99 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.736 2.291 . . . . 0.0 112.353 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.597 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -93.22 -27.05 17.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.078 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.09 -38.2 35.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.487 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 37.2 mttm -64.59 -38.46 91.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 62' ' ' PRO . 1.2 p -55.22 -21.07 12.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 42.4 24.1 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.49 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.82 -3.65 18.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 8.6 mt -136.64 141.41 43.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.935 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.8 mmtt -144.84 156.68 44.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.917 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.1 t -54.27 140.39 33.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.06 -23.87 30.91 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.434 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.0 OUTLIER -64.56 151.22 45.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.859 0.361 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.556 ' HE2' HD21 ' A' ' 76' ' ' LEU . 22.6 ttpt -100.86 119.41 38.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.769 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.1 mt -84.87 121.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.619 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.36 -25.16 13.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -165.64 152.25 9.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.88 125.75 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.129 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.12 17.03 6.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.18 33.43 8.15 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.515 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.828 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.7 p -130.34 123.91 56.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.363 . . . . 0.0 111.131 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -66.68 110.89 3.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.541 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.2 mt -111.85 1.09 16.39 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.917 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 mt-30 -48.53 -67.44 0.27 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.954 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 65.9 m-20 -86.25 27.39 0.93 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.91 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -101.06 144.91 29.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 33.0 t -78.83 -175.39 4.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.837 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 1.061 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.7 t-160 -58.56 -44.77 89.83 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.5 t -73.53 -42.09 62.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.852 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.52 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 13.9 mm-40 -54.32 -34.48 61.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.9 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.758 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.56 -38.69 16.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.104 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.729 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.36 -45.17 44.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 15.4 mt-10 -67.26 -33.61 75.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.828 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.16 -48.16 77.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -67.38 -36.41 76.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.137 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 15.9 pttt -80.44 -26.74 38.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.902 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 75.6 m-20 -106.52 18.8 21.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.744 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.95 111.27 8.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -49.3 94.64 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 15.0 t-20 -35.57 132.19 0.53 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.61 0.719 . . . . 0.0 110.91 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.555 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.73 -175.85 11.59 Favored 'Cis proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.37 -0.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.744 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.7 t -117.82 93.21 2.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.069 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.686 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.16 144.85 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.839 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -126.44 129.28 48.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -118.47 90.36 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 75' ' ' ILE . 12.0 m -120.31 177.52 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.093 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.619 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.4 mt-30 -136.8 106.23 6.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.464 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -80.23 128.66 33.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -179.867 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.738 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.6 mt -64.71 159.68 21.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.898 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -45.24 100.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.867 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.0 p -169.72 176.41 4.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.863 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 72.8 p -131.59 144.15 52.13 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.57 0.7 . . . . 0.0 111.136 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.84 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.694 2.263 . . . . 0.0 112.374 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.7 -174.88 3.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.883 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.581 HG12 ' H ' ' A' ' 116' ' ' ILE . 2.1 t -110.69 170.46 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.581 ' H ' HG12 ' A' ' 115' ' ' VAL . 2.1 pt -113.63 158.64 38.23 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.647 0.736 . . . . 0.0 111.119 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 C-N-CA 122.682 2.255 . . . . 0.0 112.358 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -135.37 -178.53 5.15 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.812 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -135.52 140.58 44.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.865 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.66 129.88 3.14 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 p -126.58 132.27 51.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.828 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.5 p -136.03 160.09 39.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.836 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.16 72.71 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 176.25 7.02 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.692 2.261 . . . . 0.0 112.347 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 46.5 54.02 9.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.883 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' SER . 32.5 t80 -162.14 157.69 23.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 10' ' ' PHE . 2.4 p 35.22 50.68 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 -86.08 94.55 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.833 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.658 ' CD1' HD21 ' A' ' 109' ' ' LEU . 76.5 m95 -85.13 110.92 19.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.946 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -69.7 -163.29 3.8 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.517 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 158.24 57.63 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.33 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 161.83 44.41 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.67 2.246 . . . . 0.0 112.387 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' CG ' ' O ' ' A' ' 17' ' ' ARG . 24.2 ptt180 -138.66 111.67 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.427 HG23 ' CG1' ' A' ' 103' ' ' VAL . 29.1 mt -82.38 131.42 33.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.17 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.72 133.67 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.407 ' HG3' HG22 ' A' ' 103' ' ' VAL . 37.4 mp0 -94.58 126.12 39.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.921 HD11 HD11 ' A' ' 69' ' ' LEU . 4.8 mt -123.12 117.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.174 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -80.4 125.69 30.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 14.1 ptt85 -67.73 149.44 49.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.87 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.513 ' HB2' HG13 ' A' ' 27' ' ' VAL . 5.0 mm-40 -112.8 155.56 43.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.65 0.738 . . . . 0.0 110.907 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -47.17 -41.16 17.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 24' ' ' GLU . 10.8 p -109.33 152.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.402 ' N ' HG22 ' A' ' 27' ' ' VAL . 1.0 OUTLIER -87.04 -164.95 1.16 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.861 -179.848 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.862 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -63.41 -26.33 68.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.98 13.21 72.36 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.465 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.767 HD11 HD13 ' A' ' 21' ' ' ILE . 12.9 mt -112.66 149.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.878 0.37 . . . . 0.0 111.09 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.2 m -131.83 173.17 11.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HG23 ' A' ' 92' ' ' VAL . 20.9 pt -142.94 152.24 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.157 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.549 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.2 179.6 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 63.33 -170.89 14.74 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.507 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 38' ' ' THR . . . 170.52 -177.5 43.65 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.494 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 36' ' ' GLY . 13.9 pt20 34.22 35.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.922 0.392 . . . . 0.0 110.967 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 36' ' ' GLY . 5.4 p -44.65 169.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 t -96.89 147.5 6.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.105 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.614 ' N ' HD12 ' A' ' 40' ' ' ILE . 0.2 OUTLIER -130.97 90.17 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.123 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HG2' ' N ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -178.68 147.22 0.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.895 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.441 ' CD ' ' H ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -69.94 80.67 0.47 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.43 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 0.1 OUTLIER -99.51 141.82 31.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.43 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 37.7 mtpt -116.96 -43.89 2.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.949 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -81.41 93.18 6.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 143.88 80.54 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -86.28 114.82 23.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.427 ' HG3' ' N ' ' A' ' 49' ' ' LEU . 1.1 pt-20 -155.96 175.54 13.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.591 ' CD1' ' CZ ' ' A' ' 53' ' ' PHE . 0.3 OUTLIER -60.57 92.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.934 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.85 134.59 48.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.918 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.419 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 110.76 175.94 20.51 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.948 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm -93.28 156.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.84 0.352 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' CD1' ' A' ' 49' ' ' LEU . 17.4 m-85 -148.99 151.67 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.48 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.8 mt -63.45 135.77 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.097 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.9 tptm -96.28 -42.47 8.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.864 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.45 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -171.88 149.01 2.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.45 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.95 125.77 58.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.08 177.38 4.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.926 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -104.28 -41.47 5.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.886 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.43 36.75 0.54 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.474 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.08 167.63 16.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.647 0.737 . . . . 0.0 110.847 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.653 ' O ' HG23 ' A' ' 66' ' ' THR . 53.8 Cg_endo -69.72 -20.67 34.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.696 2.264 . . . . 0.0 112.367 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.586 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.46 -27.46 18.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.073 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.51 -21.71 68.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.494 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -82.67 -33.05 27.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.924 0.392 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.653 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.9 p -62.77 -16.97 60.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.503 ' OD1' HG23 ' A' ' 115' ' ' VAL . 2.4 m-20 45.4 21.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -111.2 9.71 21.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.097 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.921 HD11 HD11 ' A' ' 21' ' ' ILE . 11.4 mt -143.36 134.93 26.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.861 -179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.48 ' O ' HD12 ' A' ' 54' ' ' ILE . 40.1 mmtt -144.61 157.81 44.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.6 t -58.53 137.35 57.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.147 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.54 -34.06 5.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.53 159.06 0.37 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.856 0.36 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.528 ' HG3' ' CE2' ' A' ' 53' ' ' PHE . 74.1 tttt -108.32 113.91 27.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 1.031 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -83.25 119.37 32.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.579 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.45 -25.4 13.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -165.81 151.32 8.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.12 125.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.16 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.752 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.67 16.02 5.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.63 32.39 8.14 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.853 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.57 126.07 62.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.811 0.339 . . . . 0.0 111.128 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.84 114.48 7.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.738 HD22 ' HA ' ' A' ' 91' ' ' ALA . 35.9 mt -114.45 4.88 15.42 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -52.59 -67.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 5.8 m-80 -89.11 30.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.948 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.93 137.11 42.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.093 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 26.3 p -63.46 -174.71 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 0.7 OUTLIER -63.11 -39.4 94.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.862 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 t -76.49 -46.65 25.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.874 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.506 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 17.3 mm-40 -52.46 -33.85 46.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.738 ' HA ' HD22 ' A' ' 83' ' ' LEU . . . -81.63 -40.84 22.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.103 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 33' ' ' ILE . 4.8 t -59.04 -57.56 10.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.494 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.4 mt-10 -49.36 -33.94 14.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.853 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -61.88 -49.2 77.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.146 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.862 HG23 HD12 ' A' ' 29' ' ' LEU . 3.9 mp -64.21 -41.59 92.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.9 ptmt -76.08 -26.54 56.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.494 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 76.8 m-20 -106.93 17.18 23.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.856 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.752 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -76.39 114.73 15.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.077 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.98 96.46 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.492 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.526 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.3 OUTLIER -40.61 134.71 1.59 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.611 0.719 . . . . 0.0 110.903 -179.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 171.97 51.16 Favored 'Cis proline' 0 C--N 1.342 0.203 0 C-N-CA 122.669 -1.805 . . . . 0.0 112.345 -0.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.596 HG13 ' CB ' ' A' ' 98' ' ' ALA . 20.4 t -105.03 96.91 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.126 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.427 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.4 t -75.45 151.08 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.848 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -131.07 134.06 46.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -123.4 90.34 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.088 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 1.031 HG12 ' HA ' ' A' ' 75' ' ' ILE . 17.8 m -122.75 -178.72 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.104 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.579 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.1 mt-30 -141.34 108.06 5.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.932 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.3 t -71.47 125.43 27.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.79 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.658 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.9 mt -63.54 175.8 0.98 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.874 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 16.7 t -40.96 -74.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.828 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 112' ' ' THR . 59.7 p -52.89 170.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.501 HG23 ' O ' ' A' ' 111' ' ' SER . 49.6 p -159.71 145.83 12.01 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.614 0.721 . . . . 0.0 111.129 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . 0.402 ' CG ' ' HG3' ' A' ' 70' ' ' LYS . 54.1 Cg_endo -69.79 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.551 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 4.2 ttm-85 -116.11 166.13 12.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.551 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 11.3 p -126.54 157.49 37.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.183 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.446 ' N ' HG22 ' A' ' 115' ' ' VAL . 2.0 pt -79.33 156.25 76.27 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.635 0.731 . . . . 0.0 111.124 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--N 1.342 0.194 0 C-N-CA 122.669 2.246 . . . . 0.0 112.377 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -128.03 56.39 1.6 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.354 . . . . 0.0 110.846 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.4 t -93.25 145.48 24.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.68 157.73 28.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.485 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.5 t -125.19 -43.42 1.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.862 0.363 . . . . 0.0 110.881 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.6 p 42.24 29.49 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.911 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.95 176.35 1.83 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.505 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -164.53 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.651 2.234 . . . . 0.0 112.303 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -113.96 -174.64 2.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.931 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.452 ' O ' ' C ' ' A' ' 11' ' ' SER . 59.9 t80 -119.51 -39.36 2.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.462 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 33.0 p -34.55 147.77 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.5 t-80 -118.97 69.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.836 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.67 ' CD1' HD21 ' A' ' 109' ' ' LEU . 36.8 m95 -74.09 126.11 29.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.925 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.25 -163.31 30.5 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 148.61 65.73 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.364 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 163.08 39.61 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.374 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 1.8 ptp180 -134.53 127.58 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.851 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.578 HG23 ' CG1' ' A' ' 103' ' ' VAL . 39.8 mt -90.72 130.76 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.139 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.1 t -139.31 129.76 32.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' HG3' HG22 ' A' ' 103' ' ' VAL . 31.9 mp0 -91.19 124.0 35.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.864 HD12 ' CD2' ' A' ' 104' ' ' PHE . 23.8 mt -124.13 116.19 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.599 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.3 m-85 -79.02 133.21 36.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.548 ' H ' ' ND2' ' A' ' 100' ' ' ASN . 62.7 mtp180 -68.48 157.62 35.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -122.98 150.64 59.68 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.691 0.758 . . . . 0.0 110.912 -179.968 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.96 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.685 2.256 . . . . 0.0 112.309 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -46.65 -37.28 8.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.48 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.82 146.03 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.94 -160.73 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.873 HD12 HG23 ' A' ' 95' ' ' ILE . 6.2 mt -67.46 -31.39 71.51 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.914 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.478 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.62 13.26 63.32 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.452 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 14.2 mt -112.94 149.57 15.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.781 0.324 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 74.6 m -131.69 175.07 9.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.803 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.488 ' N ' ' HB3' ' A' ' 55' ' ' LYS . 13.7 pt -146.1 151.69 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.118 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.79 179.55 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.162 179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' N ' HG23 ' A' ' 34' ' ' VAL . . . 68.5 -159.73 51.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.436 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 148.26 -9.28 1.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.443 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.436 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -35.09 137.51 0.14 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 110.975 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.555 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.4 m -56.09 160.73 2.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HD13 ' A' ' 40' ' ' ILE . 0.2 OUTLIER -130.99 157.58 43.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.598 HD13 ' O ' ' A' ' 39' ' ' VAL . 23.2 mm -149.54 147.38 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 40' ' ' ILE . 0.0 OUTLIER -34.36 -44.11 0.18 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' CG ' ' O ' ' A' ' 41' ' ' LYS . 24.0 mtm180 -166.79 -175.54 3.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.594 ' CD1' ' N ' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 59.93 45.27 12.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 9.1 tptp -115.69 131.6 56.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.71 171.79 9.11 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 169.71 118.83 0.47 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.445 ' CD ' ' O ' ' A' ' 47' ' ' GLU . 3.1 tp10 -73.02 -12.23 60.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.849 0.357 . . . . 0.0 110.898 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -126.6 -175.45 3.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.721 ' H ' HD13 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -71.69 168.23 18.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.45 137.85 51.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.591 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . 137.72 159.13 8.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.438 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.847 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.9 mm -81.25 138.68 19.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.894 0.378 . . . . 0.0 111.111 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -129.71 136.59 49.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 70' ' ' LYS . 10.6 mt -51.13 133.21 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.088 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 3.9 tptm -94.64 -45.96 7.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.917 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.451 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -171.01 150.39 3.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.908 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.451 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.6 t -131.15 126.69 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.081 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -71.42 177.46 3.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -103.11 -43.64 5.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.439 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 18.6 t70 -82.87 38.37 0.58 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.478 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.38 167.61 16.67 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.664 0.745 . . . . 0.0 110.807 -179.757 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.461 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -20.88 33.86 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.665 2.243 . . . . 0.0 112.322 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.576 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.11 -28.76 17.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.093 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.52 -31.5 58.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -69.89 -38.31 76.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.915 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -59.82 -21.83 61.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.107 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 40.93 25.0 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.921 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.43 -3.01 24.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.782 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.6 mt -136.3 135.99 39.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.869 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.518 ' O ' HD12 ' A' ' 54' ' ' ILE . 8.4 mmpt? -132.84 160.99 35.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 11.0 t -62.86 140.01 58.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.08 -29.88 9.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.474 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.54 176.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 110.829 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -123.71 104.37 8.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.862 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.983 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.1 mt -73.35 114.92 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.608 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -98.03 -25.95 14.78 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 179.908 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -164.62 151.68 11.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.579 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.68 125.63 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.111 179.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.77 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.25 15.36 5.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.93 32.09 8.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.788 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.69 126.1 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.869 0.366 . . . . 0.0 111.112 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.76 114.41 7.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.841 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.812 HD13 ' HB1' ' A' ' 91' ' ' ALA . 30.5 mt -111.13 -6.81 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.882 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -44.46 -64.25 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . 0.448 ' O ' HG11 ' A' ' 39' ' ' VAL . 11.2 m-80 -90.77 33.38 0.93 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.903 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.847 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -109.5 139.25 44.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 65.7 m -65.23 -172.18 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.852 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.624 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.7 OUTLIER -67.59 -36.46 80.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.861 179.992 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.5 t -80.36 -41.32 24.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.509 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 16.7 mm-40 -53.51 -38.5 63.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.888 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.3 -39.61 24.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.2 t -53.61 -49.78 54.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.474 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -61.23 -32.41 72.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.788 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.69 -45.95 84.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.122 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.873 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -69.05 -34.33 63.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.2 pttp -83.24 -25.7 31.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.474 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 76.3 m-20 -107.67 9.17 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.77 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -65.4 111.36 3.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.116 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -49.33 96.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.599 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.2 t-20 -39.49 136.16 1.13 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.636 0.731 . . . . 0.0 110.897 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.73 171.71 52.29 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.387 -0.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 29' ' ' LEU . 11.9 t -106.39 97.56 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.112 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.578 ' CG1' HG23 ' A' ' 18' ' ' ILE . 3.1 t -77.6 143.29 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.864 ' CD2' HD12 ' A' ' 21' ' ' ILE . 7.1 m-85 -124.41 125.64 44.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.18 89.84 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.983 HG12 ' HA ' ' A' ' 75' ' ' ILE . 30.2 m -121.3 177.53 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.154 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.608 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -140.31 107.96 5.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.8 p -76.1 125.62 29.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.67 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.9 mt -51.77 -176.67 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 4.7 t -74.63 61.26 0.95 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.79 ' O ' HG23 ' A' ' 112' ' ' THR . 11.6 p -176.79 159.62 1.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.843 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -172.17 144.37 1.42 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.6 0.714 . . . . 0.0 111.144 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -163.79 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.64 2.226 . . . . 0.0 112.361 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.461 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 5.3 tpm_? -114.81 149.66 36.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.631 HG12 ' N ' ' A' ' 116' ' ' ILE . 60.6 t -106.44 164.88 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.121 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.631 ' N ' HG12 ' A' ' 115' ' ' VAL . 4.2 pt -62.73 156.3 65.55 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.588 0.709 . . . . 0.0 111.156 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.641 2.227 . . . . 0.0 112.339 179.891 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.5 m -144.28 150.72 38.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.892 0.377 . . . . 0.0 110.871 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -166.2 175.4 8.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.7 159.34 29.95 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.464 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.5 p -150.25 169.53 21.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.874 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -151.77 169.35 22.43 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.795 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.75 173.9 30.97 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -163.82 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.677 2.251 . . . . 0.0 112.348 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -174.17 152.47 1.85 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -124.58 -54.82 1.65 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.589 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 3.2 m -50.48 -177.86 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -119.3 51.67 1.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.871 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 57.2 m95 -74.04 116.04 14.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -74.34 -162.74 9.06 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.487 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 156.7 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.243 . . . . 0.0 112.347 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 157.42 60.38 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.253 . . . . 0.0 112.386 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.8 ptp180 -128.4 117.93 22.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.898 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.65 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -84.89 130.69 35.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.083 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 68' ' ' ALA . 50.1 t -141.22 121.87 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.183 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -84.36 122.54 29.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.889 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -121.23 115.89 48.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.6 m-85 -81.69 129.26 34.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.404 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 48.2 mtp180 -64.84 154.54 36.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.492 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.2 mm-40 -119.55 150.8 50.68 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.649 0.738 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.717 2.278 . . . . 0.0 112.38 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -48.0 -36.32 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.492 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.0 p -115.85 148.05 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.122 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.68 -166.45 1.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -61.45 -30.13 70.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.03 13.7 61.77 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.484 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 14.3 mt -112.85 149.28 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.5 m -132.53 170.47 15.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG23 ' A' ' 92' ' ' VAL . 23.0 pt -141.58 148.31 21.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.146 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.594 HG23 ' N ' ' A' ' 35' ' ' GLY . 0.8 OUTLIER -100.69 -179.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.133 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' N ' HG23 ' A' ' 34' ' ' VAL . . . 35.84 -127.11 0.85 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.494 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 90.66 112.73 1.62 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.539 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.441 ' HG2' ' N ' ' A' ' 38' ' ' THR . 7.0 tt0 -163.64 158.92 21.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.865 0.364 . . . . 0.0 110.927 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.441 ' N ' ' HG2' ' A' ' 37' ' ' GLN . 1.6 t -66.46 161.09 23.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.16 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.72 HG22 ' H ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -60.51 -174.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.082 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.72 ' H ' HG22 ' A' ' 39' ' ' VAL . 32.6 mt -159.38 148.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.4 ttmm -96.01 -70.34 0.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.915 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -135.15 1.24 2.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.861 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.599 ' CD1' ' N ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -94.16 41.35 1.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.93 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 17.9 pttm -97.34 162.98 13.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 22.8 m120 -120.35 20.94 11.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.02 178.62 27.8 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -123.74 125.63 45.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.816 0.341 . . . . 0.0 110.909 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -169.43 162.29 10.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.915 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.409 HD13 ' HA ' ' A' ' 49' ' ' LEU . 4.2 mm? -41.59 133.06 2.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.4 ptpt -112.72 -23.57 10.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.22 164.75 1.42 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.721 HG22 HD12 ' A' ' 75' ' ' ILE . 9.1 mm -87.78 108.27 18.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.122 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.445 ' CD1' ' HA ' ' A' ' 74' ' ' LYS . 7.9 m-30 -98.14 140.97 31.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.8 mt -58.41 123.34 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.9 tptm -79.34 -49.64 12.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.901 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -167.57 150.01 5.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.64 127.01 61.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -72.39 173.45 8.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -99.75 -42.99 6.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.1 p-10 -82.85 37.72 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.67 167.25 17.94 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.614 0.721 . . . . 0.0 110.877 -179.77 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.677 ' O ' HG23 ' A' ' 66' ' ' THR . 53.7 Cg_endo -69.75 -21.31 33.73 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.697 2.265 . . . . 0.0 112.363 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -89.91 -27.18 20.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.35 -39.68 35.44 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.545 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.5 mttt -64.26 -38.38 90.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.677 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.1 p -54.32 -22.26 11.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 42.43 25.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.869 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -110.38 -3.13 16.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.071 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.669 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.4 mt -140.44 135.06 31.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.0 mmtt -142.66 157.7 44.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.915 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.2 t -50.54 140.48 14.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.79 -12.95 61.02 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.455 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.45 134.61 40.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.469 ' NZ ' HD21 ' A' ' 76' ' ' LEU . 11.6 tttm -86.12 116.11 24.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.91 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.721 HD12 HG22 ' A' ' 52' ' ' ILE . 6.9 mt -84.75 133.11 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.131 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.844 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -112.19 -23.4 10.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.882 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -167.43 151.22 6.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.557 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.14 125.61 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.739 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.48 16.59 6.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.61 32.73 8.42 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.869 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.59 124.43 59.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.854 0.359 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.4 t0 -66.96 112.19 4.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.86 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.458 HD21 ' HB2' ' A' ' 94' ' ' ALA . 35.6 mt -113.28 -1.48 14.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.894 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -42.89 -60.46 1.6 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 38.6 m-80 -99.41 39.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.868 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.692 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -106.04 135.75 46.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.416 ' HA ' ' N ' ' A' ' 37' ' ' GLN . 96.7 p -64.86 -173.99 0.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.5 t-160 -63.01 -37.72 88.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.88 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.8 t -81.1 -40.29 24.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.846 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.62 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.1 mm-40 -52.16 -40.07 60.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.716 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.27 -40.86 29.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.074 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.616 HG23 HD11 ' A' ' 33' ' ' ILE . 2.8 t -52.79 -50.35 43.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.074 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.488 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.2 mt-10 -61.66 -34.28 75.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.869 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.7 -50.32 67.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.08 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 29' ' ' LEU . 3.7 mp -64.82 -38.27 82.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.404 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 2.7 ptmt -78.39 -28.93 47.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.488 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.4 m-20 -104.81 21.48 16.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.785 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.84 109.34 10.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.07 95.98 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 21.5 t-20 -37.83 133.63 0.85 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.892 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 175.94 34.54 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.672 -1.804 . . . . 0.0 112.382 -0.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.785 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.5 t -110.41 94.31 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.138 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.65 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -72.84 146.1 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.174 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.889 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.3 m-85 -128.84 128.5 44.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.1 mt -118.8 89.1 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.6 m -114.63 169.64 5.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.844 ' CG ' HD11 ' A' ' 76' ' ' LEU . 6.2 mt-30 -132.45 106.81 8.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.5 t -80.35 129.1 34.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.826 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 7.8 mt -66.03 159.68 25.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 25.2 p -51.44 102.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.837 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.8 t -156.03 170.57 21.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.0 p -99.77 150.88 37.22 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.579 0.704 . . . . 0.0 111.139 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -163.86 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.687 2.258 . . . . 0.0 112.34 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 4.3 tpm_? -130.54 146.1 52.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.875 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' A' ' 116' ' ' ILE . 39.9 t -74.48 160.76 5.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.65 HG23 ' HD2' ' A' ' 117' ' ' PRO . 44.6 mt -70.5 138.62 86.29 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.598 0.713 . . . . 0.0 111.164 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.65 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.175 0 C-N-CA 122.726 2.284 . . . . 0.0 112.359 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.5 m -81.07 129.29 34.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.368 . . . . 0.0 110.871 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.4 t -146.77 142.72 28.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.864 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.94 107.34 0.52 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.487 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.8 m -112.74 178.95 4.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.848 0.356 . . . . 0.0 110.882 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 7' ' ' GLY . 54.2 p -114.41 -65.35 1.2 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' OG ' ' A' ' 6' ' ' SER . . . 154.86 150.7 5.61 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.483 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.75 2.3 . . . . 0.0 112.329 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -120.7 133.55 55.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.853 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -95.28 60.61 2.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.546 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.1 p -93.43 -175.31 3.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.0 m80 -125.97 66.98 1.19 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.811 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.702 ' CD1' HD21 ' A' ' 109' ' ' LEU . 57.7 m95 -93.66 113.51 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.29 -159.3 8.88 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 154.4 67.86 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.98 51.38 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.726 2.284 . . . . 0.0 112.304 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 1.012 ' NH1' HG23 ' A' ' 106' ' ' VAL . 2.7 ptt-85 -129.13 116.59 19.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.768 HG23 ' CG1' ' A' ' 103' ' ' VAL . 30.9 mt -82.64 131.23 34.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.101 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.574 HG21 ' CB ' ' A' ' 68' ' ' ALA . 76.7 t -140.02 125.07 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.14 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.506 ' HG3' HG22 ' A' ' 103' ' ' VAL . 18.9 mp0 -85.46 125.53 33.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.838 HD12 ' CD1' ' A' ' 104' ' ' PHE . 5.1 mt -124.86 120.67 59.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.174 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.7 130.05 34.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 18.4 mtp180 -65.76 154.03 40.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.5 mm-40 -118.1 150.93 48.38 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.604 0.716 . . . . 0.0 110.92 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -90.91 0.01 OUTLIER 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -48.37 -36.12 13.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -115.84 149.32 18.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.13 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -167.87 1.77 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.797 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.736 HD12 HG23 ' A' ' 95' ' ' ILE . 6.7 mt -59.6 -30.96 69.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.925 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.468 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 90.19 12.95 60.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.578 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 15.4 mt -111.88 149.68 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 0.0 111.077 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 68.1 m -133.15 170.89 14.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.448 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 7.8 pt -141.2 153.63 20.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.157 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.572 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.84 166.37 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.148 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 66.13 -171.48 27.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.75 -36.69 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.466 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -65.95 130.74 44.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.87 0.367 . . . . 0.0 110.917 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.669 HG22 ' H ' ' A' ' 39' ' ' VAL . 1.3 m -135.65 174.49 10.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.669 ' H ' HG22 ' A' ' 38' ' ' THR . 0.9 OUTLIER -145.57 151.35 14.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.158 179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 76.2 mt -118.47 -27.0 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.4 ttpm? -70.53 143.41 51.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 56.87 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.18 -7.71 17.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -145.2 113.93 6.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -105.09 116.11 31.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 136.16 76.84 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.442 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -146.76 142.56 27.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 110.859 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -47.39 172.91 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.91 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.687 HD23 ' CZ ' ' A' ' 53' ' ' PHE . 11.2 mp -44.51 133.63 5.65 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.889 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.474 ' NZ ' ' ND2' ' A' ' 85' ' ' ASN . 0.1 OUTLIER -128.72 -29.98 2.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.952 179.82 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -56.42 -161.22 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.515 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.926 HD11 ' O ' ' A' ' 86' ' ' ALA . 31.1 mm -109.48 126.83 66.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.905 0.383 . . . . 0.0 111.094 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.687 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 2.6 m-85 -122.97 147.03 47.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' ASP . 60.2 mt -61.19 121.87 10.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.572 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.1 tptt -80.97 -45.04 17.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.461 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -172.17 149.54 2.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.904 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.461 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.5 t -129.78 126.31 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.15 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -72.24 169.1 16.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -95.27 -44.2 7.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.443 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 20.3 t70 -82.14 39.48 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.835 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.468 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -128.25 166.67 22.56 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.663 0.744 . . . . 0.0 110.864 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.527 ' O ' HG23 ' A' ' 66' ' ' THR . 53.6 Cg_endo -69.76 -19.14 36.51 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.687 2.258 . . . . 0.0 112.327 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.578 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.67 -27.5 17.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.144 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -72.76 -38.45 56.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.44 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 59.0 mttt -64.39 -45.5 87.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.899 0.381 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 62' ' ' PRO . 2.0 p -50.42 -20.24 1.07 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.172 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 41.67 24.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.914 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.574 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -107.06 1.25 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.771 HD11 HD11 ' A' ' 21' ' ' ILE . 6.7 mt -141.17 139.24 33.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -149.46 157.83 43.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.881 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.4 t -52.32 140.36 22.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.32 -25.98 24.31 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.448 ' CG ' ' O ' ' A' ' 70' ' ' LYS . 3.5 m-20 -58.38 172.65 0.45 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -125.39 107.78 11.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.946 ' HA ' HG12 ' A' ' 106' ' ' VAL . 12.1 mt -78.13 119.09 26.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.672 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.5 OUTLIER -102.44 -24.12 13.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -166.4 151.28 7.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.62 126.03 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.46 16.11 6.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.882 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.92 33.03 8.03 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.484 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.822 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.9 p -129.96 125.03 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.878 0.371 . . . . 0.0 111.118 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -67.56 111.09 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.692 HD13 ' HB1' ' A' ' 91' ' ' ALA . 37.7 mt -111.96 -0.92 15.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.916 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.6 mt-30 -47.65 -65.13 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . 0.666 ' C ' HG21 ' A' ' 38' ' ' THR . 11.0 m120 -90.58 32.16 0.99 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.926 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -104.59 140.15 38.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.446 ' OG ' ' N ' ' A' ' 88' ' ' HIS . 31.4 t -68.13 -173.6 0.4 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.876 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.67 ' O ' HG23 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -61.9 -45.06 95.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.2 m -76.06 -37.75 57.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.593 ' HB3' ' HB1' ' A' ' 86' ' ' ALA . 20.9 mt-10 -53.99 -36.55 63.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.801 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -86.19 -38.37 17.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.67 HG23 ' O ' ' A' ' 88' ' ' HIS . 14.4 t -52.15 -51.5 30.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.183 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.5 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 5.9 mt-10 -60.09 -33.51 72.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.822 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.82 -51.15 63.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.087 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.801 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -64.56 -36.88 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 6.8 pttp -79.61 -28.79 40.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.875 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.1 m-20 -104.71 19.11 21.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.921 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.741 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.92 110.42 7.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.065 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.99 93.65 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.522 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 12.7 t-20 -35.11 131.93 0.47 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.605 0.716 . . . . 0.0 110.879 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.7 -174.04 9.07 Favored 'Cis proline' 0 C--N 1.341 0.157 0 C-N-CA 122.751 -1.77 . . . . 0.0 112.334 -0.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.741 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.1 t -118.48 96.05 4.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.768 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -76.16 142.48 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.838 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.4 m-85 -123.53 131.26 53.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 mt -119.03 90.57 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 1.012 HG23 ' NH1' ' A' ' 17' ' ' ARG . 32.9 m -121.07 179.58 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.672 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.3 mt-30 -141.99 110.27 5.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.53 ' N ' ' NH1' ' A' ' 17' ' ' ARG . 3.2 t -84.17 131.1 34.8 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.857 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.702 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.9 mt -61.64 160.46 11.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 45.4 p -57.7 95.1 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 48.5 t -125.48 16.24 8.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.86 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 55.07 163.46 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.609 0.719 . . . . 0.0 111.127 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -171.05 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.666 2.244 . . . . 0.0 112.318 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 0.6 OUTLIER -140.89 150.08 42.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.436 ' N ' ' HG2' ' A' ' 114' ' ' ARG . 5.5 p -115.0 143.61 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.4 pt -76.39 156.84 83.28 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.643 0.735 . . . . 0.0 111.14 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.657 2.238 . . . . 0.0 112.38 179.878 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.7 t -121.3 -9.35 9.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.859 0.361 . . . . 0.0 110.831 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -94.98 121.26 36.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.894 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.46 79.05 0.37 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.477 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.7 t -134.12 63.32 1.63 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.924 0.392 . . . . 0.0 110.878 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.8 p -66.52 167.31 11.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.877 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 171.32 45.61 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.47 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -46.68 1.12 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.54 160.73 15.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.589 ' CZ ' ' O ' ' A' ' 47' ' ' GLU . 5.4 t80 -175.11 -177.36 1.05 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PHE . 35.9 p -35.24 150.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.855 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -111.18 75.32 0.91 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.801 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.692 ' CD1' HD21 ' A' ' 109' ' ' LEU . 77.2 m95 -87.62 114.67 24.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.963 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.18 -162.96 10.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.463 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 159.0 55.06 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 2.249 . . . . 0.0 112.386 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 161.6 45.3 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.468 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.1 ptp180 -139.01 121.94 16.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.871 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.561 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.2 mt -90.61 133.87 31.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.121 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -143.03 128.06 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.15 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -87.11 118.89 26.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.934 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.4 mt -116.4 114.28 45.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.179 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.0 m-85 -81.16 129.55 34.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.43 ' NH2' ' O ' ' A' ' 96' ' ' LYS . 63.2 mtp180 -64.35 156.97 27.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.7 mm-40 -124.25 150.55 64.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.678 0.752 . . . . 0.0 110.858 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -90.86 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.341 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -47.26 -36.81 9.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.483 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -116.13 147.79 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.55 -163.92 0.7 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.898 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.681 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.7 mt -64.06 -27.7 69.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.457 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 86.82 13.27 67.25 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.485 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.669 HD11 HD13 ' A' ' 21' ' ' ILE . 10.3 mt -113.66 148.17 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.34 . . . . 0.0 111.118 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.9 m -131.19 170.11 15.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.798 HD12 ' CD2' ' A' ' 88' ' ' HIS . 4.5 pt -139.14 152.86 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.164 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.559 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.35 170.1 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.596 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 46.68 -145.38 3.95 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.543 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 84.9 -22.54 9.19 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' GLY . 0.0 OUTLIER -34.37 -70.52 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 0.0 110.91 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.2 p -128.05 179.14 5.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -145.58 175.2 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.118 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.461 ' N ' HG23 ' A' ' 39' ' ' VAL . 22.8 mt -150.94 140.63 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' CD ' ' O ' ' A' ' 41' ' ' LYS . 2.4 tmtp? -77.69 51.33 0.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -107.95 56.71 0.63 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.937 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.521 ' CD1' ' C ' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.05 19.51 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 20.81 13.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -171.82 158.49 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.07 139.52 6.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.589 ' O ' ' CZ ' ' A' ' 10' ' ' PHE . 3.7 mm-40 -114.32 -8.06 12.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.873 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 49' ' ' LEU . 29.8 mp0 -103.37 81.92 1.99 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.855 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.92 ' O ' HD22 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -34.55 128.78 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.925 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.36 179.56 7.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.881 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.594 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . 138.9 157.63 7.4 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.968 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.9 mm -72.87 100.9 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 0.0 111.093 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 46.7 m-85 -93.45 135.7 34.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.857 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' LYS . 4.4 mt -52.65 127.51 10.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.164 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.559 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.4 tptm -84.2 -48.59 9.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.4 OUTLIER -167.62 150.24 5.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.947 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.455 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 6.1 t -131.88 127.73 58.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -73.71 177.08 5.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 74.0 tt0 -104.0 -42.02 5.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -83.49 36.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.883 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.464 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.79 168.4 13.39 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.642 0.734 . . . . 0.0 110.878 -179.789 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.585 ' O ' HG23 ' A' ' 66' ' ' THR . 53.1 Cg_endo -69.81 -22.24 32.14 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.692 2.261 . . . . 0.0 112.324 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.612 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.66 -29.36 18.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.78 -38.62 26.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.521 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -59.27 -42.72 91.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.832 0.349 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.585 HG23 ' O ' ' A' ' 62' ' ' PRO . 4.8 p -59.62 -18.74 43.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.139 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 42.15 24.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -102.27 -0.81 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.603 ' CD1' HD11 ' A' ' 21' ' ' ILE . 5.1 mt -139.35 135.06 33.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.409 ' O ' HD12 ' A' ' 54' ' ' ILE . 3.4 mtpm? -129.89 170.24 14.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 11.8 t -71.57 142.83 50.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.34 -25.04 29.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.436 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -50.01 179.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.902 0.382 . . . . 0.0 110.86 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.743 ' CE ' HD23 ' A' ' 49' ' ' LEU . 34.6 tttm -127.41 99.53 5.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.977 ' HA ' HG12 ' A' ' 106' ' ' VAL . 32.2 mt -69.34 115.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.581 HD21 ' HD3' ' A' ' 74' ' ' LYS . 0.5 OUTLIER -100.32 -25.95 14.06 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.912 179.902 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -164.57 151.4 11.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.581 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.95 125.82 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.741 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.07 15.97 5.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.34 32.17 8.45 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.841 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.8 127.56 64.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.327 . . . . 0.0 111.134 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.45 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -69.63 114.14 7.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.875 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.848 HD13 ' HB1' ' A' ' 91' ' ' ALA . 28.7 mt -113.75 -8.75 13.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.406 ' C ' ' O ' ' A' ' 83' ' ' LEU . 64.4 mt-30 -38.07 -69.35 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.926 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -90.18 34.08 0.87 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.968 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.66 136.85 42.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.4 m -62.39 -176.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.798 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.6 t-160 -66.46 -33.64 76.15 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.888 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -84.64 -38.43 19.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.426 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 25.9 mm-40 -54.59 -38.48 66.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.848 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -84.39 -38.67 19.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.124 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 88' ' ' HIS . 2.4 t -50.32 -44.05 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 13.5 mt-10 -70.2 -32.16 69.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.907 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.841 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -44.9 88.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.781 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.5 mp -71.93 -32.06 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.43 ' O ' ' NH2' ' A' ' 23' ' ' ARG . 1.6 ptmm? -83.47 -26.51 30.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.6 m-80 -107.7 12.46 27.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.894 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.741 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -66.6 109.64 2.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.045 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -45.76 95.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.596 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 26.4 t-20 -38.82 134.1 1.04 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.625 0.726 . . . . 0.0 110.895 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.575 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.75 174.86 38.82 Favored 'Cis proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.352 -0.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.74 HG13 ' CB ' ' A' ' 98' ' ' ALA . 13.1 t -108.12 96.05 4.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.112 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.561 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -74.89 143.64 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.934 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.8 m-85 -126.65 128.37 46.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -116.89 89.46 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.977 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.1 m -120.46 177.75 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.54 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.3 mt-30 -137.07 106.69 6.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.935 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 t -73.24 131.4 41.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.692 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.2 mt -68.38 166.45 16.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 m -56.02 87.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.873 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 109' ' ' LEU . 8.3 t -151.45 -178.6 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.859 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 52.5 p -125.11 144.1 46.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.583 0.706 . . . . 0.0 111.15 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.457 ' HG2' ' N ' ' A' ' 115' ' ' VAL . 15.8 ttm-85 -149.45 150.39 32.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.6 t -92.65 179.69 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.734 ' H ' HG12 ' A' ' 115' ' ' VAL . 38.7 mt -85.21 138.64 36.56 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.621 0.724 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.682 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.364 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 63.6 52.78 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.943 0.401 . . . . 0.0 110.91 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.3 t -64.43 122.84 17.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -41.15 152.76 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.8 t -107.23 -4.81 18.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.813 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -92.69 135.76 33.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.24 178.19 34.2 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.438 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -163.89 0.12 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -113.95 177.46 4.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -175.28 -177.35 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.438 ' HB2' ' NE1' ' A' ' 13' ' ' TRP . 0.9 OUTLIER -39.92 160.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.889 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.2 m80 -110.04 84.93 2.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.677 ' CD1' HD21 ' A' ' 109' ' ' LEU . 55.0 m95 -81.0 118.06 22.15 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.881 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.38 -163.55 16.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 147.74 63.35 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.244 . . . . 0.0 112.342 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 170.49 16.41 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.73 2.287 . . . . 0.0 112.344 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -142.03 126.17 17.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.2 mt -90.9 131.25 38.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.165 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG21 ' CB ' ' A' ' 68' ' ' ALA . 39.2 t -140.73 128.95 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -87.64 120.48 29.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.883 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.9 mt -117.61 117.82 56.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.592 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -83.77 129.39 34.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtp180 -64.61 156.12 31.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.468 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 4.0 mm-40 -121.73 150.85 56.35 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.682 0.753 . . . . 0.0 110.849 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.654 2.236 . . . . 0.0 112.341 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -47.85 -36.56 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.893 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.4 p -115.49 149.12 17.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.54 -166.11 1.21 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.778 HD12 HG23 ' A' ' 95' ' ' ILE . 6.6 mt -61.58 -30.26 70.56 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.467 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 89.27 12.69 62.87 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.603 HD11 HD13 ' A' ' 21' ' ' ILE . 12.7 mt -112.78 149.07 15.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.868 0.365 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -133.04 170.73 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.866 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 92' ' ' VAL . 19.0 pt -141.73 148.66 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.529 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -100.68 175.13 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.91 -127.68 4.16 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA3' ' CA ' ' A' ' 88' ' ' HIS . . . 86.02 -46.25 3.59 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.455 ' N ' ' HB2' ' A' ' 88' ' ' HIS . 16.7 tt0 -42.09 140.72 1.04 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.881 0.372 . . . . 0.0 110.913 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -44.64 158.4 0.05 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.727 ' C ' HD12 ' A' ' 40' ' ' ILE . 0.2 OUTLIER -168.87 151.84 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.168 179.9 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.821 ' N ' HD12 ' A' ' 40' ' ' ILE . 0.3 OUTLIER -148.86 135.46 12.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.145 179.948 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -139.94 143.22 36.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.904 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.0 ptt-85 -101.32 4.96 42.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.874 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 7.8 mp -69.52 155.8 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.5 mttt -127.66 10.68 6.64 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.902 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.447 ' O ' ' C ' ' A' ' 46' ' ' GLY . 15.6 t-20 -123.26 -55.45 1.76 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.905 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 45' ' ' ASN . . . -34.49 112.58 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 48' ' ' GLU . 12.0 tp10 -97.57 113.85 25.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.879 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.434 ' CG ' ' O ' ' A' ' 47' ' ' GLU . 62.8 mt-10 -161.11 173.99 14.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.908 HD23 ' CZ ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -122.41 154.79 37.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.923 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.87 -15.49 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.864 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' ' CE1' ' A' ' 53' ' ' PHE . . . -41.81 164.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.751 HD11 ' O ' ' A' ' 86' ' ' ALA . 9.0 mm -76.29 128.92 37.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.825 0.345 . . . . 0.0 111.149 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.908 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 64.1 m-85 -122.5 137.29 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.637 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.4 mt -54.7 117.8 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.159 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.529 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.1 tptt -78.07 -49.2 14.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.449 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -167.18 149.39 6.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.905 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.449 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.2 t -130.62 126.93 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.135 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.629 HD12 ' N ' ' A' ' 58' ' ' LEU . 3.9 mp -72.97 174.52 7.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -100.61 -43.39 6.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -82.9 38.39 0.58 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.467 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.64 167.1 18.35 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.646 0.736 . . . . 0.0 110.876 -179.793 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' O ' HG23 ' A' ' 66' ' ' THR . 54.3 Cg_endo -69.72 -19.75 35.91 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -92.4 -27.51 17.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.49 -37.3 36.03 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.461 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 51.3 mttm -64.32 -40.44 95.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.483 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.2 p -54.57 -22.64 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.168 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 43.12 23.97 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.409 ' N ' ' C ' ' A' ' 66' ' ' THR . . . -106.9 -3.39 20.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.129 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.647 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.8 mt -136.76 134.96 37.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.637 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -131.42 169.92 15.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.844 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.2 t -71.84 138.43 48.26 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.2 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 107.2 -21.82 30.47 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.442 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -58.66 175.22 0.27 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.862 0.363 . . . . 0.0 110.897 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 tttt -122.53 106.07 10.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.885 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.923 ' HA ' HG12 ' A' ' 106' ' ' VAL . 19.8 mt -75.02 113.44 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.111 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.632 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -95.94 -25.23 16.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 179.87 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -165.8 151.4 9.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.543 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.49 125.73 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.117 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.597 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.31 17.32 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.88 32.88 8.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.817 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.62 124.36 59.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.813 0.339 . . . . 0.0 111.164 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -67.31 111.25 3.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.82 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.592 HD13 ' HB1' ' A' ' 91' ' ' ALA . 35.4 mt -111.97 0.07 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -45.99 -69.54 0.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . 0.454 HD22 ' N ' ' A' ' 85' ' ' ASN . 0.9 OUTLIER -88.7 32.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.751 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.15 139.68 35.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.9 p -67.32 -174.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.815 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.8 t-160 -63.89 -40.52 96.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 t -80.19 -37.44 33.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.487 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.8 mm-40 -54.17 -34.04 59.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.898 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.748 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -87.6 -38.53 15.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.093 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.529 HG23 HD11 ' A' ' 33' ' ' ILE . 2.5 t -52.9 -44.69 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.154 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.493 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.8 mt-10 -67.3 -33.29 74.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.817 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.26 -49.34 72.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.778 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.32 -36.9 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.137 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.81 -27.43 40.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.4 m-20 -106.4 19.16 20.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.877 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.794 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -73.35 111.01 8.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.48 94.21 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.513 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.592 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 22.3 t-20 -35.49 131.87 0.52 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.599 0.714 . . . . 0.0 110.877 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.0 Cg_endo -69.75 -176.96 13.51 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 -1.793 . . . . 0.0 112.359 -0.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.794 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -116.66 93.27 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.3 t -72.03 144.69 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.149 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.883 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.9 m-85 -127.32 129.25 47.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -117.81 89.86 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.923 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.2 m -120.72 174.12 5.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.632 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.8 109.29 6.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.909 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -74.58 129.64 38.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.677 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.5 mt -60.63 178.62 0.21 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.0 t -52.68 -17.17 1.18 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.7 t -61.11 -174.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 66.8 p -138.4 144.08 41.27 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.55 0.69 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.504 ' NE ' ' H ' ' A' ' 115' ' ' VAL . 0.0 OUTLIER -121.3 163.43 18.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.604 HG12 ' N ' ' A' ' 116' ' ' ILE . 21.0 t -90.72 166.36 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.707 ' H ' HD12 ' A' ' 116' ' ' ILE . 4.7 mp -62.17 138.63 96.05 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.617 0.722 . . . . 0.0 111.12 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.666 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.32 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -163.21 112.21 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.863 0.363 . . . . 0.0 110.842 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.2 p -62.8 159.46 16.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.847 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.7 83.38 0.75 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.474 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.3 p -69.98 178.92 2.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.0 m -98.05 -16.03 19.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.851 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 51.52 -164.73 1.08 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.493 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 159.11 54.63 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.657 2.238 . . . . 0.0 112.383 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 44.4 m-20 -78.16 126.24 30.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 68.1 m-85 -80.11 -178.01 6.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 1.9 p -34.56 150.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.91 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -126.69 74.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.7 ' CD1' HD21 ' A' ' 109' ' ' LEU . 67.9 m95 -84.73 112.11 20.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.904 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.47 -161.42 5.66 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 159.18 54.41 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 170.28 16.97 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.688 2.259 . . . . 0.0 112.368 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.9 ptp180 -145.64 124.52 12.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.853 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.649 HG23 ' CG1' ' A' ' 103' ' ' VAL . 22.1 mt -92.47 132.99 35.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.532 HG21 ' HB1' ' A' ' 68' ' ' ALA . 22.3 t -141.8 123.95 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -86.9 118.89 26.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.924 HD11 HD11 ' A' ' 69' ' ' LEU . 4.1 mt -113.11 109.95 30.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.16 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -74.33 114.93 13.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.519 ' HG2' HG23 ' A' ' 102' ' ' VAL . 3.1 mtm-85 -53.04 158.92 1.31 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 3.3 mm-40 -127.63 149.34 70.04 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.665 0.745 . . . . 0.0 110.882 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.684 2.256 . . . . 0.0 112.327 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -46.11 -36.41 5.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.914 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.7 p -116.82 144.43 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.131 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -78.36 -156.48 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.72 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.8 mt -73.31 -27.3 61.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.945 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.469 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.47 13.05 71.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.477 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.69 HD11 HD13 ' A' ' 21' ' ' ILE . 10.5 mt -112.31 148.4 15.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.817 0.341 . . . . 0.0 111.117 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.7 m -131.3 170.71 14.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.846 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.897 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.7 pt -141.94 150.4 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.141 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.555 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.27 166.44 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.66 -129.41 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.446 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 155.0 -82.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.483 ' HB3' ' CB ' ' A' ' 87' ' ' SER . 4.3 tt0 -149.78 114.99 5.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 110.892 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.4 t -102.36 -176.87 3.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.441 ' C ' HG13 ' A' ' 40' ' ' ILE . 46.5 t -107.66 92.32 2.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.114 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.441 HG13 ' C ' ' A' ' 39' ' ' VAL . 77.1 mt -154.53 135.99 5.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.412 ' C ' ' O ' ' A' ' 40' ' ' ILE . 2.8 ttpm? -37.01 145.49 0.05 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.937 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -79.58 50.85 1.18 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.889 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 12.4 tp -100.34 134.63 43.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.93 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -61.31 138.43 58.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.428 ' C ' ' OD1' ' A' ' 45' ' ' ASN . 26.9 t-20 -95.46 -72.49 0.62 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 163.12 -91.45 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -78.91 -6.65 56.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.787 0.327 . . . . 0.0 110.893 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -123.54 171.77 9.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.597 ' CD1' ' N ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -161.91 158.9 26.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.2 tppp? -84.73 135.92 33.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 161.62 175.4 32.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.863 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.5 mm -90.06 125.8 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.899 0.381 . . . . 0.0 111.131 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -120.96 137.72 54.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.07 132.71 17.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.146 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HB2' HG12 ' A' ' 34' ' ' VAL . 16.2 tptt -89.37 -47.67 7.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -170.0 150.69 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.887 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -131.46 128.03 60.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.061 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.623 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.36 178.06 4.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.884 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.648 ' OE2' HD11 ' A' ' 116' ' ' ILE . 55.6 tt0 -104.5 -41.91 5.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -83.44 36.21 0.52 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.87 168.65 12.77 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.658 0.742 . . . . 0.0 110.834 -179.788 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.679 ' O ' HG23 ' A' ' 66' ' ' THR . 53.5 Cg_endo -69.77 -21.67 33.1 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.694 2.263 . . . . 0.0 112.319 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.12 -26.96 18.86 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.098 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -79.58 -23.15 63.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.54 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -79.82 -36.02 37.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 110.894 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 62' ' ' PRO . 3.7 p -64.31 -15.35 60.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 44.01 22.62 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.532 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -106.23 2.06 26.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.129 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.924 HD11 HD11 ' A' ' 21' ' ' ILE . 8.6 mt -138.93 134.13 32.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.48 ' CB ' ' HG3' ' A' ' 113' ' ' PRO . 13.6 mmtp -144.11 157.26 44.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.3 t -56.76 135.35 55.39 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.136 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.39 -30.53 8.45 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.489 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -51.28 165.58 0.14 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.886 0.374 . . . . 0.0 110.87 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.401 ' HE3' ' CD2' ' A' ' 76' ' ' LEU . 25.8 tttp -116.48 109.0 16.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.86 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 1.026 ' HA ' HG12 ' A' ' 106' ' ' VAL . 13.0 mt -78.88 119.14 27.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.168 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.649 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.62 -25.86 13.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.925 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -164.84 151.43 10.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.544 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.55 125.7 8.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.163 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.1 t 59.72 18.17 6.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.87 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.13 33.35 8.91 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.785 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -130.05 123.44 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.824 0.345 . . . . 0.0 111.183 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -66.46 110.76 3.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.664 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.3 mt -111.93 -4.9 14.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 57.9 mt-30 -41.79 -69.56 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.863 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.24 134.39 40.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.483 ' CB ' ' HB3' ' A' ' 37' ' ' GLN . 24.3 p -63.39 -179.38 0.33 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.904 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.897 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -58.8 -43.29 90.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.3 t -75.8 -42.39 50.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.843 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -55.03 -31.26 60.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.739 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -93.33 -36.44 12.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.109 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.846 HG23 HD11 ' A' ' 33' ' ' ILE . 2.7 t -55.45 -42.41 67.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.452 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -69.07 -33.34 73.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.785 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.46 -43.28 99.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.739 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.0 mp -72.82 -35.54 49.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.102 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -80.21 -25.1 39.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.452 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 72.7 m-80 -106.81 11.13 30.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.679 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.1 113.5 3.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.103 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.12 92.72 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.524 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.2 OUTLIER -34.88 131.05 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.628 0.728 . . . . 0.0 110.868 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.584 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.9 Cg_endo -69.78 178.68 24.65 Favored 'Cis proline' 0 C--N 1.341 0.164 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.373 -0.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.679 HG13 ' CB ' ' A' ' 98' ' ' ALA . 42.3 t -113.61 92.97 2.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.649 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.6 t -71.65 140.68 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.099 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 21' ' ' ILE . 9.4 m-85 -121.68 134.67 54.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.849 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -122.48 90.28 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 1.026 HG12 ' HA ' ' A' ' 75' ' ' ILE . 15.6 m -122.78 -177.37 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.649 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.1 mt-30 -140.66 107.04 5.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.8 t -73.12 133.07 44.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.7 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.4 mt -69.45 168.62 14.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.954 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 47.1 t -38.65 -59.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.889 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.9 t -73.76 173.53 9.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 25.0 p -151.62 145.21 17.61 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.573 0.702 . . . . 0.0 111.115 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . 0.48 ' HG3' ' CB ' ' A' ' 70' ' ' LYS . 53.5 Cg_endo -69.73 -168.3 0.27 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.697 2.265 . . . . 0.0 112.35 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 13.3 tpp180 -144.87 156.55 44.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.443 ' N ' ' HG3' ' A' ' 114' ' ' ARG . 47.8 t -150.2 148.6 15.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.689 ' C ' HD12 ' A' ' 116' ' ' ILE . 0.9 OUTLIER -49.11 151.28 2.44 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.591 0.71 . . . . 0.0 111.121 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.585 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.674 2.25 . . . . 0.0 112.336 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -141.71 166.91 23.45 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -158.67 117.18 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.08 162.83 23.01 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.497 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -160.52 160.06 31.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.9 t -154.29 -175.57 5.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.883 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.88 83.41 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -164.6 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.705 2.27 . . . . 0.0 112.353 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -140.45 -175.25 4.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.888 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -121.73 -64.42 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 21.5 p -40.4 161.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.841 -179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 20.0 t60 -120.79 68.55 0.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.828 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.667 ' CD1' HD21 ' A' ' 109' ' ' LEU . 55.4 m95 -84.93 118.44 24.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.83 -163.72 18.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 148.21 64.46 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.646 2.231 . . . . 0.0 112.404 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 171.86 13.7 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.688 2.259 . . . . 0.0 112.333 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.406 ' NH1' ' HB3' ' A' ' 17' ' ' ARG . 1.0 OUTLIER -140.75 127.14 19.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.712 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.0 mt -90.53 130.65 39.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.441 HG21 ' CB ' ' A' ' 68' ' ' ALA . 45.8 t -139.04 123.58 20.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -85.03 116.86 23.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.843 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.8 mt -114.23 108.11 24.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.169 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' CD1' ' HB3' ' A' ' 101' ' ' PRO . 2.4 m-85 -72.41 124.29 24.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.62 ' HG3' HG23 ' A' ' 102' ' ' VAL . 30.6 mtp180 -61.98 156.91 19.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 6.1 mm-40 -122.34 150.15 56.59 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.648 0.737 . . . . 0.0 110.903 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -90.91 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.266 . . . . 0.0 112.329 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -47.7 -35.98 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.927 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 12.8 p -115.9 146.88 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.136 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -166.04 1.04 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.677 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.4 mt -62.17 -29.16 70.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.965 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 87.82 12.85 65.7 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.488 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 21' ' ' ILE . 13.1 mt -112.76 149.18 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.857 0.361 . . . . 0.0 111.134 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.3 m -131.56 171.73 13.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.565 HD11 HG23 ' A' ' 92' ' ' VAL . 3.0 pt -140.68 153.62 21.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.13 171.25 2.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.599 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.97 -145.17 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.45 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.96 100.31 2.31 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' C ' ' HB2' ' A' ' 87' ' ' SER . 71.6 mt-30 -130.21 145.78 51.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.912 0.387 . . . . 0.0 110.852 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.1 m -105.47 109.31 21.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.13 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -175.01 149.7 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 60.8 mt -152.22 110.96 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.151 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.0 mtpt -144.73 129.59 18.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.913 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 49.5 mtt180 -81.69 68.0 7.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.906 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 42.7 mt -92.58 -71.66 0.64 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -135.52 124.65 24.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -57.4 151.18 16.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.77 133.34 5.53 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -171.54 142.29 1.61 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.798 0.332 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -53.58 176.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.868 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.553 HD12 ' HZ ' ' A' ' 53' ' ' PHE . 1.8 mm? -47.1 125.94 8.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -116.67 -20.82 9.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.864 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.48 -175.04 3.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.484 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.93 HD11 ' O ' ' A' ' 86' ' ' ALA . 27.3 mm -102.81 127.57 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.908 0.385 . . . . 0.0 111.149 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 49' ' ' LEU . 43.5 m-85 -122.38 143.8 49.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.419 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.3 mt -57.34 138.16 18.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.125 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.56 ' HB2' HG12 ' A' ' 34' ' ' VAL . 17.3 tptt -97.67 -47.08 5.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.454 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.19 150.38 4.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.927 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.454 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.9 t -130.81 126.72 60.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.62 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.2 mp -71.48 175.58 5.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.925 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -101.26 -43.82 5.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.881 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 60' ' ' ASP . 17.5 t0 -82.82 38.77 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.471 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.83 167.29 17.95 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.673 0.749 . . . . 0.0 110.87 -179.743 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.706 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.7 -20.52 35.01 Favored 'Trans proline' 0 N--CA 1.466 -0.124 0 C-N-CA 122.725 2.283 . . . . 0.0 112.349 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -91.38 -28.19 17.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.088 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.48 57.7 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.457 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.9 mttt -71.89 -37.23 70.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.822 0.344 . . . . 0.0 110.896 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.706 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.5 p -57.27 -20.63 29.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.145 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 40.72 24.94 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.55 -0.05 22.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.078 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.649 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.3 mt -141.1 141.54 34.21 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mmmm -146.2 155.9 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 13.0 t -54.09 137.89 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 108.2 -25.03 21.43 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.448 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -59.13 168.31 1.42 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.916 0.389 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -116.74 108.88 16.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.907 ' HA ' HG12 ' A' ' 106' ' ' VAL . 15.8 mt -78.12 120.11 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.14 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.798 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -104.5 -23.84 13.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.933 179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -165.69 151.39 9.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.598 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.97 125.88 10.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.116 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.799 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 59.81 17.24 6.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.17 32.4 8.92 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.888 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -129.0 125.56 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.333 . . . . 0.0 111.114 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -67.35 111.92 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.587 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.3 mt -115.04 2.9 14.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 -50.88 -65.47 0.55 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.949 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.62 25.07 1.3 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.915 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.93 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -99.13 145.18 27.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.458 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 33.4 t -76.13 -175.33 3.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.599 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -58.15 -46.3 85.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.835 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 74.8 m -74.15 -40.48 62.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.596 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 30.6 mm-40 -53.42 -36.66 61.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.867 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.806 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.69 -40.11 21.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.565 HG23 HD11 ' A' ' 33' ' ' ILE . 1.9 t -50.2 -60.89 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 92' ' ' VAL . 6.3 mt-10 -49.7 -37.65 29.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.888 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -65.9 -43.16 89.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.111 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.806 HD12 ' O ' ' A' ' 91' ' ' ALA . 2.2 mp -68.17 -42.92 85.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.109 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.505 ' CE ' ' CG1' ' A' ' 92' ' ' VAL . 8.9 ptpt -74.92 -32.57 61.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 69.5 m-20 -101.83 21.85 13.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.819 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -72.4 108.57 5.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -41.11 91.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.49 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.6 OUTLIER -38.83 132.71 1.09 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.629 0.728 . . . . 0.0 110.877 -179.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.586 ' HB3' ' CD1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.7 172.44 48.75 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.722 -1.782 . . . . 0.0 112.348 -0.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.819 HG13 ' CB ' ' A' ' 98' ' ' ALA . 17.0 t -103.94 98.92 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.089 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.712 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -77.99 145.54 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.843 ' CD1' HD12 ' A' ' 21' ' ' ILE . 8.2 m-85 -126.35 126.13 43.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.8 mt -115.49 90.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.907 HG12 ' HA ' ' A' ' 75' ' ' ILE . 11.0 m -121.36 173.39 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.113 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.798 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.7 114.93 9.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.4 t -81.88 138.35 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.916 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.667 HD21 ' CD1' ' A' ' 13' ' ' TRP . 12.1 mt -67.69 172.27 5.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.932 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 24.3 t -45.84 -21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.8 t -52.11 -176.48 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.844 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 76.6 p -145.25 148.59 38.41 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.537 0.684 . . . . 0.0 111.168 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 -163.84 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -130.15 -174.79 3.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.845 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 1.5 p -122.23 152.25 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.56 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -105.2 159.96 27.63 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.622 0.725 . . . . 0.0 111.13 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.673 2.248 . . . . 0.0 112.311 179.925 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.537 -0.225 . . . . 0.0 112.537 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -110.0 177.88 4.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.897 0.38 . . . . 0.0 110.864 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.4 p -154.8 161.47 41.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.837 -179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.3 -173.28 12.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 p -148.76 162.35 39.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.859 0.361 . . . . 0.0 110.862 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -112.14 -74.94 0.62 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.18 146.19 8.04 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -163.78 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -160.78 173.39 15.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' SER . 11.9 m-85 -83.16 -75.15 0.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.884 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PHE . 0.6 OUTLIER -34.85 151.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.853 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . 0.462 ' C ' HD23 ' A' ' 109' ' ' LEU . 11.3 t60 -132.83 95.37 3.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.647 ' CD1' HD21 ' A' ' 109' ' ' LEU . 74.9 m95 -92.39 110.29 21.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.63 -163.23 4.7 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.462 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 148.37 64.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.652 2.235 . . . . 0.0 112.354 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 170.63 16.12 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.637 2.224 . . . . 0.0 112.365 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -144.39 126.26 15.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.696 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.7 mt -92.0 130.96 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.085 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.0 t -139.54 131.34 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -88.84 118.82 28.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.993 HD12 ' CD1' ' A' ' 104' ' ' PHE . 8.2 mt -119.12 118.29 57.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.589 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.7 m-85 -82.74 132.13 35.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 7.1 mtp-105 -70.05 150.73 46.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.896 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.483 ' CB ' HG13 ' A' ' 27' ' ' VAL . 4.5 mm-40 -121.63 147.93 49.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.679 0.752 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -90.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.634 2.222 . . . . 0.0 112.373 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -45.04 -37.6 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.9 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.483 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.5 p -114.53 142.02 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 t -81.74 172.62 13.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.692 HD22 ' CG2' ' A' ' 21' ' ' ILE . 5.7 mt -46.93 -20.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.899 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.511 ' HA2' HD12 ' A' ' 58' ' ' LEU . . . 85.32 -18.59 27.69 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.452 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 21' ' ' ILE . 6.9 mt -83.82 148.41 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.823 0.344 . . . . 0.0 111.145 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.412 ' CB ' ' HB3' ' A' ' 55' ' ' LYS . 13.4 m -129.07 171.21 12.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.996 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.8 pt -138.26 148.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.567 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -106.38 170.04 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.913 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.598 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 34.73 -142.31 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.465 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 88' ' ' HIS . . . 115.33 77.83 0.73 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.51 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 tm0? -119.57 166.68 12.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 0.0 110.883 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 41.0 p -79.07 -179.19 6.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.192 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.39 132.09 14.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.609 HG22 ' N ' ' A' ' 41' ' ' LYS . 35.2 mt -93.62 164.52 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.609 ' N ' HG22 ' A' ' 40' ' ' ILE . 2.1 mmmp? -83.75 88.0 7.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.917 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 14.0 tpp180 -119.41 -27.24 5.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.891 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 31.6 mt 54.85 49.58 17.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.24 -39.5 3.87 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 46' ' ' GLY . 0.6 OUTLIER -59.91 161.57 6.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 45' ' ' ASN . . . 162.66 -33.36 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -82.23 7.3 14.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.779 0.323 . . . . 0.0 110.871 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -155.07 175.18 14.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.917 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.827 HD22 ' C ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -132.81 146.73 52.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.929 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.58 -177.61 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.489 ' CA ' ' O ' ' A' ' 84' ' ' GLN . . . 139.81 -123.63 2.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.74 HD11 ' O ' ' A' ' 86' ' ' ALA . 33.3 mm -119.3 122.08 68.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -122.64 133.33 54.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.843 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 70' ' ' LYS . 7.5 mt -45.89 140.69 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.099 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.567 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.2 tptp -101.49 -40.27 7.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.858 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -178.82 150.43 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.95 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.0 115.71 42.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.511 HD12 ' HA2' ' A' ' 30' ' ' GLY . 28.7 mt -54.44 -167.48 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -115.98 -53.69 2.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -81.0 41.92 0.61 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.481 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -124.75 168.85 12.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.664 0.745 . . . . 0.0 110.85 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.599 ' O ' HG23 ' A' ' 66' ' ' THR . 54.1 Cg_endo -69.69 -15.18 37.22 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.703 2.269 . . . . 0.0 112.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -99.6 -27.07 13.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.124 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -75.41 -23.32 73.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.521 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -82.87 -38.31 23.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.371 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 62' ' ' PRO . 11.0 p -57.24 -21.99 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.114 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 41.67 24.58 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -107.29 5.81 27.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.088 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.744 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.1 mt -144.28 135.16 25.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.598 ' O ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -130.23 162.04 29.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.859 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.9 t -68.05 134.82 51.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 112.43 -25.22 12.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -51.59 179.06 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.646 ' CE ' HD23 ' A' ' 49' ' ' LEU . 34.7 tttm -124.05 101.14 7.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.981 ' HA ' HG12 ' A' ' 106' ' ' VAL . 24.0 mt -71.67 116.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.159 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.6 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -101.32 -24.43 14.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.875 179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -165.84 151.41 8.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.07 125.69 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.139 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.772 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.51 15.76 5.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.819 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.45 32.05 8.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.838 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.2 p -128.94 125.83 63.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.808 0.337 . . . . 0.0 111.133 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -67.25 109.7 3.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.458 ' HG ' HG13 ' A' ' 81' ' ' VAL . 38.1 mt -111.9 -7.25 14.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.489 ' O ' ' CA ' ' A' ' 51' ' ' GLY . 45.7 mt-30 -36.83 -70.94 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -90.71 35.51 0.89 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.74 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.37 135.32 45.22 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.142 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.8 m -63.93 -174.29 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.996 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.3 t-160 -66.63 -37.61 85.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.1 t -76.61 -43.4 38.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -54.89 -38.54 67.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.766 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.25 -39.64 25.01 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.081 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.746 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -52.59 -44.31 45.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.6 mt-10 -68.61 -34.28 75.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.923 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.838 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.93 -50.86 64.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.766 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.1 mp -66.0 -34.55 71.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.422 ' CD ' ' HA ' ' A' ' 93' ' ' GLU . 0.0 OUTLIER -81.88 -27.49 33.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 70.1 m-20 -107.38 15.58 24.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.866 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.772 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -70.52 110.11 5.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -46.13 95.27 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.46 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.589 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 29.8 t-20 -39.49 135.55 1.17 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.733 . . . . 0.0 110.887 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.573 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.8 172.49 48.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.348 0.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.602 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.5 t -105.47 97.25 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.129 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.696 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -76.59 141.98 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.993 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.6 m-85 -123.4 128.52 49.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -117.31 89.95 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.105 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 75' ' ' ILE . 29.9 m -122.27 173.5 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.165 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.6 ' CG ' HD11 ' A' ' 76' ' ' LEU . 0.6 OUTLIER -136.43 115.32 12.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.4 t -76.32 127.58 33.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.824 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.647 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.5 mt -62.53 -178.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.3 p -34.55 150.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 112' ' ' THR . 67.4 m -37.9 156.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 111' ' ' SER . 6.8 p -157.74 144.26 13.02 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.607 0.718 . . . . 0.0 111.102 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 163.74 37.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.657 2.238 . . . . 0.0 112.4 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 16.6 ttm-85 -174.79 153.69 1.79 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.876 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 116' ' ' ILE . 13.4 p -145.71 166.51 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.171 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.631 HG22 ' HD2' ' A' ' 117' ' ' PRO . 0.9 OUTLIER -118.02 138.1 25.12 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.637 0.732 . . . . 0.0 111.086 179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.631 ' HD2' HG22 ' A' ' 116' ' ' ILE . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.175 0 C-N-CA 122.731 2.287 . . . . 0.0 112.349 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.6 m -64.5 144.22 57.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.92 0.391 . . . . 0.0 110.832 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 p -127.22 47.79 2.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.837 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.12 13.7 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t -168.73 165.38 11.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.89 0.376 . . . . 0.0 110.895 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -143.04 152.78 42.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.43 73.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.512 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 9' ' ' ASN . 53.7 Cg_endo -69.76 2.45 3.52 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.677 2.251 . . . . 0.0 112.394 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 8' ' ' PRO . 8.1 m-80 -34.38 147.45 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -123.88 -19.8 5.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.578 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 32.4 m -49.14 179.24 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.917 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -125.11 62.5 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.857 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.729 ' CD1' HD21 ' A' ' 109' ' ' LEU . 50.5 m95 -89.23 114.61 25.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -72.88 -160.68 5.65 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 159.78 52.11 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.664 2.243 . . . . 0.0 112.367 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 159.01 54.97 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.696 2.264 . . . . 0.0 112.316 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.15 128.55 36.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG23 ' CG1' ' A' ' 103' ' ' VAL . 6.9 mt -95.22 135.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.107 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.8 t -144.27 119.11 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.11 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.489 ' HG3' HG22 ' A' ' 103' ' ' VAL . 8.1 mp0 -81.4 124.6 29.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.91 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.5 mt -123.27 119.43 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.593 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 3.0 m-85 -84.84 128.82 34.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.866 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -65.62 148.95 50.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 5.5 mm-40 -115.92 150.04 44.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.632 0.729 . . . . 0.0 110.91 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.652 2.235 . . . . 0.0 112.332 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -46.99 -36.43 7.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 13.1 p -115.93 144.45 23.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 t -79.1 -167.09 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.863 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.839 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.5 -26.58 68.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.951 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.474 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 84.7 13.95 71.46 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.453 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.668 HD11 ' HB2' ' A' ' 63' ' ' ALA . 8.5 mt -113.48 149.59 15.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 111.181 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 66.7 m -132.26 168.13 18.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.997 HD12 ' CD2' ' A' ' 88' ' ' HIS . 1.9 pt -137.37 154.32 30.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -107.92 164.77 4.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.098 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 41.06 -148.79 0.24 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.51 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.33 87.28 1.88 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.462 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -104.67 151.06 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 0.0 110.895 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.7 p -51.55 154.61 1.82 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 39' ' ' VAL . 2.2 t -153.39 113.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.094 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.6 mt -104.96 -70.63 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.102 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.425 ' HE3' HD12 ' A' ' 43' ' ' LEU . 31.7 mtmt -106.75 171.3 7.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.884 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.4 ' HD3' ' N ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -101.18 35.56 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.425 HD12 ' HE3' ' A' ' 41' ' ' LYS . 41.5 mt -77.23 -58.38 3.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.55 93.11 6.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -138.55 172.24 13.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 104.13 78.29 1.24 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.06 175.33 8.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 0.0 110.908 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.45 ' O ' ' C ' ' A' ' 49' ' ' LEU . 17.5 mm-40 -43.89 167.87 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 48' ' ' GLU . 3.2 mm? -34.34 126.28 0.47 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.83 -15.16 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.916 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.39 -171.52 5.32 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.496 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.92 HD11 ' O ' ' A' ' 86' ' ' ALA . 24.5 mm -98.63 133.55 40.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' CE2' ' HB2' ' A' ' 74' ' ' LYS . 13.0 m-85 -125.36 153.43 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 70' ' ' LYS . 13.3 mt -70.42 117.67 13.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 6.6 tptp -75.78 -48.51 21.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.463 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -168.77 149.1 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.869 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.463 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 19.5 t -130.33 127.17 62.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.099 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.607 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.4 mp -74.58 162.0 29.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -89.97 -41.87 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.64 38.55 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.482 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -129.11 169.06 13.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.642 0.734 . . . . 0.0 110.844 -179.766 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.646 ' O ' HG23 ' A' ' 66' ' ' THR . 54.0 Cg_endo -69.77 -21.59 33.23 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.625 2.217 . . . . 0.0 112.367 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -89.3 -26.0 21.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.045 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.48 -39.71 25.14 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.51 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.0 mttm -63.02 -37.54 87.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.904 0.383 . . . . 0.0 110.919 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.646 HG23 ' O ' ' A' ' 62' ' ' PRO . 8.5 p -55.69 -19.34 10.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.115 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 38.99 26.45 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.847 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -112.36 -2.3 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.071 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.616 ' CD1' HD11 ' A' ' 21' ' ' ILE . 11.7 mt -137.25 133.19 34.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.929 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.568 ' O ' HD12 ' A' ' 54' ' ' ILE . 9.8 mtpt -127.51 172.83 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.89 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 14.1 t -76.51 138.99 40.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.134 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 104.75 -16.21 47.74 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.46 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -61.78 177.13 0.45 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.854 0.359 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.456 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 40.2 tttp -123.95 107.63 11.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.857 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.9 mt -74.8 118.93 21.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.685 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -102.89 -23.83 13.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -167.42 152.09 6.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.845 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.562 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.59 125.75 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.121 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.642 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.41 17.25 7.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.69 33.59 8.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.479 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.799 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -130.4 124.37 57.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.881 0.372 . . . . 0.0 111.138 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -67.27 110.88 3.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.897 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.696 HD13 ' HB1' ' A' ' 91' ' ' ALA . 41.8 mt -111.78 -1.93 15.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.904 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 59.8 mt-30 -45.83 -68.42 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -85.74 27.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.92 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -100.08 144.93 28.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.078 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.4 t -75.35 -175.58 2.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.997 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -62.18 -38.13 87.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -80.31 -41.58 24.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.849 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.445 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 31.2 mm-40 -53.99 -36.46 62.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.876 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.811 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.0 -38.9 18.69 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.732 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -51.48 -45.41 34.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' HB3' ' ND2' ' A' ' 97' ' ' ASN . 12.6 mt-10 -66.8 -32.12 73.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.799 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.74 -50.09 68.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.106 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.839 ' CG2' HD12 ' A' ' 29' ' ' LEU . 4.8 mp -66.5 -35.23 74.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.118 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 3.8 ptmt -80.76 -27.93 36.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' ND2' ' HB3' ' A' ' 93' ' ' GLU . 72.1 m-20 -106.77 16.96 23.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.726 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.35 111.77 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.087 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -48.44 94.87 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.467 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.593 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 19.3 t-20 -35.6 132.21 0.53 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.569 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 54.1 Cg_endo -69.71 -174.15 9.2 Favored 'Cis proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 -1.806 . . . . 0.0 112.352 -0.094 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.726 HG13 ' CB ' ' A' ' 98' ' ' ALA . 14.5 t -119.05 94.62 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.162 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.654 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.2 t -74.59 143.6 13.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.165 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.91 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.6 m-85 -125.17 129.05 49.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -117.21 90.29 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.857 HG12 ' HA ' ' A' ' 75' ' ' ILE . 35.1 m -119.8 177.33 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.11 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.685 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.7 mt-30 -138.04 106.35 5.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 1.1 m -81.62 117.76 22.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.729 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.2 mt -48.94 167.53 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 18.5 t -37.13 -29.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.487 ' N ' ' O ' ' A' ' 109' ' ' LEU . 45.2 t -41.56 163.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 69.8 p -127.25 149.22 69.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.558 0.694 . . . . 0.0 111.167 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -163.85 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.701 2.267 . . . . 0.0 112.327 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.448 ' HG3' ' N ' ' A' ' 115' ' ' VAL . 14.3 tpp85 -137.52 158.0 45.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.674 HG22 ' H ' ' A' ' 116' ' ' ILE . 0.5 OUTLIER -92.0 -174.97 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.131 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.674 ' H ' HG22 ' A' ' 115' ' ' VAL . 49.7 mt -101.47 138.67 19.96 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 0.0 111.117 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.664 ' HD2' HG23 ' A' ' 116' ' ' ILE . 54.5 Cg_endo . . . . . 0 C--O 1.231 0.143 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.483 -0.247 . . . . 0.0 112.483 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.3 m -155.38 177.81 10.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.863 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.4 p -93.17 89.47 6.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.85 -163.32 53.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.466 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.7 t -119.55 150.37 40.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.89 0.376 . . . . 0.0 110.865 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.9 t -95.14 159.16 15.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.82 146.25 16.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 9' ' ' ASN . 54.0 Cg_endo -69.76 -23.68 30.52 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.372 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 8' ' ' PRO . 31.6 m-80 -34.54 146.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.9 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -131.75 132.7 44.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.555 ' HB2' ' CD1' ' A' ' 13' ' ' TRP . 5.8 p -175.31 178.88 1.6 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -133.43 64.44 1.61 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.843 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 60.1 m95 -88.77 111.46 22.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -72.18 -161.13 5.18 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.528 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 159.55 52.94 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.692 2.261 . . . . 0.0 112.312 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 166.14 28.58 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.357 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -139.26 130.5 26.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.625 HG23 ' CG1' ' A' ' 103' ' ' VAL . 34.9 mt -97.65 131.46 44.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.4 t -142.45 122.72 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -83.93 112.65 20.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.854 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.948 HD12 ' CD1' ' A' ' 104' ' ' PHE . 6.3 mt -110.5 115.35 49.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.585 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.5 m-85 -78.87 126.02 30.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.876 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.577 ' HG2' HG21 ' A' ' 102' ' ' VAL . 19.5 mtp85 -65.38 149.82 49.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.491 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.9 mm-40 -119.38 149.34 47.41 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.652 0.739 . . . . 0.0 110.881 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.7 2.266 . . . . 0.0 112.385 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -45.92 -37.01 5.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.491 HG13 ' CB ' ' A' ' 24' ' ' GLU . 14.2 p -115.09 143.58 24.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.108 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -79.89 -167.64 1.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.847 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.712 HD22 ' CG2' ' A' ' 21' ' ' ILE . 6.5 mt -65.5 -18.29 65.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.908 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.522 ' HA2' HD13 ' A' ' 58' ' ' LEU . . . 84.44 -16.58 34.08 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.508 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.909 HD11 HD13 ' A' ' 21' ' ' ILE . 4.7 mt -87.75 146.27 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 111.131 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 57.1 m -129.7 176.37 8.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.876 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.626 HD11 HG23 ' A' ' 92' ' ' VAL . 7.8 pt -142.28 148.1 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.111 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.84 172.97 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.169 179.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.547 ' O ' ' CG ' ' A' ' 88' ' ' HIS . . . 35.35 -122.05 0.55 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' HG3' ' A' ' 37' ' ' GLN . . . 94.18 102.75 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.427 ' HG3' ' C ' ' A' ' 36' ' ' GLY . 30.1 mt-30 -155.72 174.01 15.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.942 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.538 ' CG2' ' N ' ' A' ' 39' ' ' VAL . 2.2 m -159.64 159.36 32.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.124 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.538 ' N ' ' CG2' ' A' ' 38' ' ' THR . 88.6 t -75.44 142.8 14.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.408 ' O ' ' C ' ' A' ' 41' ' ' LYS . 9.8 mt -105.99 -60.4 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 40' ' ' ILE . 34.7 ttpt -37.23 155.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.18 70.5 4.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' A' ' 44' ' ' LYS . 11.9 tp -135.57 155.08 51.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.469 ' N ' ' HG ' ' A' ' 43' ' ' LEU . 6.5 mmpt? -87.78 114.51 24.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.878 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' ND2' ' OE2' ' A' ' 47' ' ' GLU . 6.2 t30 -175.06 168.36 3.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' C ' ' CD ' ' A' ' 47' ' ' GLU . . . -156.9 177.48 33.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.498 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.494 ' OE2' ' ND2' ' A' ' 45' ' ' ASN . 18.7 mp0 -153.03 165.25 36.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 0.0 110.892 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.442 ' O ' ' C ' ' A' ' 49' ' ' LEU . 4.4 mm-40 -101.58 172.65 6.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.893 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 48' ' ' GLU . 0.6 OUTLIER 34.46 49.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.9 -14.55 7.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.885 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.85 -145.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.515 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.869 HD11 ' O ' ' A' ' 86' ' ' ALA . 30.6 mm -115.02 144.16 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.851 0.357 . . . . 0.0 111.145 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -137.32 143.86 42.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.619 HD12 ' O ' ' A' ' 70' ' ' LYS . 11.4 mt -57.91 122.5 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.134 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.553 ' HB2' HG12 ' A' ' 34' ' ' VAL . 4.7 tptm -82.03 -46.73 13.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.474 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.0 OUTLIER -169.27 149.31 4.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.531 HG22 HG23 ' A' ' 31' ' ' ILE . 54.0 t -135.45 123.73 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.176 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -69.08 -172.24 0.39 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.944 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.03 -40.61 3.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.837 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -79.05 12.32 2.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.853 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.487 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -102.44 169.43 7.57 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.643 0.735 . . . . 0.0 110.878 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.487 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 54.1 Cg_endo -69.79 -13.35 34.47 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -101.7 -17.59 16.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -86.01 -32.25 18.12 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.9 mttt -72.14 -36.65 69.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.839 0.352 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 62' ' ' PRO . 17.5 p -57.73 -24.76 58.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 45.76 23.98 0.19 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -107.19 0.3 23.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.671 ' CD1' HD11 ' A' ' 21' ' ' ILE . 7.1 mt -140.93 134.85 30.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.619 ' O ' HD12 ' A' ' 54' ' ' ILE . 7.2 mtpt -129.09 171.55 12.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.0 t -74.65 142.89 44.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.65 -21.18 41.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.79 174.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.827 0.346 . . . . 0.0 110.882 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -122.02 104.98 9.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.982 ' HA ' HG12 ' A' ' 106' ' ' VAL . 21.4 mt -70.57 118.65 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.663 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -103.13 -23.56 13.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -167.36 151.21 6.54 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.882 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.553 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -143.8 125.6 10.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.149 179.926 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.744 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 60.2 18.11 7.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.25 32.82 9.24 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.449 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.86 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.19 123.73 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.859 0.361 . . . . 0.0 111.098 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -66.61 111.23 3.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 ' HB2' ' A' ' 94' ' ' ALA . 36.3 mt -112.66 -4.75 14.04 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -39.46 -65.41 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.93 34.15 1.02 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.869 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.4 137.37 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.076 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 58.0 m -67.8 -174.37 0.44 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.547 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -63.25 -37.22 86.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.835 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.7 t -81.3 -41.25 22.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.466 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 22.7 mm-40 -54.14 -36.39 63.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.734 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.07 -41.1 23.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.072 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.626 HG23 HD11 ' A' ' 33' ' ' ILE . 4.0 t -52.98 -51.38 38.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.4 mt-10 -59.1 -35.17 72.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.86 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.56 -45.97 90.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.734 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.7 mp -67.72 -38.7 80.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.142 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -78.98 -25.58 43.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.7 m-20 -106.29 18.7 21.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.744 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -81.6 116.71 21.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.124 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.85 96.51 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.54 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 15.2 t-20 -38.73 136.58 0.91 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.608 0.718 . . . . 0.0 110.929 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.585 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.7 Cg_endo -69.78 171.31 54.37 Favored 'Cis proline' 0 C--N 1.341 0.159 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.329 -0.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.577 HG21 ' HG2' ' A' ' 23' ' ' ARG . 21.0 t -105.73 96.11 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.7 t -74.99 147.47 8.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.948 ' CD1' HD12 ' A' ' 21' ' ' ILE . 13.3 m-85 -128.09 129.97 47.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.864 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.3 mt -117.76 89.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.982 HG12 ' HA ' ' A' ' 75' ' ' ILE . 33.6 m -119.64 -179.78 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.128 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.663 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.5 mt-30 -138.04 106.29 5.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 20.0 p -78.08 120.31 22.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.845 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 10.4 mt -49.83 173.55 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 109' ' ' LEU . 2.6 t -34.58 -74.37 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.577 ' O ' HG23 ' A' ' 112' ' ' THR . 10.5 m -109.47 -178.16 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.577 HG23 ' O ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -163.52 160.36 17.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.613 0.721 . . . . 0.0 111.116 -179.929 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -173.4 0.71 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.696 2.264 . . . . 0.0 112.311 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -143.28 177.55 8.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.646 HG12 ' H ' ' A' ' 116' ' ' ILE . 3.0 t -141.97 171.76 10.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.646 ' H ' HG12 ' A' ' 115' ' ' VAL . 3.7 pt -47.74 150.84 1.72 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.582 0.706 . . . . 0.0 111.139 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.165 0 C-N-CA 122.688 2.259 . . . . 0.0 112.344 179.876 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 1.4 t -78.52 -30.48 47.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.907 0.384 . . . . 0.0 110.88 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 22.7 p 35.86 39.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.87 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.56 97.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.8 p -89.98 75.55 7.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.895 0.379 . . . . 0.0 110.852 -179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.1 m 55.53 33.01 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.862 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.98 147.08 16.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 179.05 3.95 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.651 2.234 . . . . 0.0 112.384 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 36.3 t30 -86.36 179.82 6.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.9 t80 -166.75 152.51 8.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.562 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 51.6 m -40.72 160.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 3.3 t-80 -110.28 66.27 0.63 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.719 ' CD1' HD21 ' A' ' 109' ' ' LEU . 70.6 m95 -84.94 109.14 17.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.923 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -70.21 -162.18 3.8 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 147.55 62.86 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.653 2.236 . . . . 0.0 112.306 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 162.55 41.63 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.484 ' HD3' ' CG2' ' A' ' 106' ' ' VAL . 0.0 OUTLIER -131.41 137.71 48.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.803 HG23 ' CG1' ' A' ' 103' ' ' VAL . 35.1 mt -98.65 131.55 45.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.3 t -136.51 120.6 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.098 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -84.65 109.93 18.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 1.061 HD12 ' CD1' ' A' ' 104' ' ' PHE . 11.9 mt -110.45 115.57 50.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.148 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.8 m-85 -78.06 131.38 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.601 ' HG2' HG21 ' A' ' 102' ' ' VAL . 14.9 mtm105 -69.59 146.04 52.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.854 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.482 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -111.35 150.25 41.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.635 0.731 . . . . 0.0 110.884 -179.907 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -90.88 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.664 2.242 . . . . 0.0 112.311 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 12.5 m-80 -46.75 -36.71 7.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.861 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.482 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.9 p -115.64 144.23 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.29 -161.87 0.25 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.819 HD12 HG23 ' A' ' 95' ' ' ILE . 7.0 mt -67.97 -27.69 66.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.472 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 85.37 13.98 69.61 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.487 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.735 HD11 HD13 ' A' ' 21' ' ' ILE . 13.3 mt -112.56 149.2 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.836 0.35 . . . . 0.0 111.173 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.7 m -131.92 171.61 13.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.447 ' C ' ' HB2' ' A' ' 55' ' ' LYS . 8.6 pt -142.38 150.8 18.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.146 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.552 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.58 165.76 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.848 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.6 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 57.78 -150.31 31.78 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.501 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' HB2' ' A' ' 88' ' ' HIS . . . 85.04 145.18 7.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.436 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.468 ' N ' ' H ' ' A' ' 88' ' ' HIS . 5.2 pt20 46.52 33.87 2.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.877 0.37 . . . . 0.0 110.931 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.1 p -102.83 113.8 27.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 82.2 t -130.24 117.1 38.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 40' ' ' ILE . 4.5 mp -115.68 -64.31 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.088 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.47 175.3 9.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.416 ' NE ' ' HA ' ' A' ' 42' ' ' ARG . 7.9 tpm_? -54.92 98.41 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 19.4 mt -96.75 114.91 26.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.905 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 28.8 mmtp -76.94 170.03 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 33.1 p-10 -98.71 117.3 32.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.87 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.66 60.39 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 -150.27 176.75 10.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.805 0.336 . . . . 0.0 110.91 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -46.69 146.89 1.4 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.876 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.907 ' O ' HD22 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -37.53 129.91 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.938 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.484 ' CG ' ' N ' ' A' ' 51' ' ' GLY . 13.6 ttpt -115.06 163.09 16.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.484 ' N ' ' CG ' ' A' ' 50' ' ' LYS . . . 150.35 -161.75 29.04 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.491 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.85 HD11 ' O ' ' A' ' 86' ' ' ALA . 42.5 mm -95.98 117.56 40.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 111.134 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 5.1 m-85 -110.24 151.17 27.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.896 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.41 ' CG2' ' HA ' ' A' ' 71' ' ' THR . 11.4 mt -61.19 134.15 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.156 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' HB2' HG12 ' A' ' 34' ' ' VAL . 11.8 tptt -93.65 -47.29 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.456 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.3 tt0 -169.94 150.83 3.92 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.909 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.99 127.17 60.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.1 mp -71.84 177.79 4.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -103.78 -42.82 5.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -83.08 37.83 0.57 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.472 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -126.65 168.3 14.86 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.667 0.746 . . . . 0.0 110.82 -179.733 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.686 ' O ' HG23 ' A' ' 66' ' ' THR . 53.9 Cg_endo -69.77 -21.72 33.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.693 2.262 . . . . 0.0 112.347 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.573 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -90.47 -27.1 19.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.117 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.51 -27.3 59.54 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.509 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.3 mttm -77.52 -34.27 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.686 HG23 ' O ' ' A' ' 62' ' ' PRO . 6.4 p -59.44 -22.57 61.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.155 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 43.17 25.14 0.05 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -108.54 -2.39 18.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.736 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.8 mt -136.01 137.02 40.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 29.5 mmtt -134.29 152.7 51.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.87 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.41 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 12.5 t -55.97 139.62 45.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.9 -24.19 25.84 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -55.93 165.5 0.93 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.886 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.704 ' CE ' HD23 ' A' ' 49' ' ' LEU . 25.6 tttm -112.59 102.83 10.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.632 ' HA ' HG12 ' A' ' 106' ' ' VAL . 11.0 mt -72.93 117.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.679 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -101.99 -23.51 14.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 81' ' ' VAL . 6.4 tt0 -166.5 153.75 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.589 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.18 127.0 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.147 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.7 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 59.3 15.8 4.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.35 32.71 8.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.447 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.843 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.5 p -130.1 127.13 62.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.819 0.342 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.445 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.6 OUTLIER -68.94 114.66 7.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.857 179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.788 HD13 ' HB1' ' A' ' 91' ' ' ALA . 26.7 mt -113.94 -8.81 13.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.424 ' C ' ' O ' ' A' ' 83' ' ' LEU . 69.9 mt-30 -36.68 -70.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.892 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -91.65 35.79 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.85 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -103.32 134.94 45.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.416 ' HB2' ' CA ' ' A' ' 37' ' ' GLN . 11.9 p -61.5 174.39 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.739 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.7 t-160 -56.69 -36.61 69.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.3 m -81.23 -40.6 23.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.877 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.477 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.7 mm-40 -53.57 -37.95 63.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.788 ' HB1' HD13 ' A' ' 83' ' ' LEU . . . -83.79 -39.12 20.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.077 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 88' ' ' HIS . 5.0 t -51.51 -48.81 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.1 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.492 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 9.4 mt-10 -64.63 -31.71 73.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.829 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.843 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.77 -48.6 73.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.077 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.819 HG23 HD12 ' A' ' 29' ' ' LEU . 4.2 mp -66.25 -38.04 81.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.161 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.7 -30.26 51.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.884 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.492 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.9 m-80 -105.84 22.29 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.867 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.971 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -70.69 119.97 15.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.127 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -52.35 87.92 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.452 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.4 OUTLIER -34.25 129.58 0.44 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.627 0.727 . . . . 0.0 110.86 -179.913 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.579 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.4 Cg_endo -69.78 174.13 41.86 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.708 -1.789 . . . . 0.0 112.315 -0.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.971 HG13 ' CB ' ' A' ' 98' ' ' ALA . 12.8 t -107.23 95.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.803 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.9 t -73.65 149.09 8.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.114 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 1.061 ' CD1' HD12 ' A' ' 21' ' ' ILE . 12.5 m-85 -130.62 125.18 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 mt -112.6 89.77 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.156 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.632 HG12 ' HA ' ' A' ' 75' ' ' ILE . 4.0 m -118.16 177.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.155 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.679 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.7 mt-30 -139.42 106.25 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 t -74.9 131.5 40.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.719 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.7 mt -68.24 159.62 30.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.4 t -44.7 92.1 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.827 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.46 ' N ' ' O ' ' A' ' 109' ' ' LEU . 27.0 t -158.83 177.09 11.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.871 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 30.0 p -112.57 145.21 32.47 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.587 0.708 . . . . 0.0 111.149 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -163.81 0.11 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.711 2.274 . . . . 0.0 112.361 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -122.35 -174.32 2.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.845 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.9 t -106.32 164.96 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.598 ' N ' HD13 ' A' ' 116' ' ' ILE . 0.0 OUTLIER -119.49 158.66 48.51 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.62 0.724 . . . . 0.0 111.117 179.924 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.203 0 C-N-CA 122.685 2.256 . . . . 0.0 112.326 179.908 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -161.6 151.39 16.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.864 0.364 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.4 p -141.89 131.87 24.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.858 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.39 -101.31 2.43 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 t 45.52 45.52 10.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 110.877 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.0 t -70.33 -59.52 2.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.65 160.49 14.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.466 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.7 175.81 7.56 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.396 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -104.3 143.99 32.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -141.21 -175.11 4.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.524 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.8 m -48.93 178.64 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.848 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -116.34 55.83 0.8 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.744 ' CD1' HD21 ' A' ' 109' ' ' LEU . 59.1 m95 -75.19 117.71 17.31 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.911 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -78.93 -161.6 20.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.495 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 158.76 55.97 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.696 2.264 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 163.57 37.71 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.734 2.289 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 108' ' ' SER . 8.4 ptt180 -136.22 112.33 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.891 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.816 HG23 ' CG1' ' A' ' 103' ' ' VAL . 37.9 mt -82.84 130.81 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' CB ' ' A' ' 68' ' ' ALA . 66.5 t -140.39 123.51 16.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -83.2 119.51 24.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.865 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.6 mt -118.18 117.45 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.185 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.6 ' CE2' ' OD1' ' A' ' 100' ' ' ASN . 2.5 m-85 -82.73 129.1 34.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.905 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 5.3 mtp-105 -65.81 152.33 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.481 ' CB ' HG13 ' A' ' 27' ' ' VAL . 3.5 mm-40 -115.96 151.85 46.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.647 0.737 . . . . 0.0 110.873 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -90.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.69 2.26 . . . . 0.0 112.34 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -48.45 -36.97 16.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.921 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.481 HG13 ' CB ' ' A' ' 24' ' ' GLU . 13.7 p -114.41 149.88 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.149 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.45 -166.05 1.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.732 HD12 ' CG2' ' A' ' 95' ' ' ILE . 6.7 mt -61.53 -29.34 69.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.461 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 88.87 13.88 61.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.5 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.556 HD11 HD13 ' A' ' 21' ' ' ILE . 13.7 mt -113.06 149.52 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.836 0.35 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 67.4 m -132.05 171.85 13.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.841 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.501 HD11 HG23 ' A' ' 92' ' ' VAL . 11.0 pt -143.53 149.12 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.543 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -102.23 168.11 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 179.832 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.595 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 49.05 -134.65 22.74 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.487 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 95.85 96.27 1.77 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.438 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -152.84 -175.99 5.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.903 0.382 . . . . 0.0 110.89 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -46.55 173.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.144 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -129.58 140.83 48.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.133 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 41' ' ' LYS . 0.3 OUTLIER -118.68 -179.94 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.728 ' H ' HG22 ' A' ' 40' ' ' ILE . 0.0 OUTLIER -127.16 47.31 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.815 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.473 ' CG ' ' HG2' ' A' ' 44' ' ' LYS . 9.6 ttt180 -62.05 91.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.886 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.471 ' H ' ' CD2' ' A' ' 43' ' ' LEU . 0.2 OUTLIER -82.07 40.05 0.6 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.473 ' HG2' ' CG ' ' A' ' 42' ' ' ARG . 13.7 ptpt -130.65 -174.8 3.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.956 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 44' ' ' LYS . 26.2 m-80 -37.47 156.38 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -167.84 116.79 0.69 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.13 8.32 36.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.902 0.382 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -138.57 165.23 27.42 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.784 ' H ' HD13 ' A' ' 49' ' ' LEU . 0.0 OUTLIER -110.98 159.39 17.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.97 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.4 138.95 54.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 151.15 176.03 23.6 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 86' ' ' ALA . 41.1 mm -86.4 124.05 40.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.901 0.381 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.678 ' CZ ' HD23 ' A' ' 49' ' ' LEU . 71.3 m-85 -120.0 141.41 49.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.551 HD12 ' HB2' ' A' ' 73' ' ' ASP . 15.9 mt -55.1 136.19 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.158 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.543 ' HB2' HG12 ' A' ' 34' ' ' VAL . 2.5 tptm -96.08 -47.69 5.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 1.1 tt0 -169.69 150.59 4.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.452 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 4.9 t -130.53 127.9 62.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.625 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.0 mp -73.43 170.57 14.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.6 tt0 -96.54 -43.99 7.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -82.21 39.57 0.59 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.879 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.461 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -128.53 167.7 18.25 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 0.0 110.862 -179.772 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.684 ' O ' HG23 ' A' ' 66' ' ' THR . 53.2 Cg_endo -69.84 -22.43 31.73 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.31 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -88.05 -30.42 19.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.049 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -70.62 -38.68 67.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 44.3 mttt -65.05 -39.65 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.876 0.369 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 62' ' ' PRO . 10.6 p -57.23 -19.88 23.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.138 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 39.03 27.06 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.678 ' CB ' HG21 ' A' ' 19' ' ' VAL . . . -108.83 2.68 21.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.601 ' CD1' HD11 ' A' ' 21' ' ' ILE . 6.3 mt -143.85 140.38 29.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.5 mmtp -147.55 154.76 41.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.3 t -49.74 145.73 5.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.99 -30.62 9.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.563 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.551 ' HB2' HD12 ' A' ' 54' ' ' ILE . 1.3 m-20 -55.23 169.81 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 53' ' ' PHE . 56.9 tttt -120.47 109.37 15.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.915 ' HA ' HG12 ' A' ' 106' ' ' VAL . 14.8 mt -77.19 117.83 22.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.063 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.586 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -100.27 -26.04 14.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.911 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -165.51 151.91 9.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -145.17 125.67 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.17 179.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.679 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.69 15.56 5.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.86 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.54 32.83 7.88 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.807 HG11 ' HB1' ' A' ' 94' ' ' ALA . 1.8 p -129.94 124.45 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.827 0.346 . . . . 0.0 111.101 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -66.87 111.03 3.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.593 HD13 ' HB1' ' A' ' 91' ' ' ALA . 36.1 mt -111.43 -7.28 14.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -40.16 -57.66 1.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 69.6 m-20 -100.6 38.94 1.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.793 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -108.65 132.97 53.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 11.7 m -60.57 -174.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.603 ' O ' HG23 ' A' ' 92' ' ' VAL . 1.6 t-160 -63.94 -32.88 74.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.7 m -86.6 -39.12 16.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.579 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 4.5 mm-40 -53.92 -35.75 62.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.914 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.764 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -85.88 -38.8 17.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.126 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 88' ' ' HIS . 3.0 t -53.0 -45.09 51.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.484 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 12.9 mt-10 -67.23 -32.6 73.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.807 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.91 -51.41 62.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 91' ' ' ALA . 4.4 mp -64.31 -37.69 80.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 -29.29 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.484 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 68.8 m-20 -105.46 21.46 17.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.733 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -76.14 111.66 11.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -46.88 93.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.6 ' OD1' ' CE2' ' A' ' 22' ' ' PHE . 27.3 t-20 -36.53 132.65 0.64 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.603 0.716 . . . . 0.0 110.905 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.577 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.76 -179.06 18.12 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.35 -0.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.733 HG13 ' CB ' ' A' ' 98' ' ' ALA . 16.9 t -114.77 95.07 3.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.816 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -74.65 144.05 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.865 ' CD1' HD12 ' A' ' 21' ' ' ILE . 10.2 m-85 -124.54 131.05 53.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mt -119.44 89.95 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.19 179.84 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.119 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.586 ' CG ' HD11 ' A' ' 76' ' ' LEU . 4.9 mt-30 -141.05 106.46 5.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.419 ' HB2' ' CZ ' ' A' ' 17' ' ' ARG . 29.0 t -78.07 131.2 37.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.85 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.744 HD21 ' CD1' ' A' ' 13' ' ' TRP . 7.9 mt -66.34 159.78 26.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.5 t -44.71 101.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.834 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.9 p -151.67 -177.98 6.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.873 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.2 p -121.97 147.98 50.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.517 0.675 . . . . 0.0 111.175 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -163.8 0.12 Allowed 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.686 2.257 . . . . 0.0 112.366 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 11.1 mtm180 -113.44 -174.41 2.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.726 HG12 ' H ' ' A' ' 116' ' ' ILE . 1.9 t -87.4 177.74 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.142 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.726 ' H ' HG12 ' A' ' 115' ' ' VAL . 0.0 OUTLIER -114.25 158.37 39.89 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.615 0.721 . . . . 0.0 111.143 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.14 0 C-N-CA 122.675 2.25 . . . . 0.0 112.366 179.868 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.6 t -94.78 9.83 37.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 0.0 110.853 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 m -133.49 148.49 51.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 165.45 77.27 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.425 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.9 p -140.88 178.9 7.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.916 0.388 . . . . 0.0 110.805 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.2 m -105.42 -176.1 2.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.842 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.71 82.85 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.515 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -50.72 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.695 2.263 . . . . 0.0 112.311 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.548 ' O ' ' CG ' ' A' ' 10' ' ' PHE . 41.8 t30 -95.6 112.77 24.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.866 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' A' ' 9' ' ' ASN . 9.4 m-85 -174.24 166.51 4.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' CD1' ' A' ' 13' ' ' TRP . 3.7 m -47.4 175.3 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 9.1 m-70 -111.12 58.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.842 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 67.4 m95 -80.44 114.28 19.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -76.09 -161.77 11.64 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.472 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 159.97 51.42 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.687 2.258 . . . . 0.0 112.296 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 157.11 61.49 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.68 2.254 . . . . 0.0 112.309 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.462 ' CZ ' ' HB3' ' A' ' 17' ' ' ARG . 2.2 ptp180 -130.01 121.93 27.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.89 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.576 HG23 ' CG1' ' A' ' 103' ' ' VAL . 40.2 mt -93.65 131.29 41.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 t -141.86 127.35 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -88.3 113.19 23.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.928 HD12 ' CD2' ' A' ' 104' ' ' PHE . 24.6 mt -110.68 117.79 55.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.562 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.3 m-85 -81.83 125.63 30.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.448 ' HG3' ' CG2' ' A' ' 102' ' ' VAL . 0.1 OUTLIER -61.09 160.29 10.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.457 ' CB ' ' O ' ' A' ' 27' ' ' VAL . 0.0 OUTLIER -124.6 151.56 67.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.63 0.729 . . . . 0.0 110.89 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -90.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.339 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -47.72 -37.43 13.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.457 ' O ' ' CB ' ' A' ' 24' ' ' GLU . 11.1 p -113.93 146.4 18.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.148 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 t -79.36 -159.13 0.18 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.82 HD12 HG23 ' A' ' 95' ' ' ILE . 5.7 mt -69.95 -23.72 63.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.47 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 80.95 13.2 81.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.656 HD11 HD13 ' A' ' 21' ' ' ILE . 13.5 mt -111.94 149.34 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.857 0.36 . . . . 0.0 111.122 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 69.8 m -133.18 168.17 19.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.513 HD11 HG23 ' A' ' 92' ' ' VAL . 8.0 pt -139.07 150.62 23.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.556 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -104.12 172.3 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.131 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.597 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 40.25 -132.86 2.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.488 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.35 92.75 1.81 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.463 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -156.74 172.7 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.919 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.613 HG23 ' HB3' ' A' ' 87' ' ' SER . 1.7 p -132.05 164.01 27.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.806 HG13 ' N ' ' A' ' 40' ' ' ILE . 0.3 OUTLIER -123.45 -168.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.104 179.895 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.806 ' N ' HG13 ' A' ' 39' ' ' VAL . 14.8 mm -141.29 -47.12 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.149 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.8 mtpp -67.46 121.05 14.95 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.906 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 53.1 mmt-85 -81.29 -27.04 35.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.897 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.533 ' CD1' ' C ' ' A' ' 43' ' ' LEU . 0.1 OUTLIER -83.52 13.24 4.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.931 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.5 tmtt? -133.67 125.25 28.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -144.66 160.5 41.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 47' ' ' GLU . . . -114.18 12.67 21.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 46' ' ' GLY . 20.5 pt-20 36.55 39.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.329 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -129.62 173.31 10.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.533 HD12 ' HZ ' ' A' ' 53' ' ' PHE . 3.3 mm? -59.0 118.09 5.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.972 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.4 ' C ' ' HD3' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -107.13 -18.11 13.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.893 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.02 -177.5 33.02 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.95 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.1 mm -93.17 152.38 3.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.838 0.351 . . . . 0.0 111.189 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.533 ' HZ ' HD12 ' A' ' 49' ' ' LEU . 19.3 m-85 -139.59 149.14 43.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.857 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.5 mt -66.18 116.82 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.092 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.556 ' HB2' HG12 ' A' ' 34' ' ' VAL . 20.8 tptt -74.54 -48.65 25.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.902 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.9 OUTLIER -169.09 149.78 4.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.457 ' N ' ' HG3' ' A' ' 56' ' ' GLN . 5.7 t -130.88 126.0 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.165 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.612 HD12 ' N ' ' A' ' 58' ' ' LEU . 4.3 mp -70.92 178.01 3.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -104.51 -41.75 5.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -83.59 36.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.838 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.47 ' CB ' ' HA3' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -125.18 168.55 13.23 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.641 0.734 . . . . 0.0 110.911 -179.824 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.557 ' O ' HG23 ' A' ' 66' ' ' THR . 53.4 Cg_endo -69.77 -20.51 34.71 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.709 2.273 . . . . 0.0 112.365 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.571 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -92.46 -23.9 19.0 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.125 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.94 -21.6 59.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.542 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -81.76 -33.27 31.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 62' ' ' PRO . 1.4 p -62.95 -19.22 64.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 42.14 24.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.86 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 66' ' ' THR . . . -104.56 -3.58 23.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.732 ' CD1' HD11 ' A' ' 21' ' ' ILE . 3.8 mt -140.44 146.79 38.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -148.81 154.53 39.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.909 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 t -48.39 136.19 12.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.164 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 110.42 -31.54 7.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -59.61 129.76 43.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.876 0.369 . . . . 0.0 110.86 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.585 ' HE3' HD21 ' A' ' 76' ' ' LEU . 19.5 ttpp -80.64 117.16 21.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 1.02 ' HA ' HG12 ' A' ' 106' ' ' VAL . 8.7 mt -80.34 119.49 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.08 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.585 HD21 ' HE3' ' A' ' 74' ' ' LYS . 0.7 OUTLIER -102.61 -23.22 13.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -166.6 153.13 8.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.866 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.585 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -146.09 126.12 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.137 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.722 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.1 t 59.9 15.39 4.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 92.9 32.65 7.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.502 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.821 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.4 p -130.06 126.38 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.453 ' O ' ' CG ' ' A' ' 82' ' ' ASP . 0.5 OUTLIER -68.68 114.29 6.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.857 179.902 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 27.9 mt -112.7 -2.66 14.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -46.79 -68.34 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -85.1 26.11 0.9 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.898 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.95 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -102.17 139.11 38.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.613 ' HB3' HG23 ' A' ' 38' ' ' THR . 69.1 p -69.59 -174.8 0.75 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.597 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.7 t-160 -62.16 -40.82 97.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.3 t -76.21 -40.06 53.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.507 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 6.0 mm-40 -58.44 -36.12 73.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.78 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -79.54 -36.68 38.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.103 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.513 HG23 HD11 ' A' ' 33' ' ' ILE . 3.0 t -57.85 -58.84 4.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.497 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 11.7 mt-10 -49.56 -33.11 14.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.821 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -64.36 -53.38 49.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.083 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.82 HG23 HD12 ' A' ' 29' ' ' LEU . 3.6 mp -59.41 -41.11 83.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.138 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.51 -30.75 57.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.88 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 73.3 m-20 -103.28 21.99 14.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.722 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -72.75 127.77 33.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.079 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -61.22 89.36 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 1.6 t-20 -34.67 129.5 0.47 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.581 0.705 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.562 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.6 Cg_endo -69.74 172.18 50.09 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.715 -1.785 . . . . 0.0 112.322 -0.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.697 HG13 ' CB ' ' A' ' 98' ' ' ALA . 27.0 t -102.65 94.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.138 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.576 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.1 t -72.47 152.9 7.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.928 ' CD2' HD12 ' A' ' 21' ' ' ILE . 4.5 m-85 -133.03 129.86 38.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -120.49 90.51 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.152 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 1.02 HG12 ' HA ' ' A' ' 75' ' ' ILE . 10.2 m -124.55 179.88 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.109 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.507 ' CG ' HD11 ' A' ' 76' ' ' LEU . 5.2 mt-30 -136.86 106.47 6.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 4.1 t -79.45 125.37 29.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.832 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 8.6 mt -60.25 159.43 9.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 5.6 t -34.61 93.48 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 109' ' ' LEU . 4.9 p -79.9 -174.63 4.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.855 -179.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.8 160.67 52.49 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.59 0.71 . . . . 0.0 111.15 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 166.45 27.52 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.709 2.273 . . . . 0.0 112.393 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.42 165.03 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.542 HG12 ' N ' ' A' ' 116' ' ' ILE . 12.6 t -101.52 164.52 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.68 HG23 ' HD2' ' A' ' 117' ' ' PRO . 10.1 mm -78.63 138.7 58.47 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.568 0.699 . . . . 0.0 111.139 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.68 ' HD2' HG23 ' A' ' 116' ' ' ILE . 53.6 Cg_endo . . . . . 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.355 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.1 p -146.28 148.92 32.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.861 0.362 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -72.47 175.47 6.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.75 -134.11 2.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.435 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -136.07 159.29 42.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.919 0.39 . . . . 0.0 110.861 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.1 m -137.08 168.07 20.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.06 74.24 1.11 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.432 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -38.88 7.26 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.404 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 53.52 52.35 13.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.437 ' HZ ' HD11 ' A' ' 49' ' ' LEU . 2.5 t80 -119.8 -175.54 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.458 ' HB2' ' NE1' ' A' ' 13' ' ' TRP . 1.9 m -51.74 -174.8 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.851 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -121.27 81.98 1.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.846 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.743 ' CD1' HD21 ' A' ' 109' ' ' LEU . 54.7 m95 -87.07 112.97 22.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.894 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -76.31 -163.36 15.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.47 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 159.75 52.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.632 2.221 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 157.06 61.54 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.638 2.226 . . . . 0.0 112.372 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -128.86 132.1 47.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.843 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.737 HG23 ' CG1' ' A' ' 103' ' ' VAL . 38.3 mt -97.25 130.9 45.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.503 HG21 ' HB1' ' A' ' 68' ' ' ALA . 40.9 t -140.82 122.23 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.758 ' HG3' HG22 ' A' ' 103' ' ' VAL . 9.9 mp0 -84.88 123.71 30.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 1.079 HD11 HD11 ' A' ' 69' ' ' LEU . 6.5 mt -123.73 121.15 61.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 3.1 m-85 -82.32 121.81 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 10.5 ptt180 -70.02 142.51 52.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HB2' HG13 ' A' ' 27' ' ' VAL . 3.0 mm-40 -109.63 155.19 41.8 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.66 0.743 . . . . 0.0 110.865 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -90.85 0.01 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.735 2.29 . . . . 0.0 112.327 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -43.77 -43.42 6.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.89 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.606 HG13 ' HB2' ' A' ' 24' ' ' GLU . 12.0 p -107.37 145.95 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.138 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 t -82.42 -169.76 2.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.765 HD12 HG23 ' A' ' 95' ' ' ILE . 6.1 mt -62.65 -22.7 66.64 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.475 ' HA3' ' CB ' ' A' ' 61' ' ' SER . . . 83.26 10.07 82.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.517 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 57' ' ' VAL . 3.7 mt -110.86 145.45 17.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.816 0.341 . . . . 0.0 111.144 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 62.0 m -125.64 167.08 15.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.537 HD11 HG23 ' A' ' 92' ' ' VAL . 5.8 pt -137.21 154.26 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.15 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 1.0 OUTLIER -109.08 -179.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.835 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.594 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 42.16 -156.65 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.494 ' O ' ' CG ' ' A' ' 37' ' ' GLN . . . 88.7 154.06 27.86 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.482 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.589 ' N ' ' H ' ' A' ' 88' ' ' HIS . 1.2 pt20 49.15 33.27 4.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.864 0.364 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 39' ' ' VAL . 0.3 OUTLIER -106.36 -12.51 15.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 -179.932 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.471 ' CG1' ' N ' ' A' ' 40' ' ' ILE . 23.4 t -155.57 156.61 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.471 ' N ' ' CG1' ' A' ' 39' ' ' VAL . 49.0 mt -109.36 -62.79 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 41.7 tttt -97.1 144.05 27.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' C ' HD22 ' A' ' 43' ' ' LEU . 3.9 tpm_? -172.06 138.9 1.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.8 HD22 ' N ' ' A' ' 43' ' ' LEU . 0.3 OUTLIER -112.99 -177.41 3.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 20.3 mtmm -59.87 97.25 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.883 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -119.03 -24.37 6.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.23 169.52 35.03 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.518 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.04 29.31 7.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.787 0.327 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -56.43 -175.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.762 HD13 ' N ' ' A' ' 49' ' ' LEU . 0.0 OUTLIER -106.07 71.11 0.87 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.3 -12.37 15.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.73 -146.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.445 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.949 HD11 ' O ' ' A' ' 86' ' ' ALA . 7.6 mm -99.03 107.51 20.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.853 0.358 . . . . 0.0 111.114 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.662 ' CZ ' ' CB ' ' A' ' 49' ' ' LEU . 2.9 m-85 -111.3 144.6 40.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.905 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 73' ' ' ASP . 11.1 mt -53.47 116.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.122 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 25.8 tptt -78.42 -43.51 27.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' HG3' ' N ' ' A' ' 57' ' ' VAL . 0.5 OUTLIER -174.46 149.19 1.28 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.948 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.728 HG22 HG23 ' A' ' 31' ' ' ILE . 77.4 t -129.77 128.38 65.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.108 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 58' ' ' LEU . 5.0 mp -75.91 163.89 26.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -91.3 -44.77 8.98 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -81.32 40.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.879 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.494 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -128.09 169.63 12.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.701 0.762 . . . . 0.0 110.821 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.494 ' HD2' ' CB ' ' A' ' 61' ' ' SER . 53.8 Cg_endo -69.8 -17.57 37.3 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.674 2.249 . . . . 0.0 112.329 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.584 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.84 -19.25 17.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.109 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.43 -23.29 58.82 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.478 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -78.76 -39.44 36.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 p -60.2 -16.76 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 44.17 23.92 0.07 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 19' ' ' VAL . . . -107.28 4.38 26.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.082 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 1.079 HD11 HD11 ' A' ' 21' ' ' ILE . 17.0 mt -136.17 137.6 41.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.875 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 mmtp -149.8 154.39 38.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.905 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 54' ' ' ILE . 14.6 t -56.4 133.43 53.0 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 113.18 -26.09 10.75 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.515 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.552 ' HB2' HD12 ' A' ' 54' ' ' ILE . 47.1 m-20 -60.52 158.32 12.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.495 ' HG3' ' CE1' ' A' ' 53' ' ' PHE . 53.5 tttp -110.41 111.18 22.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.912 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 1.016 ' HA ' HG12 ' A' ' 106' ' ' VAL . 17.3 mt -77.62 118.41 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.084 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.729 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.6 OUTLIER -103.55 -23.26 13.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.884 179.89 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.473 ' OE1' HD12 ' A' ' 105' ' ' ILE . 6.5 tt0 -167.16 151.61 6.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.55 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.26 125.85 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.753 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.2 t 60.11 16.94 6.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.39 32.57 8.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.847 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.0 p -129.06 124.75 61.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.106 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -67.81 112.79 5.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.662 HD22 ' HA ' ' A' ' 91' ' ' ALA . 61.2 mt -114.55 -2.53 13.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -44.27 -66.49 0.38 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.67 26.3 1.53 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.949 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -98.45 136.97 37.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.45 ' CB ' ' H ' ' A' ' 37' ' ' GLN . 12.2 p -62.65 -175.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.838 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 35' ' ' GLY . 1.6 t-160 -66.0 -36.54 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.856 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.0 m -82.22 -37.58 25.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.852 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.411 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 19.5 mm-40 -57.08 -34.73 68.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.724 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -81.48 -41.25 22.04 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.072 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.537 HG23 HD11 ' A' ' 33' ' ' ILE . 4.6 t -51.63 -54.63 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.106 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 6.0 mt-10 -54.76 -34.61 62.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.847 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -63.51 -47.89 79.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.765 HG23 HD12 ' A' ' 29' ' ' LEU . 4.0 mp -65.37 -38.24 82.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.146 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -80.02 -26.41 39.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 71.7 m-20 -106.81 17.6 22.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.753 ' HB1' ' HB2' ' A' ' 79' ' ' SER . . . -75.01 121.73 22.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.24 94.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.517 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 0.5 OUTLIER -40.03 133.46 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 110.916 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.5 Cg_endo -69.78 172.77 47.51 Favored 'Cis proline' 0 C--O 1.232 0.189 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.332 -0.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.626 HG13 ' CB ' ' A' ' 98' ' ' ALA . 18.6 t -105.26 99.86 9.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.149 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.758 HG22 ' HG3' ' A' ' 20' ' ' GLU . 2.6 t -80.97 151.58 4.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.155 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.756 ' CD1' HD12 ' A' ' 21' ' ' ILE . 11.3 m-85 -128.52 137.24 51.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.473 HD12 ' OE1' ' A' ' 77' ' ' GLU . 2.4 mt -124.07 89.64 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.117 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 1.016 HG12 ' HA ' ' A' ' 75' ' ' ILE . 6.3 m -122.16 -177.95 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.154 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.729 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.6 mt-30 -140.18 107.44 5.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.891 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 11.6 t -80.29 131.23 35.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.831 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.743 HD21 ' CD1' ' A' ' 13' ' ' TRP . 11.3 mt -62.31 165.88 5.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.96 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 109' ' ' LEU . 7.1 t -34.52 -33.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.489 ' N ' ' O ' ' A' ' 109' ' ' LEU . 11.4 m -46.26 172.26 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.844 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 8.0 p -146.33 144.16 20.61 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.591 0.71 . . . . 0.0 111.167 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -163.83 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.721 2.281 . . . . 0.0 112.344 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.514 ' CG ' ' N ' ' A' ' 115' ' ' VAL . 19.4 ttp180 -145.72 164.29 32.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.818 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.514 ' N ' ' CG ' ' A' ' 114' ' ' ARG . 9.7 p -128.02 164.05 30.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.703 ' C ' HD12 ' A' ' 116' ' ' ILE . 1.2 pp -69.78 151.1 96.48 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 111.114 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.437 ' C ' HD12 ' A' ' 116' ' ' ILE . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.16 0 C-N-CA 122.721 2.281 . . . . 0.0 112.337 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.0 p -153.78 171.97 18.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.839 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.1 p -174.68 131.47 0.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.58 174.89 34.83 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.5 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -87.64 -71.83 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 m 62.4 54.83 2.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.828 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.544 ' N ' ' CD ' ' A' ' 8' ' ' PRO . . . -155.75 46.24 0.52 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.452 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 7' ' ' GLY . 53.8 Cg_endo -69.75 -13.57 34.87 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.625 2.217 . . . . 0.0 112.326 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.438 ' H ' ' ND2' ' A' ' 9' ' ' ASN . 1.1 m120 -34.78 144.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.849 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.96 107.31 11.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.549 ' HB3' ' CD1' ' A' ' 13' ' ' TRP . 6.3 t -175.15 -174.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.11 77.15 1.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.849 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.728 ' CD1' HD21 ' A' ' 109' ' ' LEU . 56.0 m95 -96.75 113.9 25.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' O ' ' NE2' ' A' ' 107' ' ' GLN . . . -73.91 -159.6 6.18 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 158.04 58.27 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.677 2.251 . . . . 0.0 112.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 159.36 53.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.666 2.244 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.43 ' NH1' ' HB3' ' A' ' 108' ' ' SER . 5.1 ptp180 -131.09 118.54 20.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.62 HG23 ' CG1' ' A' ' 103' ' ' VAL . 36.8 mt -87.27 131.33 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.155 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.3 t -143.34 127.21 13.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.403 ' HG3' HG22 ' A' ' 103' ' ' VAL . 3.3 mp0 -88.17 124.99 34.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.724 HD13 HD11 ' A' ' 31' ' ' ILE . 1.5 mt -120.93 124.95 73.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.138 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.571 ' CE1' ' HB3' ' A' ' 101' ' ' PRO . 2.1 m-85 -93.79 111.88 23.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.488 ' CD ' ' H ' ' A' ' 23' ' ' ARG . 0.0 OUTLIER -47.36 160.26 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.852 -179.889 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.487 ' CB ' HG13 ' A' ' 27' ' ' VAL . 5.7 mm-40 -131.34 146.89 63.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.649 0.738 . . . . 0.0 110.886 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD2' ' CD ' ' A' ' 24' ' ' GLU . 53.7 Cg_endo -69.76 -90.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -45.58 -36.31 4.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.487 HG13 ' CB ' ' A' ' 24' ' ' GLU . 12.0 p -116.38 142.29 30.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.129 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.3 t -80.59 174.25 11.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.879 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.656 HD22 ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -49.12 -18.73 0.35 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.488 ' HA2' ' CD1' ' A' ' 58' ' ' LEU . . . 84.57 -18.96 22.07 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.501 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.724 HD11 HD13 ' A' ' 21' ' ' ILE . 5.6 mt -85.38 147.59 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.879 0.371 . . . . 0.0 111.12 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 60.7 m -132.08 172.81 11.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.942 HD12 ' CD2' ' A' ' 88' ' ' HIS . 3.6 pt -141.72 148.36 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -105.65 167.17 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 179.85 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.593 ' O ' ' CD2' ' A' ' 88' ' ' HIS . . . 33.86 -143.56 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 37' ' ' GLN . . . 126.87 -52.64 0.81 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.448 ' C ' ' O ' ' A' ' 36' ' ' GLY . 4.3 mm100 -34.16 113.65 0.18 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 9.6 t -59.62 179.63 0.11 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -145.5 155.67 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 77.3 mt -109.63 -53.57 5.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.419 ' C ' ' CG ' ' A' ' 42' ' ' ARG . 43.0 tttp -109.44 25.18 12.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.419 ' CG ' ' C ' ' A' ' 41' ' ' LYS . 6.8 ptm180 41.76 29.37 0.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.835 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 14.0 mt -72.53 -10.03 59.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 mmmm -94.63 -62.63 1.29 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -84.49 157.41 21.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.41 -75.73 0.83 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.503 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.08 -6.17 10.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.824 0.345 . . . . 0.0 110.88 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.4 mp0 -68.82 -177.46 1.0 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.488 HD22 ' HZ ' ' A' ' 53' ' ' PHE . 5.2 mp -100.58 168.97 9.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.895 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 15.5 ptmt -114.16 -28.23 7.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.915 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 53' ' ' PHE . . . -46.58 151.4 1.54 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.458 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.877 HD11 ' O ' ' A' ' 86' ' ' ALA . 13.4 mm -69.35 123.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.892 0.377 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.7 m-85 -115.54 142.56 46.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 73' ' ' ASP . 8.2 mt -57.43 125.2 13.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.156 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.57 ' HB2' HG12 ' A' ' 34' ' ' VAL . 28.7 tptt -83.47 -41.24 18.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -179.45 148.93 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.06 116.24 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.488 ' CD1' ' HA2' ' A' ' 30' ' ' GLY . 23.8 mt -55.17 -165.86 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -119.36 -50.63 2.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.888 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -82.74 38.36 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.479 ' CB ' ' HD2' ' A' ' 62' ' ' PRO . 0.1 OUTLIER -121.18 168.94 9.86 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.625 0.726 . . . . 0.0 110.873 -179.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.575 ' HG2' HD23 ' A' ' 29' ' ' LEU . 54.1 Cg_endo -69.75 -14.08 35.6 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.704 2.27 . . . . 0.0 112.344 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 31' ' ' ILE . . . -97.97 -33.17 11.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.096 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.25 -33.94 58.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.531 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 34.7 mtmt -64.43 -46.29 83.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.829 0.347 . . . . 0.0 110.859 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.405 ' H ' HG23 ' A' ' 66' ' ' THR . 1.3 p -54.41 -23.74 17.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 45.31 23.22 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -99.21 -3.0 35.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.117 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mt -133.61 153.2 51.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.937 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -144.66 153.19 41.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.907 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 54' ' ' ILE . 15.0 t -57.15 142.54 42.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.43 -25.24 28.64 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.528 ' HB2' HD12 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -47.87 172.63 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.875 0.369 . . . . 0.0 110.892 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -119.76 108.87 14.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.921 ' HA ' HG12 ' A' ' 106' ' ' VAL . 10.5 mt -78.36 118.84 26.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.621 HD11 ' CG ' ' A' ' 107' ' ' GLN . 0.4 OUTLIER -102.49 -23.72 13.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.942 179.889 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -167.56 152.31 6.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.536 ' O ' HG12 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -144.66 125.86 8.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.138 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.685 ' HB2' ' HB1' ' A' ' 98' ' ' ALA . 1.3 t 60.96 13.03 4.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.855 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.28 32.04 7.25 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.829 HG11 ' HB1' ' A' ' 94' ' ' ALA . 2.3 p -129.34 125.39 61.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -67.26 110.42 3.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.464 HD11 ' HB3' ' A' ' 94' ' ' ALA . 35.9 mt -110.71 4.43 20.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.869 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -50.07 -65.62 0.53 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 35.0 m-20 -89.78 26.57 1.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.877 ' O ' HD11 ' A' ' 52' ' ' ILE . . . -97.41 145.64 25.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.4 ' N ' ' HB2' ' A' ' 90' ' ' GLU . 58.2 p -81.48 176.68 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' HIS . . . . . 0.942 ' CD2' HD12 ' A' ' 33' ' ' ILE . 1.5 t-160 -51.14 -47.41 62.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 31.2 t -69.96 -43.86 70.68 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.476 ' CB ' ' HB1' ' A' ' 86' ' ' ALA . 21.4 mt-10 -54.27 -36.83 64.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.915 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.699 ' O ' HD12 ' A' ' 95' ' ' ILE . . . -82.66 -39.93 21.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.093 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.742 HG23 HD11 ' A' ' 33' ' ' ILE . 2.3 t -53.32 -45.22 55.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.495 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 7.1 mt-10 -67.6 -35.92 79.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.829 ' HB1' HG11 ' A' ' 81' ' ' VAL . . . -62.79 -42.49 99.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.123 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.699 HD12 ' O ' ' A' ' 91' ' ' ALA . 3.2 mp -72.25 -37.25 58.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 17.5 pttt -80.01 -24.57 40.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 93' ' ' GLU . 77.5 m-20 -105.04 8.72 34.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.718 ' CB ' HG13 ' A' ' 102' ' ' VAL . . . -65.76 109.34 2.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 100' ' ' ASN . . . -45.13 93.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.493 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.497 ' HA ' ' C ' ' A' ' 101' ' ' PRO . 38.0 t-20 -33.95 131.06 0.41 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.896 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.571 ' HB3' ' CE1' ' A' ' 22' ' ' PHE . 53.8 Cg_endo -69.78 -171.02 6.29 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.329 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.718 HG13 ' CB ' ' A' ' 98' ' ' ALA . 21.8 t -120.12 93.21 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.165 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.62 ' CG1' HG23 ' A' ' 18' ' ' ILE . 2.5 t -70.4 143.65 14.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.706 ' CE1' HD12 ' A' ' 21' ' ' ILE . 10.0 m-85 -125.39 129.68 50.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.897 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.1 89.98 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.106 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.921 HG12 ' HA ' ' A' ' 75' ' ' ILE . 32.9 m -121.82 177.81 3.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.621 ' CG ' HD11 ' A' ' 76' ' ' LEU . 3.9 mt-30 -139.9 107.21 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.43 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . 1.3 t -77.45 119.4 21.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.728 HD21 ' CD1' ' A' ' 13' ' ' TRP . 9.0 mt -56.16 157.44 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.918 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 109' ' ' LEU . 1.8 t -36.8 103.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.2 m -175.36 163.23 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.861 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 65.0 p -117.06 144.17 33.09 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.571 0.701 . . . . 0.0 111.129 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 -163.8 0.12 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.663 2.242 . . . . 0.0 112.376 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -124.53 -174.79 3.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.874 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.564 HG22 ' N ' ' A' ' 116' ' ' ILE . 10.2 p -80.16 165.69 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.157 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.564 ' N ' HG22 ' A' ' 115' ' ' VAL . 0.7 OUTLIER -78.26 145.2 68.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.617 0.723 . . . . 0.0 111.149 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.39 179.865 . . . . . . . . 0 0 . 1 stop_ save_